Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
eeaedc59a97f4cb215f7a4a3c390ec1d082df1b49531b160d004dec1453c28eb.png
simple
<table><tr><td>Outcome</td><td>Unadjusted Estimate (95% CI)</td><td>Unadjusted <i>p</i> Value</td><td>Adjusted Estimate (95% CI)</td><td>Adjusted <i>p</i> Value</td></tr><tr><td>BPD</td><td></td><td>0.507 <sup>&#8224;</sup></td><td></td><td>0.546 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>0.01 (&#8722;0.10, 0.11)</td><td>0.921</td><td>&#8722;0.01 (&#8722;0.11, 0.10)</td><td>0.914</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.03 (&#8722;0.12, 0.11)</td><td>0.466</td><td>&#8722;0.04 (&#8722;0.13, 0.05)</td><td>0.361</td></tr><tr><td>BPD <i>z</i>-score</td><td></td><td>0.153 <sup>&#8224;</sup></td><td></td><td>0.210 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>0.13 (&#8722;0.18, 0.44)</td><td>0.414</td><td>0.10 (&#8722;0.21, 0.42)</td><td>0.522</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.10 (&#8722;0.35, 0.44)</td><td>0.400</td><td>&#8722;0.11 (&#8722;0.35, 0.14)</td><td>0.399</td></tr><tr><td>HC</td><td></td><td>0.991 <sup>&#8224;</sup></td><td></td><td>0.802 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.05 (&#8722;0.38, 0.27)</td><td>0.755</td><td>&#8722;0.12 (&#8722;0.45, 0.22)</td><td>0.489</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.05 (&#8722;0.33, 0.27)</td><td>0.723</td><td>&#8722;0.07 (&#8722;0.34, 0.20)</td><td>0.618</td></tr><tr><td>HC <i>z</i>-score</td><td></td><td>0.983 <sup>&#8224;</sup></td><td></td><td>0.806 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.05 (&#8722;0.26, 0.16)</td><td>0.621</td><td>&#8722;0.08 (&#8722;0.30, 0.13)</td><td>0.440</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.05 (&#8722;0.23, 0.16)</td><td>0.588</td><td>&#8722;0.05 (&#8722;0.24, 0.13)</td><td>0.567</td></tr><tr><td>FL</td><td></td><td>0.212 <sup>&#8224;</sup></td><td></td><td>0.269 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.06 (&#8722;0.14, 0.02)</td><td>0.143</td><td>&#8722;0.06 (&#8722;0.14, 0.01)</td><td>0.110</td></tr><tr><td>- 36 Weeks</td><td>0.00 (&#8722;0.07, 0.02)</td><td>0.994</td><td>&#8722;0.01 (&#8722;0.08, 0.05)</td><td>0.692</td></tr><tr><td>FL <i>z</i>-score</td><td></td><td>0.499 <sup>&#8224;</sup></td><td></td><td>0.633 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.14 (&#8722;0.37, 0.09)</td><td>0.224</td><td>&#8722;0.14 (&#8722;0.36, 0.09)</td><td>0.235</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.04 (&#8722;0.26, 0.09)</td><td>0.719</td><td>&#8722;0.07 (&#8722;0.29, 0.15)</td><td>0.547</td></tr><tr><td>AC</td><td></td><td>0.264 <sup>&#8224;</sup></td><td></td><td>0.187 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.16 (&#8722;0.60, 0.29)</td><td>0.490</td><td>&#8722;0.29 (&#8722;0.74, 0.16)</td><td>0.208</td></tr><tr><td>- 36 Weeks</td><td>0.13 (&#8722;0.28, 0.29)</td><td>0.531</td><td>0.06 (&#8722;0.35, 0.47)</td><td>0.785</td></tr><tr><td>AC <i>z</i>-score</td><td></td><td>0.501 <sup>&#8224;</sup></td><td></td><td>0.281 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.06 (&#8722;0.27, 0.15)</td><td>0.584</td><td>&#8722;0.13 (&#8722;0.34, 0.08)</td><td>0.211</td></tr><tr><td>- 36 Weeks</td><td>0.02 (&#8722;0.18, 0.15)</td><td>0.839</td><td>&#8722;0.00 (&#8722;0.21, 0.21)</td><td>0.992</td></tr><tr><td>EFW</td><td></td><td>0.175 <sup>&#8224;</sup></td><td></td><td>0.173 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;40.93 (&#8722;105.51, 23.64)</td><td>0.214</td><td>&#8722;56.34 (&#8722;123.01, 10.33)</td><td>0.098</td></tr><tr><td>- 36 Weeks</td><td>22.54 (&#8722;62.18, 23.64)</td><td>0.602</td><td>7.75 (&#8722;76.06, 91.57)</td><td>0.856</td></tr><tr><td>EFW <i>z</i>-score</td><td></td><td>0.478 <sup>&#8224;</sup></td><td></td><td>0.351 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.09 (&#8722;0.28, 0.10)</td><td>0.350</td><td>&#8722;0.14 (&#8722;0.33, 0.05)</td><td>0.155</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.01 (&#8722;0.20, 0.10)</td><td>0.915</td><td>&#8722;0.03 (&#8722;0.22, 0.16)</td><td>0.753</td></tr><tr><td>MTLM</td><td></td><td>0.433 <sup>&#8224;</sup></td><td></td><td>0.395 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>0.09 (&#8722;0.26, 0.44)</td><td>0.617</td><td>0.05 (&#8722;0.31, 0.41)</td><td>0.800</td></tr><tr><td>- 36 Weeks</td><td>0.33 (&#8722;0.18, 0.44)</td><td>0.201</td><td>0.31 (&#8722;0.19, 0.81)</td><td>0.227</td></tr><tr><td>MTFM</td><td></td><td>0.833 <sup>&#8224;</sup></td><td></td><td>0.823 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>0.08 (&#8722;0.35, 0.51)</td><td>0.711</td><td>0.07 (&#8722;0.37, 0.51)</td><td>0.765</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.02 (&#8722;0.91, 0.51)</td><td>0.968</td><td>&#8722;0.04 (&#8722;0.93, 0.85)</td><td>0.932</td></tr><tr><td>AFM</td><td></td><td>0.467 <sup>&#8224;</sup></td><td></td><td>0.661 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.10 (&#8722;0.41, 0.22)</td><td>0.548</td><td>&#8722;0.17 (&#8722;0.49, 0.14)</td><td>0.288</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.26 (&#8722;0.68, 0.22)</td><td>0.216</td><td>&#8722;0.27 (&#8722;0.68, 0.14)</td><td>0.194</td></tr><tr><td>SSFM</td><td></td><td>0.872 <sup>&#8224;</sup></td><td></td><td>0.736 <sup>&#8224;</sup></td></tr><tr><td>- 28 Weeks</td><td>&#8722;0.18 (&#8722;0.44, 0.09)</td><td>0.189</td><td>&#8722;0.21 (&#8722;0.48, 0.05)</td><td>0.119</td></tr><tr><td>- 36 Weeks</td><td>&#8722;0.14 (&#8722;0.57, 0.09)</td><td>0.524</td><td>&#8722;0.13 (&#8722;0.55, 0.29)</td><td>0.550</td></tr></table>
800876e86dfcc61fefffa65f17e0cc7320fb4b24119ed7844cb8811c58ce0e70.png
complex
<table><tr><td>Cooking fuel</td><td colspan="3">Numbers of patients</td><td colspan="2">Cases vs non-eye-disease controls</td><td colspan="2">Case vs non-cataract eye-disease patients</td><td colspan="2">Case vs combined controls</td></tr><tr><td></td><td>CS</td><td>NE</td><td>NC</td><td>a-OR (95% CI)</td><td>p- value*</td><td>a-OR (95% CI)</td><td>p- value*</td><td>a-OR (95% CI)</td><td>p- value*</td></tr><tr><td><underline>Females</underline></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Family h/o cataract</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>53</td><td>66</td><td>67</td><td>1 (ref)</td><td>0.03</td><td>1 (ref)</td><td>0.02</td><td>1 (ref)</td><td>0.007</td></tr><tr><td> Yes</td><td>27</td><td>14</td><td>13</td><td>2.14 (1.03, 4.43)</td><td></td><td>2.66 (1.15, 6.15)</td><td></td><td>2.31 (1.25, 4.26)</td><td></td></tr><tr><td>Formal education</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> At least secondary</td><td>6</td><td>17</td><td>13</td><td>1 (ref)</td><td>0.02</td><td>1 (ref)</td><td>0.35</td><td>1 (ref)</td><td>0.02</td></tr><tr><td> Primary</td><td>39</td><td>28</td><td>23</td><td>4.21 (1.40, 12.6)</td><td></td><td>2.19 (0.62, 5.65)</td><td></td><td>3.66 (1.35, 9.95)</td><td></td></tr><tr><td> None</td><td>35</td><td>35</td><td>34</td><td>3.07 (1.05, 8.93)</td><td></td><td>1.87 (0.62, 5.65)</td><td></td><td>3.00 (1.12, 8.04)</td><td></td></tr><tr><td>Rice straw</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Never used</td><td>54</td><td>64</td><td>59</td><td>1 (ref)</td><td>0.02</td><td>1 (ref)</td><td>0.29</td><td>1 (ref)</td><td>0.04</td></tr><tr><td> Used</td><td>26</td><td>16</td><td>21</td><td>2.86 (1.10, 7.45)</td><td></td><td>1.47 (0.71, 3.01)</td><td></td><td>1.95 (1.03, 3.69)</td><td></td></tr><tr><td>Cow dung</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Never used</td><td>55</td><td>47</td><td>43</td><td>1 (ref)</td><td>0.04</td><td>1 (ref)</td><td>0.03</td><td>1 (ref)</td><td>0.009</td></tr><tr><td> Used</td><td>25</td><td>33</td><td>37</td><td>0.46 (0.21, 1.00)</td><td></td><td>0.45 (0.21, 0.93)</td><td></td><td>0.45 (0.24, 0.84)</td><td></td></tr><tr><td><underline>Males</underline><sup>#</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Family h/o cataract</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>44</td><td>59</td><td>56</td><td>1 (ref)</td><td>0.009</td><td>1 (ref)</td><td>0.08</td><td>1 (ref)</td><td>0.01</td></tr><tr><td> Yes</td><td>26</td><td>12</td><td>16</td><td>3.59 (1.27, 10.2)</td><td></td><td>2.41 (0.86, 6.74)</td><td></td><td>2.68 (1.22, 5.87)</td><td></td></tr><tr><td>Smoking status</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Never smoked</td><td>18</td><td>28</td><td>37</td><td>1(ref)</td><td>0.12</td><td>1(ref)</td><td>0.003</td><td>1(ref)</td><td>0.009</td></tr><tr><td> Current or past</td><td>52</td><td>43</td><td>35</td><td>2.05 (0.82, 5.11)</td><td></td><td>3.40 (1.42, 8.14)</td><td></td><td>2.43 (1.21, 4.88)</td><td></td></tr><tr><td>Formal education</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> At least secondary</td><td>12</td><td>27</td><td>20</td><td>1 (ref)</td><td>0.007</td><td>1 (ref)</td><td>0.39</td><td>1 (ref)</td><td>0.05</td></tr><tr><td> Primary</td><td>34</td><td>25</td><td>31</td><td>5.65 (1.67, 19.1)</td><td></td><td>1.97 (0.62, 6.30)</td><td></td><td>3.08 (1.18, 8.00)</td><td></td></tr><tr><td> None</td><td>24</td><td>19</td><td>21</td><td>4.90 (1.23, 19.5)</td><td></td><td>2.27 (0.67, 7.66)</td><td></td><td>2.73 (1.00, 7.42)</td><td></td></tr><tr><td>Wood or dry leaves</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Never used</td><td>47</td><td>58</td><td>51</td><td>1 (ref)</td><td>0.01</td><td>1 (ref)</td><td>0.42</td><td>1 (ref)</td><td>0.10</td></tr><tr><td> Used</td><td>23</td><td>13</td><td>21</td><td>3.51 (1.24, 9.95)</td><td></td><td>1.46 (0.57, 3.74)</td><td></td><td>1.84 (0.89, 3.83)</td><td></td></tr></table>
f36039a5af3b894a9c9a4414af9602f8a44c80f61934375d04bcac83174a91cd.png
simple
<table><tr><td>Monkey Species and ID</td><td>Protein(ng/ml)</td><td>Levels of p27 (ng/ml)</td><td>TCID50I.U./ml</td><td>Viral copy #x 10<sup>7 </sup>per ml</td></tr><tr><td>SM-FYy</td><td>784.8</td><td>119.41</td><td>2.2355</td><td>3.13</td></tr><tr><td>SM-FMy</td><td>474.6</td><td>63.03</td><td>1.1771</td><td>2.76</td></tr><tr><td>SM-FJt</td><td>384.8</td><td>48.7</td><td>4.1347</td><td>3.83</td></tr><tr><td>RM-RDd3</td><td>1786.9</td><td>351.18</td><td>4.9960</td><td>2.75</td></tr><tr><td>RM-RVe7</td><td>1059.4</td><td>151.30</td><td>2.5674</td><td>2.79</td></tr><tr><td>RM-RLg10</td><td>557.6</td><td>69.30</td><td>1.2364</td><td>2.55</td></tr></table>
f8ed179d053a243a6fc53f46264a61b7e85e36cf4eef684570bbf5586cb4b88d.png
simple
<table><tr><td>Cut-off</td><td>Maxillary</td><td>Anterior ethmoid</td><td>Posterior ethmoid</td><td>Frontal</td><td>Sphenoid</td></tr><tr><td>&gt;3 mm*</td><td>26</td><td>4</td><td>4</td><td>2</td><td>3.5</td></tr><tr><td>&gt;4 mm*</td><td>25</td><td>3</td><td>2.8</td><td>1.4</td><td>3.2</td></tr></table>
ca4f46d83f055f1532bbcf0717215808a3c2bf7fc97d4695d3b54bcbbe46c7aa.png
complex
<table><tr><td colspan="2">Molecular function</td><td colspan="2">Biological process</td><td colspan="2">Cellular function</td></tr><tr><td>GO term</td><td>GO score</td><td>GO term</td><td>GO score</td><td>GO term</td><td>GO score</td></tr><tr><td>GO:0043169</td><td>0.96</td><td>GO:0006689</td><td>0.80</td><td>GO:0016020</td><td>0.80</td></tr><tr><td>GO:0046982</td><td>0.80</td><td>GO:0030203</td><td>0.80</td><td>GO:0005764</td><td>0.80</td></tr><tr><td>GO:0005529</td><td>0.56</td><td>GO:0042552</td><td>0.80</td><td>GO:0005625</td><td>0.56</td></tr><tr><td>GO:0016231</td><td>0.56</td><td>GO:0050885</td><td>0.80</td><td>GO:0001669</td><td>0.56</td></tr><tr><td>GO:0042803</td><td>0.56</td><td>GO:0019915</td><td>0.80</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>GO:0007605</td><td>0.80</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>GO:0007040</td><td>0.80</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>GO:0001501</td><td>0.80</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>GO:0008219</td><td>0.80</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td>GO:0031323</td><td>0.56</td><td> </td><td> </td></tr></table>
352f172e4738b0bdc46cce510ef3762f15f5b26415908347dde06b4575950242.png
complex
<table><tr><td rowspan="2"></td><td>RMAP</td><td>Posterior PMR</td><td>Anterior PMR</td><td rowspan="2">P-value</td></tr><tr><td>(n = 23)</td><td>(n = 10)</td><td>(n = 6)</td></tr><tr><td>Age, years</td><td>70 &#177; 6</td><td>65 &#177; 7</td><td>68 &#177; 8</td><td>0.16</td></tr><tr><td>Male</td><td>17 (73.9)</td><td>9 (90.0)</td><td>3 (50.0)</td><td>0.21</td></tr><tr><td colspan="5">NYHA functional class</td></tr><tr><td>1</td><td>2 (8.7)</td><td>0</td><td>0</td><td>0.48</td></tr><tr><td>2</td><td>12 (52.2)</td><td>3 (30.0)</td><td>1 (16.7)</td><td>0.21</td></tr><tr><td>3</td><td>8 (34.8)</td><td>4 (40.0)</td><td>3 (50.0)</td><td>0.79</td></tr><tr><td>4</td><td>1 (4.3)</td><td>3 (30.0)</td><td>2 (33.3)</td><td>0.071</td></tr><tr><td>Preoperative inotropic support</td><td>2 (8.7)</td><td>3 (30.0)</td><td>2 (33.3)</td><td>0.19</td></tr><tr><td colspan="5">Etiology</td></tr><tr><td>Ischemic</td><td>23 (100)</td><td>8 (80.0)</td><td>1 (16.7)</td><td>&lt;0.001</td></tr><tr><td>Non-ischemic</td><td>0</td><td>2 (20.0)</td><td>5 (83.3)</td><td>&lt;0.001</td></tr><tr><td colspan="5">Echocardiographic data</td></tr><tr><td>MR grade</td><td>2.6 &#177; 0.6</td><td>3.8 &#177; 0.4<sup>a</sup></td><td>3.7 &#177; 0.5<sup>a</sup></td><td>&lt;0.01</td></tr><tr><td>LVEDD (mm)</td><td>66.3 &#177; 6.4</td><td>70.4 &#177; 7.4</td><td>66.2 &#177; 3.6</td><td>0.24</td></tr><tr><td>LVESD (mm)</td><td>48.7 &#177; 12.0</td><td>61.2 &#177; 9.7<sup>a</sup></td><td>57.3 &#177; 4.2</td><td>&lt;0.01</td></tr><tr><td>LVEF (%)</td><td>40.4 &#177; 11.7</td><td>31.9 &#177; 5.4<sup>a</sup></td><td>29.7 &#177; 7.4<sup>a</sup></td><td>0.026</td></tr></table>
681b9b3638cbccb3c26969c0e8af2de971981a1df20b1544876b6f369322cd68.png
complex
<table><tr><td colspan="4">Center</td></tr><tr><td>Parameter</td><td>R<sup>2*</sup></td><td><i>P</i><sup>*</sup></td><td>Correlation</td></tr><tr><td> p120-catenin membrane vs. &#946;-catenin membrane</td><td>0.15</td><td>&lt;0.01</td><td>positive</td></tr><tr><td> vs. &#946;-catenin cytoplasm</td><td>0.07</td><td>0.03</td><td>inverse</td></tr><tr><td> p120-catenin cytoplasm vs. &#946;-catenin membrane</td><td>0.13</td><td>&lt;0.01</td><td>inverse</td></tr><tr><td> vs. &#946;-catenin cytoplasm</td><td>0.15</td><td>&lt;0.01</td><td>positive</td></tr><tr><td colspan="4">Invasive front</td></tr><tr><td>Parameter</td><td>R<sup>2*</sup></td><td><i>P</i><sup>*</sup></td><td>Correlation</td></tr><tr><td> p120-catenin membrane vs. &#946;-catenin membrane</td><td>0.33</td><td>&lt;0.01</td><td>positive</td></tr><tr><td> vs. E-cadherin membrane</td><td>0.60</td><td>&lt;0.01</td><td>positive</td></tr><tr><td> &#946;-catenin membrane vs. E-cadherin membrane</td><td>0.29</td><td>&lt;0.01</td><td>positive</td></tr></table>
54e0d0547d30a94a245d6b8b8b9cf91e69722f4cd86f34694e4c4cb0047ba569.png
complex
<table><tr><td></td><td colspan="4">Age and sex-adjusted</td></tr><tr><td></td><td>Beta</td><td>95% CI</td><td>p</td><td>R<sup>2</sup></td></tr><tr><td colspan="5">Vascular risk factors (VRFs)</td></tr><tr><td> Hypertension</td><td>&#8722;0.049</td><td>(&#8722;0.617, 0.519)</td><td>0.87</td><td>0.04</td></tr><tr><td> Hypercholesterolemia</td><td>0.262</td><td>(&#8722;0.153, 0.676)</td><td>0.22</td><td>0.05</td></tr><tr><td> Diabetes mellitus</td><td>0.128</td><td>(&#8722;0.592, 0.848)</td><td>0.73</td><td>0.04</td></tr><tr><td> Overweight (BMI &#8805;25)</td><td>&#8722; 0.391</td><td>(&#8722; 0.840, 0.059)</td><td>0.09</td><td>0.04</td></tr><tr><td> Smoking (current)</td><td>0.050</td><td>(&#8722;0.677, 0.778)</td><td>0.89</td><td>0.04</td></tr><tr><td>&#8805; 2 VRFs</td><td>0.121</td><td>(&#8722;0.370, 0.612)</td><td>0.63</td><td>0.03</td></tr><tr><td>&#8805; 3 VRFs</td><td>&#8722;0.371</td><td>(&#8722;0.889, 0.147)</td><td>0.16</td><td>0.04</td></tr><tr><td> Framingham Stroke Risk Profile, women*</td><td>&#8722;0.297</td><td>(&#8722;2.769, 2.175)</td><td>0.81</td><td>0.00</td></tr><tr><td> Framingham Stroke Risk Profile, men*</td><td>0.930</td><td>(&#8722;1.638, 3498)</td><td>0.47</td><td>0.01</td></tr><tr><td> ApoE &#949;4 carrier</td><td>0.384</td><td>(&#8722;0.069, 0.836)</td><td>0.10</td><td>0.06</td></tr><tr><td colspan="5">Vascular diseases</td></tr><tr><td> Heart disease</td><td>0.196</td><td>(&#8722;0.380, 0.771)</td><td>0.50</td><td>0.04</td></tr><tr><td> Atrial fibrillation</td><td>&#8722;0.159</td><td>(0.902, 0.583)</td><td>0.67</td><td>0.04</td></tr><tr><td> Peripheral vascular disease</td><td>0.512</td><td>(&#8722;0.834, 1.858)</td><td>0.46</td><td>0.04</td></tr><tr><td> Cerebrovascular event (stroke and/or TIA)</td><td>&#8722;0.315</td><td>(&#8722;0.896, 0.265)</td><td>0.29</td><td>0.04</td></tr><tr><td colspan="5">MRI findings</td></tr><tr><td> Cortical infarcts (1 = cortical infarcts, 0 = no cortical infarcts)</td><td>0.707</td><td>(&#8722;0.518, 1.932)</td><td>0.26</td><td>0.04</td></tr><tr><td> Lacunes (1 = &#8805;1 lacune on MRI, 0 = no lacunes)</td><td>&#8722;0.177</td><td>(&#8722;0.867, 0.514)</td><td>0.61</td><td>0.04</td></tr><tr><td> Infarcts (cortical and/or lacunes)</td><td>0.038</td><td>(&#8722;0.611, 0.687)</td><td>0.91</td><td>0.03</td></tr><tr><td> White matter hyperintensities Fazekas 3</td><td>&#8722;0.291</td><td>(&#8722;0.872, 0.290)</td><td>0.32</td><td>0.04</td></tr><tr><td> White matter hyperintensities Fazekas 2 or 3</td><td>&#8722;0.207</td><td>(&#8722;0.776, 0.362)</td><td>0.47</td><td>0.04</td></tr><tr><td> Infarcts and/or WMH Fazekas 3</td><td>&#8722;0.079</td><td>(&#8722;0.625, 0.468)</td><td>0.78</td><td>0.03</td></tr><tr><td> Infarcts and/or WMH Fazekas 2 or 3</td><td>&#8722;0.298</td><td>(&#8722;0.872, 0.277)</td><td>0.31</td><td>0.04</td></tr><tr><td> MTA (mean of right and left side)</td><td>0.036</td><td>(&#8722;0.262, 0.334)</td><td>0.81</td><td>0.04</td></tr></table>
dd5cd9825cb67953f028df82656a46e023cbe4aae8b877101d5d5da0da74d5c2.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Placebo</td><td colspan="3">Coffee</td></tr><tr><td>base</td><td>30 min</td><td>60 min</td><td>base</td><td>30 min</td><td>60 min</td></tr><tr><td>HR (bpm)</td><td>68.1 <i>&#177;</i> 13.3</td><td>64.4 <i>&#177;</i> 13.4</td><td>66.3 <i>&#177;</i> 15.3</td><td>73.6 <i>&#177;</i> 10.1</td><td>68.7 <i>&#177;</i> 12.4</td><td>69.4 &#177; 14.4</td></tr><tr><td>SBP (mmHg)</td><td>114.3 &#177; 5.2</td><td>117.9 &#177; 7.3</td><td>119.6 &#177; 7.5a</td><td>117.2 &#177; 6.7</td><td>130.6 &#177; 8.5a<sup>,</sup>b</td><td>134.7 &#177; 8.9a<sup>,</sup>b</td></tr><tr><td>DBP (mmHg)</td><td>69.1 &#177; 6.0</td><td>72.0 &#177; 7.0</td><td>76.7 &#177; 9.5a</td><td>66.8 &#177; 4.9</td><td>78.3 &#177; 6.7a<sup>,</sup>b</td><td>80.4 &#177; 6.1a</td></tr><tr><td>MAP (mmHg)</td><td>84.2 &#177; 5.1</td><td>87.2 &#177; 6.1</td><td>91.0 &#177; 7.9a</td><td>83.6 &#177; 4.8</td><td>96.7 &#177; 6.8a<sup>,</sup>b</td><td>98.5 &#177; 5.8a<sup>,</sup>b</td></tr><tr><td>Pulse pressure (mmHg)</td><td>45.2 &#177; 3.9</td><td>45.8 &#177; 6.1</td><td>42.9 &#177; 6.5</td><td>50.4 &#177; 4.8</td><td>52.3 &#177; 3.4</td><td>54.3 &#177; 7.9</td></tr><tr><td>Systolic MCAv (cm/s)</td><td>88.8 &#177; 10.9</td><td>86.7 &#177; 14.4</td><td>83.6 &#177; 12.9</td><td>88.9 &#177; 13.2</td><td>78.6 &#177; 14.0</td><td>77.2 &#177; 11.7</td></tr><tr><td>Diastolic MCAv (cm/s)</td><td>36.4 &#177; 5.2</td><td>36.8 &#177; 6.1</td><td>36.2 &#177; 6.1</td><td>37.0 &#177; 4.5</td><td>32.7 &#177; 5.2a</td><td>32.1 &#177; 3.7a</td></tr><tr><td>Mean MCAv (cm/s)</td><td>53.8 &#177; 6.2</td><td>53.5 &#177; 7.5</td><td>52.1 &#177; 7.4</td><td>54.3 &#177; 6.6</td><td>48.0 &#177; 7.6a</td><td>47.1 &#177; 5.8a</td></tr><tr><td>Pulse MCAv (cm/s)</td><td>52.4 <i>&#177;</i> 7.9</td><td>49.9 &#177; 11.7</td><td>47.3 <i>&#177;</i> 8.9</td><td>51.9 &#177; 10.3</td><td>45.9 &#177; 9.4</td><td>45.1 &#177; 8.7</td></tr><tr><td>MCA PI</td><td>0.99 &#177; 0.10</td><td>0.95 &#177; 0.15</td><td>0.94 &#177; 0.11</td><td>0.96 &#177; 0.10</td><td>0.98 &#177; 0.07</td><td>0.99 &#177; 0.07</td></tr><tr><td>MCA CVCi (cm/s/mmHg)</td><td>0.65 &#177; 0.07</td><td>0.61 &#177; 0.10</td><td>0.57 &#177; 0.10a</td><td>0.66 &#177; 0.09</td><td>0.50 &#177; 0.06a<sup>,</sup>b</td><td>0.48 &#177; 0.06a<sup>,</sup>b</td></tr><tr><td>baPWV (cm/s)</td><td>1056 &#177; 87</td><td>1067 <i>&#177;</i> 121</td><td>1064 &#177; 134</td><td>1030 &#177; 82</td><td>1117 &#177; 143a</td><td>1131 &#177; 126a<sup>,</sup>b</td></tr><tr><td>petCoz (mmHg)</td><td>38.6 &#177; 2.2</td><td>38.7 &#177; 1.8</td><td>38.3 &#177; 1.6</td><td>38.3 &#177; 2.3</td><td>37.0 &#177; 1.9a<sup>,</sup>b</td><td>36.1 &#177; 2.7a<sup>,</sup>b</td></tr></table>
86bea152e1772f3da349350573fef53ad2e7b8f517ee4ae39fde93fddae315a6.png
complex
<table><tr><td colspan="2">Type of test</td><td>G1</td><td>G2</td><td>G3</td><td>G4</td></tr><tr><td rowspan="2">LR_tests of fixed effects</td><td>Spatial fixed effects</td><td>6732.35**</td><td>2607.12**</td><td>2021.77**</td><td>415.62**</td></tr><tr><td>Temporal fixed effects</td><td>7461.23**</td><td>2729.13**</td><td>753.29**</td><td>309.58**</td></tr><tr><td>LM_Tests</td><td>LM Lag test</td><td>1506.82**</td><td>2939.76**</td><td>47.13**</td><td>6.42*</td></tr><tr><td></td><td>Robust LM Lag test</td><td>6.84**</td><td>186.74**</td><td>20.45**</td><td>7.11**</td></tr><tr><td></td><td>LM Error test</td><td>1500.82**</td><td>2773.34**</td><td>39.29**</td><td>4.62*</td></tr><tr><td></td><td>Robust LM Error test</td><td>0.84</td><td>20.32**</td><td>12.61**</td><td>5.30*</td></tr></table>
70c30d51c54355e3b7c5e77a009809cba7537584e0d85349ce9b510b3512be95.png
simple
<table><tr><td> </td><td>Br</td><td>Au</td><td>In</td><td>Vi</td></tr><tr><td>Br</td><td>-</td><td>0.146</td><td>0.108</td><td>0.177</td></tr><tr><td>Au</td><td>0.216</td><td>-</td><td>0.037</td><td>0.092</td></tr><tr><td>In</td><td>0.211</td><td>0.168</td><td>-</td><td>0.052</td></tr><tr><td>Vi</td><td>0.196</td><td>0.155</td><td>0.103</td><td>-</td></tr></table>
c11cf525fc242608e0e1c694f37246f154298c022752ab0da1207733bfc6bb65.png
simple
<table><tr><td>Operation Mode</td><td>Operation Current</td><td>Power Consumption</td></tr><tr><td>Idle</td><td>2 mA</td><td>2 mAh</td></tr><tr><td>Data sampling</td><td>80 mA</td><td>0.178 mAh</td></tr><tr><td>Data transmitting</td><td>60 mA</td><td>0.067 mAh</td></tr></table>
661b905a736dcff3f0d278d04641040317ac9de347f0099f36de6bfc5fefcb2b.png
simple
<table><tr><td>Categories emerged</td><td>Positive valued</td><td>Negative valued</td></tr><tr><td>The degree of difficulty/demand of the studies</td><td>The degree of difficulty/demand was experienced as stimulating</td><td>The degree of difficulty/demand was experienced as too heavy</td></tr><tr><td>The teachers engagement</td><td>Very engaged teachers</td><td>Not engaged teachers</td></tr><tr><td>The organisation of the program</td><td>A stimulating organisation of the program was noticed</td><td>No stimulating organisation of the program was noticed</td></tr><tr><td>Contents in the studies associated to the profession</td><td>The certificate to be a nurse is attractive &#8211; long for working as a nurse</td><td>The certificate and the profession frightened the student</td></tr><tr><td>The attitude towards the studies</td><td>Having a positive attitude towards the studies</td><td>Having a negative attitude towards the studies</td></tr><tr><td>The study result achieved</td><td>Achieving a good study result</td><td>Not achieving a good study results</td></tr><tr><td>The life situation surrounding the studies</td><td>Having a good life situation</td><td>Having a bad life situation</td></tr><tr><td>Friendship during the studies</td><td>A good friendship is experienced</td><td>A bad or no friendship is experienced</td></tr></table>
a9a0b19370a7d3b424ba1984c2e4311869728787214bd09c893e980168bb936d.png
complex
<table><tr><td> </td><td colspan="3">Population</td><td colspan="2">Intervention</td><td colspan="2">Assessment tool(s)<sup>a</sup></td><td colspan="2">Analysis</td></tr><tr><td>Papers</td><td>Randomization</td><td>Justification of sample size</td><td>Control group</td><td>Allocation concealment</td><td>Underlying theory</td><td>Validity</td><td>Reliability</td><td>Intention-to-treat</td><td>Attrition rate</td></tr><tr><td>Alonso, Fernandez, Mataix <i>et al</i>. (1999)</td><td>No</td><td>Not mentioned</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Beasley, Capossela, Brigham, Gunderson and Gortmaker (1997)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Bleakley (2010)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="2">Dettle, Sagel and Chrysler (1994)</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">Yes (but no statistical comparison between groups)</td><td rowspan="2">Not mentioned</td><td rowspan="2">None</td><td rowspan="2">Not mentioned</td><td rowspan="2">Not mentioned</td><td rowspan="2">no</td><td>40% attrition;</td></tr><tr><td>No analysis of dropouts</td></tr><tr><td>Kittur, McMenamin and Knott (1990)</td><td>No</td><td>No</td><td>Yes</td><td>Not randomly assigned</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Light (1987)</td><td>No</td><td>No</td><td>Yes (but no statistical comparison between groups)</td><td>Not randomly assigned</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Milane&#769;s, Gonzalez, Hernandez, Arminio, Clesca and Rivas-Vetencourt (2003)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Nelson, Marymont, Durand, Reyes and Davis (1992)</td><td>Random cluster probability method</td><td>No</td><td>Yes</td><td>Not randomly assigned</td><td>None</td><td colspan="2">Field testing of the questionnaire (but validity/reliability assessment not detailed)</td><td>N/A</td><td>N/A</td></tr><tr><td>Niday, Painter, Peak <i>et al</i>. (2007)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Riker and White (1995)</td><td>No</td><td>No</td><td>Yes</td><td>Not randomly assigned</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Shafer, Durand, Hueneke, <i>et al</i>. (1998)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Stark, Wikoren and Martone (1994)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Taylor, Young and Kneteman (1997)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>&#8216;Change theory&#8217; (not referenced)</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Van Gelder, Van Hees, de Roey, Monbaliu, Aerts, Coosemans <i>et al</i>. (2006)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Wight, Cohen, Roels and Miranda (2000)</td><td>No</td><td>No</td><td>No</td><td>N/A</td><td>None</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></table>
a0b26ede6f4dc63e1964df4db654ea0261e5f3e48b261ef0475770b69a9aac95.png
complex
<table><tr><td rowspan="2">Parameter</td><td colspan="3">Youth (<i>n</i> = 618)</td><td colspan="3">Middle age (<i>n</i> = 613)</td><td colspan="3">Senior (<i>n</i> = 279)</td></tr><tr><td>Total sample</td><td>Men </td><td>Women </td><td>Total sample</td><td>Men </td><td>Women </td><td>Total sample</td><td>Men </td><td>Women </td></tr><tr><td>Age (yr)</td><td>30.8 &#177; 5.7</td><td>30.4 &#177; 5.5</td><td>31.1 &#177; 5.8</td><td>49.2 &#177; 5.5</td><td>49.2 &#177; 5.8</td><td>49.2 &#177; 5.8</td><td>68.1 &#177; 4.5</td><td>68.9 &#177; 4.2</td><td>67.5 &#177; 4.6</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>22.5 &#177; 3.6</td><td>23.5 &#177; 3.6</td><td>21.7 &#177; 3.4</td><td>24.3 &#177; 3.3</td><td>24.5 &#177; 3.1</td><td>24.2 &#177; 3.4</td><td>25.0 &#177; 3.4</td><td>24.6 &#177; 2.9</td><td>25.4 &#177; 3.6</td></tr><tr><td>25(OH)D (ng/mL)</td><td>18.2 &#177; 9.2<sup>a</sup></td><td>17.6 &#177; 9.5<sup>a</sup></td><td>18.7 &#177; 9.0</td><td>22.8 &#177; 8.7</td><td>23.4 &#177; 8.5</td><td>22.4 &#177; 8.1</td><td>19.9 &#177; 7.8<sup>a</sup></td><td>22.2 &#177; 8.4</td><td>18.2 &#177; 6.9<sup>b</sup></td></tr><tr><td>iPTH (pg/mL)</td><td>33.0 &#177; 13.2<sup>a</sup></td><td>32.3 &#177; 12.3</td><td>33.5 &#177; 13.8</td><td>30.8 &#177; 13.3</td><td>35.0 &#177; 13.9</td><td>27.9 &#177; 12.1<sup>b</sup></td><td>32.8 &#177; 15.2<sup>a</sup></td><td>35.6 &#177; 14.1</td><td>30.8 &#177; 15.7<sup>b</sup></td></tr><tr><td>Total calcium (mmol/mL)</td><td>2.4 &#177; 0.1</td><td>2.4 &#177; 0.1</td><td>2.4 &#177; 0.1</td><td>2.4 &#177; 0.2</td><td>2.4 &#177; 0.1</td><td>2.4 &#177; 0.2</td><td>2.4 &#177; 0.2</td><td>2.4 &#177; 0.2</td><td>2.4 &#177; 0.2</td></tr><tr><td>Phosphate (mmol/mL)</td><td>1.1 &#177; 0.2</td><td>1.1 &#177; 0.2</td><td>1.1 &#177; 0.1</td><td>1.1 &#177; 0.2</td><td>1.0 &#177; 0.2</td><td>1.1 &#177; 0.1<sup>b</sup></td><td>1.0 &#177; 0.2</td><td>1.0 &#177; 0.1</td><td>1.1 &#177; 0.1<sup>b</sup></td></tr><tr><td>Creatinine (umol/L)</td><td>67.1 &#177; 14.1</td><td>69.3 &#177; 11.5</td><td>66.5 &#177; 14.7</td><td>73.8 &#177; 10.4</td><td>74.2 &#177; 12.3</td><td>71.9 &#177; 11.1</td><td>76.6 &#177; 13.1<sup>c</sup></td><td>78.4 &#177; 11.5</td><td>74.7 &#177; 10.6</td></tr></table>
85df2df029d39c9f0910572c7a6a76186443bff44cbe2003e523582aa8b1704d.png
simple
<table><tr><td>Mediator</td><td>Control</td><td>S</td><td>S+D</td><td>S+C1</td><td>S+C2</td><td>S+C3</td></tr><tr><td>Total protein</td><td>5.35&#177;0.25</td><td>9.1&#177;0.32</td><td>7.36&#177;1.81</td><td>14.80&#177;2.66</td><td>4.90&#177;1.18</td><td>3.94&#177;0.51</td></tr><tr><td>PLA2</td><td>7.49&#177;0.54</td><td>12.12&#177;1.34</td><td>7.68&#177;0.75</td><td>22.05&#177;3.07</td><td>7.48&#177;0.09</td><td>7.39&#177;0.04</td></tr><tr><td>Histamine</td><td>7.73&#177;1.15</td><td> 32.92&#177;1.62</td><td>28.45&#177;2.01</td><td>27.05&#177;1.81</td><td>17.34&#177;2.3 </td><td>1.84&#177;0.25***</td></tr></table>
c6af92501ff1443aeac8f5fba3996d01ac576c5df8a4088b352e6cc342003d41.png
complex
<table><tr><td> </td><td>Mean</td><td>SD</td><td>Cronbach's <i>&#945;</i></td><td>RA</td><td>PC</td><td>EU</td><td>IUMHS</td></tr><tr><td rowspan="2">RA</td><td rowspan="2">2.37</td><td rowspan="2">0.92</td><td rowspan="2">0.90</td><td>CR = 0.93</td><td rowspan="2"> </td><td rowspan="2"> </td><td rowspan="2"> </td></tr><tr><td>AVE = 0.72</td></tr><tr><td rowspan="2">PC</td><td rowspan="2">2.51</td><td rowspan="2">0.96</td><td rowspan="2">0.78</td><td rowspan="2">0.31<sup><i>&#8727;&#8727;</i></sup></td><td>CR = 0.90</td><td rowspan="2"> </td><td rowspan="2"> </td></tr><tr><td>AVE = 0.82</td></tr><tr><td rowspan="2">EU</td><td rowspan="2">2.45</td><td rowspan="2">1.13</td><td rowspan="2">0.81</td><td rowspan="2">0.13</td><td rowspan="2">0.09</td><td>CR = 0.89</td><td rowspan="2"> </td></tr><tr><td>AVE = 0.74</td></tr><tr><td rowspan="2">IUMHS</td><td rowspan="2">2.70</td><td rowspan="2">0.83</td><td rowspan="2">0.93</td><td rowspan="2">0.57<sup><i>&#8727;&#8727;</i></sup></td><td rowspan="2">0.39<sup><i>&#8727;&#8727;</i></sup></td><td rowspan="2">0.38<sup><i>&#8727;&#8727;</i></sup></td><td>CR = 0.95</td></tr><tr><td>AVE = 0.83</td></tr></table>
1455d5b5941b5d9ab964630995427e14a634b353d4d00c33b9bceea9b1dd3049.png
simple
<table><tr><td>Disease</td><td>Regimen</td><td>No. pts.</td><td>PFS</td><td>Efficacy</td><td>Ref.</td></tr><tr><td>Metastatic head and neck cancer</td><td><i>Vorinostat:</i> 400 mg orally daily</td><td>13</td><td></td><td>SD 2 pts. OR 0%</td><td>[51]</td></tr><tr><td>Metastatic breast cancer</td><td><i>Vorinostat:</i> 400 mg orally daily</td><td>14</td><td></td><td>SD 4 pts</td><td>[52]</td></tr><tr><td>Relapsed NSCLC</td><td><i>Vorinostat</i>: 400 mg or 300 mg once daily on days 1&#8211;14 of the 21 day cycle</td><td>16</td><td>Median: 2.3 m. </td><td>SD 57%</td><td>[53]</td></tr><tr><td>Metastatic prostate cancer</td><td><i>Vorinostat:</i> 400 mg orally daily</td><td>27</td><td>Median: 2.8 m. </td><td>SD 2 pts.</td><td>[54]</td></tr><tr><td>Ovarian or primary peritoneal carcinoma</td><td><i>Vorinostat:</i> 400 mg orally daily</td><td>27</td><td></td><td>PR 1 pt.</td><td>[55]</td></tr><tr><td>Recurrent GBM </td><td><i>Vorinostat</i>: 200 mg p.o.twice a day for 14 days, followed by a 7-day rest period</td><td>66</td><td>6-m.-PFS: 9 of the first 52 patients</td><td>OR 2 pts.</td><td>[56]</td></tr><tr><td>Metastatic colorectal cancer</td><td><i>Vorinostat:</i> 800 or 1,400 mg/day once a day &#215; 3 days, every 2 weeks <i>+5-FU:</i> preceded by leucovorin, at 400 mg/m<sup>2</sup> followed by a 46 h infusion at 2.400 mg/m<sup>2</sup> on days 2&#8211;3 </td><td>58</td><td>PFS rate did not reach the threshold of 27 out of 43 patients</td><td>PR 1 pt.</td><td>[57]</td></tr><tr><td>Untreated stage IIIB or IV NSCLC</td><td><i>Vorinostat</i>: 400 mg or Placebo on days 1 through 14 of each 3-week cycle +<i>Carboplatin</i>: AUC 6 +<i>Paclitaxel</i>: 200 mg/m<sup>2</sup>, both on day 3 of each 21-day cycle</td><td>94</td><td>Median: <i>Vorinostat</i>: 6.0 m. <i>Placebo</i>: 4.1 m. <i>P =</i> ns</td><td><i>RR Vorinostat</i>: 34% <i>Placebo</i>: 12.5% <i>P</i> = 02</td><td>[58]</td></tr><tr><td>Advanced thyroid cancer</td><td><i>Vorinostat:</i> 400 mg orally daily</td><td>19</td><td></td><td>SD 56% OR 0</td><td>[59]</td></tr><tr><td>Recurrent GBM</td><td><i>Vorinostat:</i> 400 mg daily for 14 days of a 21-day cycle + <i>Bortezomib</i>: 1.3 mg/m2 intravenously on days 1,4, 8, and 11 of a 21-day cycle</td><td>37</td><td>Median: 1.5 m. </td><td>PR 1 pt.</td><td>[60]</td></tr></table>
8f4b427de9f60fc46025f0ff65e69e834bc29c0917fe094835c2c92822deccf2.png
complex
<table><tr><td>Bacteria, plasmid, or gene</td><td>Relevant features or sequence (5&#8242;&#8211;3&#8242;)</td><td>References or sources</td></tr><tr><td colspan="3">Bacteria</td></tr><tr><td> <i>E. coli</i> DH5&#945;</td><td>endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR F- &#934;80d<i>lacZ</i>&#916;M15 &#916;(<i>lacZYA</i>-<i>argF</i>)U169, hsdR17(rK- mK +), &#955;&#8211;</td><td>Invitrogen</td></tr><tr><td> <i>L. lactis</i> NZ9000</td><td>MG1363 <i>nisRK</i> &#916;<i>pepN</i></td><td>NIZO [35, 36]</td></tr><tr><td> <i>Lb. plantarum</i> ATCC 8014</td><td>Wild type</td><td>ATCC</td></tr><tr><td colspan="3">Plasmid</td></tr><tr><td> pNZ8148</td><td>pSH71 derivative, P<i>nisA,</i> CmR, nisin-controlled expression</td><td>NIZO [35, 36]</td></tr><tr><td> pNZRK</td><td>pNZ8148 containing <i>nisR</i> and <i>nisK</i> genes</td><td>This work</td></tr><tr><td> pNZ-IRFP713</td><td>pNZ8148 containing <i>irfp713</i> gene</td><td>This work</td></tr><tr><td> pNZ-IRFP682</td><td>pNZ8148 containing <i>irfp682</i> gene</td><td>This work</td></tr><tr><td> pNZRK-IRFP713</td><td>pNZ8148 containing <i>irfp713, nisR</i> and <i>nisK</i> genes</td><td>This work</td></tr><tr><td> pMA-T-IRFP713</td><td>pMA-T containing <i>irfp713</i> gene</td><td>This work</td></tr><tr><td> pMSP3545</td><td>Em<sup>r</sup>, P<sub><i>nisA</i></sub>, <i>nisRK</i>, <i>Nco</i>I for translational fusion, ColE1 and pAM&#946;1 replicons</td><td>[37]</td></tr><tr><td> pMSP3545-IRFP713</td><td>pMSP3545 containing <i>irfp713</i> gene</td><td>This work</td></tr><tr><td> pGEM::CP25-IRFP</td><td>pGEM-T Easy containing <i>irfp713</i> gene under the control of CP25 promoter</td><td>[27]</td></tr><tr><td colspan="3">Gene</td></tr><tr><td> <i>irfp713</i></td><td><underline>CCATGG</underline>CTGAGGGATCTGTAGCTCGTCAACCTGATTTACTTACTTGTGACGATGAACCTATTCATATTCCAGGTGCTATTCAACCACACGGACTTTTATTAGCTCTTGCCGCTGACATGACTATCGTCGCTGGATCAGATAATTTACCTGAATTGACTGGTTTAGCAATTGGAGCCCTTATTGGACGATCAGCAGCAGATGTTTTTGATTCAGAAACTCATAATCGTCTTACTATTGCATTGGCAGAACCTGGTGCTGCAGTAGGTGCTCCTATTACAGTAGGTTTCACTATGCGTAAGGATGCTGGTTTTATTGGTTCTTGGCATCGTCATGATCAACTTATTTTTTTAGAGTTGGAACCACCACAAAGAGACGTTGCAGAGCCTCAAGCTTTTTTTCGTCGTACTAATTCAGCAATTCGTAGACTTCAAGCTGCTGAAACTCTTGAATCTGCATGTGCAGCAGCAGCACAAGAGGTACGAAAAATTACAGGTTTTGATAGAGTTATGATTTACAGATTTGCCTCAGACTTTTCTGGTGAAGTAATCGCAGAGGATAGATGTGCCGAGGTTGAAAGTAAATTGGGATTGCATTATCCTGCCAGTACTGTTCCAGCCCAAGCACGTCGTCTTTATACTATTAATCCTGTTAGAATTATCCCAGATATTAATTATCGACCAGTTCCAGTTACTCCTGACTTAAATCCTGTAACTGGTAGACCTATTGACTTGTCATTTGCCATCTTACGATCTGTTTCACCTGTTCATTTAGAGTTTATGCGTAATATTGGTATGCATGGTACTATGTCTATCTCAATCCTTCGAGGAGAACGTTTATGGGGACTTATTGTTTGTCATCATAGAACACCTTATTATGTCGATTTAGATGGACGTCAAGCTTGTGAATTAGTTGCTCAAGTCTTGGCTTGGCAAATTGGTGTAATGGAAGAATAA<underline>TCTAGA</underline></td><td>This work</td></tr><tr><td colspan="3">Primers</td></tr><tr><td> nisR-F</td><td>GATGATAAGCTGTCCAAAC</td><td>This work</td></tr><tr><td> nisK-R</td><td>TTTAGGATAACTTCTGCCC</td><td>This work</td></tr><tr><td> 682-1F</td><td>CTCAGACTTTTCTGGTGTAGTAATCGCAGAGGATAG</td><td>This work</td></tr><tr><td> 682-2F</td><td>GCATTATCCTGCCAGTGCTGTTCCAGCCCAAGC</td><td>This work</td></tr><tr><td> 682-3F</td><td>CCATCTTACGATCTGTTTCACCTTGTCATTTAGAGTTTATGCG</td><td>This work</td></tr><tr><td> 682-1R</td><td>CTATCCTCTGCGATTACTACACCAGAAAAGTCTGAG</td><td>This work</td></tr><tr><td> 682-2R</td><td>GCTTGGGCTGGAACAGCACTGGCAGGATAATGC</td><td>This work</td></tr><tr><td> 682-3R</td><td>CGCATAAACTCTAAATGACAAGGTGAAACAGATCGTAAGATGG</td><td>This work</td></tr></table>
e8a0c736b0fbe9d8629352b6bd3f41c06bbfff940445f8defc3f12c209ae0106.png
complex
<table><tr><td>Predictors</td><td colspan="2">Model 8</td><td colspan="2">95% CI</td></tr><tr><td colspan="5"><i>Fixed effects</i></td></tr><tr><td> Intercept</td><td>&#8722;0.81 *</td><td>(0.35)</td><td>&#8722;1.55</td><td>&#8722;0.09</td></tr><tr><td> Ego gender</td><td>0.25</td><td>(0.51)</td><td>&#8722;0.80</td><td>1.30</td></tr><tr><td> Change in activity score<sup>a</sup></td><td>0.38 **</td><td>(0.11)</td><td>0.16</td><td>0.59</td></tr><tr><td> Change in contact frequency<sup>a</sup></td><td>&#8722;0.71 ***</td><td>(0.17)</td><td>&#8722;1.03</td><td>&#8722;0.38</td></tr><tr><td> Participant mean change in activity score</td><td>0.18</td><td>(0.24)</td><td>&#8722;0.31</td><td>0.68</td></tr><tr><td> Participant mean change in contact frequency</td><td>&#8722;0.20</td><td>(0.27)</td><td>&#8722;0.76</td><td>0.35</td></tr><tr><td> Gender &#215; change in activity score</td><td>0.35 *</td><td>(0.15)</td><td>0.06</td><td>0.64</td></tr><tr><td> Gender &#215; change in contact frequency</td><td>0.51 *</td><td>(0.25)</td><td>0.03</td><td>1.00</td></tr><tr><td colspan="5"><i>Covariance parameters</i></td></tr><tr><td> Random intercept (participants)</td><td>1.12 **</td><td>(0.38)</td><td>0.58</td><td>2.20</td></tr></table>
5b54140d2ccbf939ec6b8c191681588794b949c4fd6a84a69677cb90fc0164c2.png
simple
<table><tr><td>miRNA</td><td>RT (Primer)</td><td>PCR (Forward primer)</td><td>PCR (Reverse primer)</td></tr><tr><td>mir-144</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGTACA</td><td>CGGCCGGTACAGTATAGATGA</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-106b*</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCAGCA</td><td>AATGCCGCACTGTGGGTACT</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-669k*</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCACAC</td><td>GCCCGGTGTGCATGTGTGTATAGTT</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-142-3p</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTCCATA</td><td>GCGCTGTAGTGTTTCCTACTT</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-223</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGGGGT</td><td>CCGCCCGTGTCAGTTTGTCAAAT</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-210</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTCAGCC</td><td>AATCCTGTGCGTGTGACAGC</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-32*</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAATATC</td><td>CGCGCGGCCAATTTAGTGTGTGT</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-669C</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACACAC</td><td>CGCGCCATAGTTGTGTGTGGAT</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-466i-5p</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCACACA</td><td>CGCCCTGTGTGTGTGTGTG</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-122*</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTTAGTG</td><td>CGCCCAAACGCCATTATCA</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-34C*</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCCTGGC</td><td>GCCCAATCACTAACCACACA</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>mir-541*</td><td>GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGTATG</td><td>ACACCCTGGCGAACACAGAATC</td><td>GTGCAGGGTCCGAGGT</td></tr><tr><td>U6</td><td></td><td>CTCGCTTCGGCAGCACA</td><td>AACGCTTCACGAATTTGCGT</td></tr></table>
81f4c9186cfb69a47e699fa8f07778634ef6044ae39d8b7e5af554df8bc0a839.png
simple
<table><tr><td>Quality Index items</td><td>Imamura et al. (1998)</td><td>Tillu and Gupta (1998)</td><td>Perez Millan and Foster (2001)</td></tr><tr><td>Reporting</td><td></td><td></td><td></td></tr><tr><td>1. Study hypothesis/aim/objective</td><td>1</td><td>1</td><td>1</td></tr><tr><td>2. Main outcomes</td><td>1</td><td>1</td><td>1</td></tr><tr><td>3. Characteristics of the participants</td><td>0</td><td>0</td><td>0</td></tr><tr><td>4. Interventions of interest</td><td>0</td><td>1</td><td>0</td></tr><tr><td>5. Distributions of principal confounders in each group</td><td>0</td><td>0</td><td>0</td></tr><tr><td>6. Main findings</td><td>0</td><td>1</td><td>1</td></tr><tr><td>7. Estimates of random variability for main outcomes</td><td>1</td><td>0</td><td>1</td></tr><tr><td>8. All the important adverse events that may be a consequence of intervention</td><td>0</td><td>0</td><td>0</td></tr><tr><td>9. Characteristics of patients lost to follow-up</td><td>0</td><td>1</td><td>1</td></tr><tr><td>10. Actual probability values for main outcomes</td><td>0</td><td>1</td><td>0</td></tr><tr><td>External validity</td><td></td><td></td><td></td></tr><tr><td>11. Were subjects who were asked to participate representative of the entire population from which they were recruited?</td><td>1</td><td>1</td><td>0</td></tr><tr><td>12. Were subjects who were prepared to participate representative of the entire population from which they were recruited?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>13. Were the staff, places, and facilities representative of the treatment the majority of subjects received?</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Internal validity (bias)</td><td></td><td></td><td></td></tr><tr><td>14. Was an attempt made to blind subjects to the intervention they received?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>15. Was an attempt made to blind those measuring main outcomes of the intervention?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>16. If any of the results of the study were based on"data dredging", was this made clear?</td><td>0</td><td>1</td><td>1</td></tr><tr><td>17. Do analyses adjust for different lengths of follow-up?</td><td>0</td><td>1</td><td>1</td></tr><tr><td>18. Were appropriate statistical tests used to assess the main outcomes?</td><td>1</td><td>1</td><td>1</td></tr><tr><td>19. Was compliance with the intervention reliable?</td><td>1</td><td>1</td><td>1</td></tr><tr><td>20. Were main outcome measures reliable and valid?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Internal validity (selection bias)</td><td></td><td></td><td></td></tr><tr><td>21. Were patients in different intervention groups recruited from the same population?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>22. Were subjects in different intervention groups recruited over the same period of time?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>23. Were subjects randomized to intervention groups?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>24. Was the randomized intervention assignment concealed from both patients and staff until recruitment was complete and irrevocable?</td><td>0</td><td>0</td><td>0</td></tr><tr><td>* 25. Was there adequate adjustment for confounding in the analyses from which main findings were drawn?</td><td>x</td><td>x</td><td>x</td></tr><tr><td>26. Were losses of subjects to follow-up taken into account?</td><td>0</td><td>1</td><td>1</td></tr><tr><td>Power</td><td></td><td></td><td></td></tr><tr><td>* 27. Did the study have sufficient power to detect a clinically important effect where the probability for a difference due to chance was less than 5%?</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Total score (/27)</td><td>7</td><td>12</td><td>11</td></tr></table>
270e9062448627d6b70a87eae60424d339d349ad52d772a608c6ef40bf49e204.png
simple
<table><tr><td>Paraclinical findings</td><td>Number <sup>a</sup>(%)</td><td>Number <sup>b</sup> (%)</td></tr><tr><td>Chest X ray</td><td></td><td></td></tr><tr><td>Normal</td><td>98 (94,2)</td><td>57 (96,6)</td></tr><tr><td>Abnormal</td><td>6 (5,8)</td><td>3 (5,1)</td></tr><tr><td>Cardiomegaly</td><td>2 (1,9)</td><td>1 (1,7)</td></tr><tr><td>Enlargement of the superior mediastinum</td><td>3 (2,9)</td><td>1 (1,7)</td></tr><tr><td>Interstitial Syndrome</td><td>1 (1)</td><td>0</td></tr><tr><td>Spirometry</td><td></td><td></td></tr><tr><td>Normal</td><td>94 (90,4)</td><td>56</td></tr><tr><td>Restrictive profile</td><td>7 (6,7)</td><td>1 (1,7)</td></tr><tr><td>Obstructive ventilatory defect</td><td>3 (2,9)</td><td>2 (3,4)</td></tr><tr><td>Electrocardiogram</td><td></td><td></td></tr><tr><td>Normal</td><td>92 (88,5)</td><td>54</td></tr><tr><td>Abnormal</td><td>12 (11,5)</td><td>5 (8,5)</td></tr><tr><td>Right atrial hypertrophy</td><td>10 (9,6)</td><td>4 (6,8)</td></tr><tr><td>Arrhythmia</td><td>2 (1,9)</td><td>1 (1,7)</td></tr></table>
f264aae8790a95279eacb32dcab0bc719e51a0910718308adb528a728cf083dc.png
complex
<table><tr><td rowspan="2">PANTHER Pathways</td><td rowspan="2">Annotated</td><td colspan="4">Dapulian (DT_DC)</td><td colspan="4">Landrace (LT_LC)</td></tr><tr><td>Significant</td><td>Expected</td><td>Fold Enrichment</td><td><i>p</i>-Value</td><td>Significant</td><td>Expected</td><td>Fold Enrichment</td><td><i>p</i>-Value</td></tr><tr><td>Angiogenesis (P00005)</td><td>147</td><td>27</td><td>13.37</td><td>2.02</td><td>6.50 &#215; 10<sup>&#8722;</sup><sup>4</sup></td><td>27</td><td>14.56</td><td>1.85</td><td>2.16 &#215; 10<sup>&#8722;</sup><sup>3</sup></td></tr><tr><td>Cholecystokinin receptor(CCKR) signaling map (P06959)</td><td>155</td><td>30</td><td>14.1</td><td>2.13</td><td>1.43 &#215; 10<sup>&#8722;</sup><sup>4</sup></td><td>23</td><td>15.35</td><td>1.5</td><td>4.00 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Epidermal growth factor (EGF) receptor signaling pathway (P00018)</td><td>134</td><td>24</td><td>12.19</td><td>1.97</td><td>1.73 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>23</td><td>13.27</td><td>1.73</td><td>9.35 &#215; 10<sup>&#8722;</sup><sup>3</sup></td></tr><tr><td>Fibroblast growth factor (FGF) signaling pathway (P00021)</td><td>124</td><td>21</td><td>11.28</td><td>1.86</td><td>5.97 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>19</td><td>12.28</td><td>1.55</td><td>4.47 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Parkinson disease (P00049)</td><td>104</td><td>20</td><td>9.46</td><td>2.11</td><td>1.82 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>23</td><td>10.3</td><td>2.23</td><td>4.26 &#215; 10<sup>&#8722;</sup><sup>4</sup></td></tr><tr><td>PI3 kinase pathway (P00048)</td><td>45</td><td>10</td><td>4.09</td><td>2.44</td><td>9.36 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>11</td><td>4.46</td><td>2.47</td><td>6.18 &#215; 10<sup>&#8722;</sup><sup>3</sup></td></tr><tr><td>Ras Pathway (P04393)</td><td>80</td><td>22</td><td>7.28</td><td>3.02</td><td>7.76 &#215; 10<sup>&#8722;</sup><sup>6</sup></td><td>14</td><td>7.92</td><td>1.77</td><td>3.17 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>T cell activation (P00053)</td><td>83</td><td>16</td><td>7.55</td><td>2.12</td><td>4.81 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>15</td><td>8.22</td><td>1.82</td><td>2.11 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Toll receptor signaling pathway (P00054)</td><td>59</td><td>10</td><td>5.37</td><td>1.86</td><td>4.69 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>11</td><td>5.84</td><td>1.88</td><td>3.63 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Ubiquitin proteasome pathway (P00060)</td><td>65</td><td>11</td><td>5.91</td><td>1.86</td><td>3.89 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>13</td><td>6.44</td><td>2.02</td><td>1.48 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Gonadotropin releasing hormone receptor pathway (P06664)</td><td>223</td><td>41</td><td>20.28</td><td>2.02</td><td>3.09 &#215; 10<sup>&#8722;</sup><sup>5</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Apoptosis signaling pathway (P00006)</td><td>129</td><td>24</td><td>11.73</td><td>2.05</td><td>1.06 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Fas signaling pathway (P00020)</td><td>41</td><td>11</td><td>3.73</td><td>2.95</td><td>1.65 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Vascaular endothelial growth factor (VEGF) signaling pathway (P00056)</td><td>61</td><td>13</td><td>5.55</td><td>2.34</td><td>4.71 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Integrin signaling pathway (P00034)</td><td>153</td><td>24</td><td>13.92</td><td>1.72</td><td>8.50 &#215; 10<sup>&#8722;</sup><sup>3</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>p53 pathway feedback loops 2 (P04398)</td><td>53</td><td>11</td><td>4.82</td><td>2.28</td><td>1.06 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>De novo purine biosynthesis (P02738)</td><td>46</td><td>10</td><td>4.18</td><td>2.39</td><td>1.08 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Oxidative stress response (P00046)</td><td>29</td><td>7</td><td>2.64</td><td>2.65</td><td>1.83 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Transforming growth factor beta(TGF-&#946;) signaling pathway (P00052)</td><td>90</td><td>15</td><td>8.19</td><td>1.83</td><td>2.04 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Hypoxia response via HIF activation (P00030)</td><td>30</td><td>7</td><td>2.73</td><td>2.57</td><td>2.15 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Platelet derived growth factor (PDGF) signaling pathway (P00047)</td><td>141</td><td>21</td><td>12.82</td><td>1.64</td><td>2.17 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Interleukin signaling pathway (P00036)</td><td>101</td><td>16</td><td>9.19</td><td>1.74</td><td>2.56 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Inflammation mediated by chemokine and cytokine signaling pathway (P00031)</td><td>228</td><td>30</td><td>20.74</td><td>1.45</td><td>3.19 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Heme biosynthesis (P02746)</td><td>14</td><td>4</td><td>1.27</td><td>3.14</td><td>4.04 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032)</td><td>35</td><td>7</td><td>3.18</td><td>2.2</td><td>4.35 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>p53 pathway (P00059)</td><td>92</td><td>14</td><td>8.37</td><td>1.67</td><td>4.60 &#215; 10<sup>&#8722;</sup><sup>2</sup></td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Coenzyme A biosynthesis (P02736)</td><td>11</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>5</td><td>1.09</td><td>4.59</td><td>5.21 &#215; 10<sup>&#8722;</sup><sup>3</sup></td></tr><tr><td>Salvage pyrimidine ribonucleotides (P02775)</td><td>13</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>5</td><td>1.29</td><td>3.88</td><td>1.02 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>B cell activation (P00010)</td><td>68</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>13</td><td>6.74</td><td>1.93</td><td>2.05 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>General transcription regulation (P00023)</td><td>34</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>8</td><td>3.37</td><td>2.38</td><td>2.19 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Lysine biosynthesis (P02751)</td><td>6</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>3</td><td>0.59</td><td>&gt;5</td><td>2.25 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Insulin/insulin-like growth factor (IGF) pathway-protein kinase B signaling cascade (P00033)</td><td>49</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>10</td><td>4.85</td><td>2.06</td><td>2.67 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Angiotensin II-stimulated signaling through G proteins and &#946;-arrestin (P05911)</td><td>30</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>7</td><td>2.97</td><td>2.36</td><td>3.20 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr><tr><td>Notch signaling pathway (P00045)</td><td>40</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>8</td><td>3.96</td><td>2.02</td><td>4.88 &#215; 10<sup>&#8722;</sup><sup>2</sup></td></tr></table>
f651d356110361baf4d819bc9a1d1c9acc82a11c0790b60b00e7aded52a1cc11.png
complex
<table><tr><td colspan="2">Diagnosis</td></tr><tr><td>Guillain-Barre&#769; syndrome, n (%)</td><td>26 (63.4)</td></tr><tr><td>Autoimmune encephalitis, n (%)</td><td>6 (14.6)</td></tr><tr><td>Miller-Fisher syndrome, n (%)</td><td>2 (4.9)</td></tr><tr><td>Chronic relapsing inflammatory optic neuropathy (CRION), n (%)</td><td>1 (2.4)</td></tr><tr><td>Multiple sclerosis, n (%)</td><td>1 (2.4)</td></tr><tr><td>Parainfectious myelitis, n (%)</td><td>1 (2.4)</td></tr><tr><td>Myasthenia gravis, n (%)</td><td>1 (2.4)</td></tr><tr><td>Anti-Yo-associated paraneoplastic cerebellar degeneration, n (%)</td><td>1 (2.4)</td></tr><tr><td>Anti-Hu-associated polyneuropathy, n (%)</td><td>1 (2.4)</td></tr><tr><td>Neuromyelitis optica, n (%)</td><td>1 (2.4)</td></tr></table>
8b80577db167aa6bcca43dfbeec45cd34a16f9a7c688580ab2e081cc42fe1032.png
simple
<table><tr><td>Variables</td><td>Algorithm</td></tr><tr><td>P(X) = base rate of event for person X</td><td>Produce a time series for C and S events:</td></tr><tr><td>P(X|Y) = rate of event for X given Y did</td><td></td></tr><tr><td>P(X|X) = probability of event repetition</td><td>Do 1000 timesIf rand &lt; P(C)C outputs event (=1)Else if rand &lt; P(C|C) and C = 1C outputs eventOtherwiseC outputs no event (=0)If rand &lt; P(S|C) and C = 1S outputs event (=1)Else if rand &lt; P(S)S outputs eventElse if rand &lt; P(S|S) and S = 1S outputs eventOtherwiseS outputs no event (=0)</td></tr></table>
dd8ba999bea83867d1033b5532e65cca641153c377aaa2118c76771e5d62e088.png
complex
<table><tr><td></td><td>Disability screening but not in regression model</td><td>In regression model</td><td>p Value</td><td>Number of missing values/4219 (%)</td></tr><tr><td>Allocation to intervention in original trial</td><td>316/901 (35%)</td><td>1786/3318 (54%)</td><td>&lt;0.001</td><td rowspan="4"></td></tr><tr><td>Household appliance score: none of assets on list</td><td>475/901 (53%)</td><td>1754/3318 (53%)</td><td rowspan="2">0.801</td></tr><tr><td>Household appliance score: most expensive assets</td><td>58/901 (6%)</td><td>187/3318 (6%)</td></tr><tr><td>Positive disability screen</td><td>73/901 (8%)</td><td>241/3318 (7%)</td><td>0.395</td></tr><tr><td colspan="5">Included in initial regression model but dropped from final model</td></tr><tr><td> Four skilled antenatal care visits</td><td>87/901 (10%)</td><td>296/3315 (9%)</td><td>0.501</td><td>3 (&lt;1%)</td></tr><tr><td> Possible symptoms of preeclampsia</td><td>499/873 (57%)</td><td>1697/3210 (53%)</td><td>0.024</td><td>136 (3%)</td></tr><tr><td> Delivery room heated</td><td>681/901 (76%)</td><td>2651/3318 (80%)</td><td>0.005</td><td>0</td></tr><tr><td> Infant had fever in neonatal period</td><td>156/901 (17%)</td><td>489/3318 (15%)</td><td>0.057</td><td>0</td></tr><tr><td colspan="5">Retained in final logistic regression model</td></tr><tr><td> Maternal underweight (BMI&lt;18&#8729;5)</td><td>89/675 (13%)</td><td>382/3318 (12%)</td><td>0.220</td><td>226 (5%)</td></tr><tr><td> Mother cohabited with husband when &lt;16 years old</td><td>178/716 (25%)</td><td>812/3318 (24%)</td><td>0.827</td><td>185 (4%)</td></tr><tr><td> Skilled birth attendant</td><td>18/733 (3%)</td><td>91/3318 (3%)</td><td>0.664</td><td>168 (4%)</td></tr><tr><td> Infant size &#8216;very small&#8217;</td><td>12/901 (1%)</td><td>108/3318 (3%)</td><td>0.002</td><td>0</td></tr><tr><td> Infant illness: diarrhoea and repeated vomiting</td><td>46/901 (5%)</td><td>159/3318 (5%)</td><td>0.698</td><td>0</td></tr><tr><td> Mean weight in grams at 1 month (SD)</td><td>4395(963) n=335</td><td>4271(898) n=3318</td><td>0.017</td><td>566 (13%)</td></tr></table>
42bffe36394f38aaa0a49f1caa549740fe5dc41752cabf5e8e534a70ba6cb041.png
simple
<table><tr><td>Target</td><td>Active compounds</td><td>Inactive compounds</td><td>Ratio (active/inactive compounds)</td><td>Sensitivity</td><td>Precision</td><td>Specificity</td><td>&#954;</td></tr><tr><td>PPARA</td><td>1955</td><td>1465</td><td>1.33</td><td>0.96</td><td>0.94</td><td>0.92</td><td>0.89</td></tr><tr><td>MMP2</td><td>2742</td><td>2363</td><td>1.16</td><td>0.96</td><td>0.96</td><td>0.96</td><td>0.92</td></tr><tr><td>MAOA</td><td>732</td><td>733</td><td>1.00</td><td>0.79</td><td>0.80</td><td>0.81</td><td>0.59</td></tr><tr><td>NR1I2</td><td>249</td><td>1090</td><td>0.23</td><td>0.82</td><td>0.73</td><td>0.93</td><td>0.72</td></tr><tr><td>TMPRSS15</td><td>139</td><td>724</td><td>0.19</td><td>0.43</td><td>0.54</td><td>0.93</td><td>0.39</td></tr><tr><td>HSD17B10</td><td>3410</td><td>11,510</td><td>0.30</td><td>0.41</td><td>0.40</td><td>0.82</td><td>0.23</td></tr><tr><td>KDM4E</td><td>3938</td><td>35,059</td><td>0.11</td><td>0.22</td><td>0.29</td><td>0.94</td><td>0.18</td></tr><tr><td>LMNA</td><td>14,533</td><td>171,164</td><td>0.09</td><td>0.49</td><td>0.13</td><td>0.72</td><td>0.10</td></tr><tr><td>TDP1</td><td>23,133</td><td>276,782</td><td>0.08</td><td>0.76</td><td>0.38</td><td>0.90</td><td>0.45</td></tr><tr><td>TARDBP</td><td>12,193</td><td>387,934</td><td>0.03</td><td>0.22</td><td>0.08</td><td>0.92</td><td>0.08</td></tr><tr><td>ALOX15</td><td>1932</td><td>69,362</td><td>0.03</td><td>0.49</td><td>0.12</td><td>0.90</td><td>0.16</td></tr><tr><td>BRCA1</td><td>8619</td><td>363,912</td><td>0.02</td><td>0.72</td><td>0.20</td><td>0.93</td><td>0.29</td></tr><tr><td>DRD2</td><td>4613</td><td>343,076</td><td>0.01</td><td>0.96</td><td>0.93</td><td>1.00</td><td>0.94</td></tr><tr><td>GSK3B</td><td>3334</td><td>300,186</td><td>0.01</td><td>0.85</td><td>0.72</td><td>1.00</td><td>0.78</td></tr><tr><td>JAK2</td><td>2158</td><td>213,915</td><td>0.01</td><td>0.85</td><td>0.81</td><td>1.00</td><td>0.83</td></tr><tr><td>POLK</td><td>773</td><td>389,418</td><td>0.002</td><td>0.55</td><td>0.17</td><td>0.99</td><td>0.26</td></tr><tr><td>FEN1</td><td>1050</td><td>381,575</td><td>0.003</td><td>0.35</td><td>0.03</td><td>0.96</td><td>0.04</td></tr><tr><td>HDAC3</td><td>369</td><td>311,425</td><td>0.001</td><td>0.98</td><td>0.76</td><td>1.00</td><td>0.86</td></tr></table>
3c4356618f329d537c601cae15a87d2103b4f2923a7609219ee5f6af864f3d78.png
complex
<table><tr><td>Prediction set</td><td>Published [14]</td><td>BRAKER1/soft-masked</td></tr><tr><td>Number of protein coding genes predicted</td><td>20,964</td><td>15,747</td></tr><tr><td>Mean protein length (amino acids)</td><td>218.8</td><td>344.5</td></tr><tr><td>Number of single exon genes</td><td>1,728</td><td>2,326</td></tr><tr><td>Mean number of exons per gene<sup>a</sup></td><td>5.9</td><td>7.8</td></tr><tr><td>Proportion of noncanonical (GC-AG) introns</td><td>8.87%</td><td>0.79%</td></tr><tr><td colspan="3">Percentage mapping to publicly available transcriptome reads</td></tr><tr><td><i>Sanger ESTs</i></td><td>80.45%</td><td>84.26%</td></tr><tr><td><i>Roche 454 reads</i></td><td>37.18%</td><td>58.03%</td></tr><tr><td colspan="3">BUSCO score for proteome</td></tr><tr><td><i>Complete</i></td><td>47.8%</td><td>94%</td></tr><tr><td><i>Fragmented</i></td><td>34.7%</td><td>4.3%</td></tr><tr><td>Number of proteins with no hits in Uniref90</td><td>8,962</td><td>2,889</td></tr><tr><td>Protein singletons in clustering</td><td>5,442</td><td>1,112</td></tr><tr><td colspan="3">Conserved, single-copy orthologues<sup>b</sup></td></tr><tr><td><i>Total</i></td><td>2,089</td><td>2,330</td></tr><tr><td><i>Missing</i></td><td>377</td><td>141</td></tr><tr><td><i>Expanded</i></td><td>184</td><td>84</td></tr></table>
b578e2102183ba1d6e70b2573940749a25475b0d5aa145241f48445d14c8b369.png
simple
<table><tr><td>Factors</td><td><i>B</i></td><td>SE</td><td>Df</td><td>Sig.</td><td>Exp ( <i>B </i>)</td><td>95% confidence interval lower/upper</td></tr><tr><td>Sex</td><td>&#8722;0.795</td><td>0.857</td><td>1</td><td>0.354</td><td>0.452</td><td>0.084/2.423</td></tr><tr><td>Age</td><td>0.135</td><td>0.061</td><td>1</td><td>0.026</td><td>1.145</td><td>1.016/1.291</td></tr><tr><td>FEV1 (%)</td><td>0.018</td><td>0.026</td><td>1</td><td>0.490</td><td>1.018</td><td>0.968/1.070</td></tr><tr><td>Tumour side</td><td>0.014</td><td>0.597</td><td>1</td><td>0.982</td><td>1.014</td><td>0.314/3.268</td></tr><tr><td>pT*</td><td>1.390</td><td>0.424</td><td>1</td><td>0.001</td><td>4.014</td><td>1.749/9.213</td></tr><tr><td>pN**</td><td>0.796</td><td>0.576</td><td>1</td><td>0.167</td><td>2.217</td><td>0.717/6.861</td></tr><tr><td>Neoadjuvant</td><td>&#8722;0.579</td><td>0.800</td><td>1</td><td>0.469</td><td>0.561</td><td>0.117/2.687</td></tr></table>
4a74271fe8a62a2b15ba6e649df2b52089f1aa4d8dafb0a70a62a7184d56a9a1.png
simple
<table><tr><td>Organism</td><td>Group</td><td>tag</td><td>Lanes in Figure 2</td></tr><tr><td><i>Gallus gallus</i></td><td>Animals</td><td>CACTCACAAGCTCGACGTACAC</td><td>1 and 8</td></tr><tr><td><i>Canis familiaris</i></td><td>Animals</td><td>CAGACAGCACTCGTTCGTACAC</td><td>2 and 9</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>Plants</td><td>GACTGAACGTGCTCTGCTACTG</td><td>3 and 10</td></tr><tr><td><i>Sulfolobus acidocaldarius </i>str. DSM639</td><td>Crenarchaeota</td><td>CAGTCACAGCACACGAGTACAC</td><td>4 and 11</td></tr><tr><td><i>Bartonella henselae </i>str. Houston-1</td><td>Alphaproteobacteria</td><td>CAGACACGAGCAACGACTACAC</td><td>5 and 12</td></tr><tr><td><i>Bartonella henselae </i>str. UGA 8</td><td>Alphaproteobacteria</td><td>CAGACACGAGCAACGACTACAC</td><td>6 and 13</td></tr><tr><td><i>Anabaena </i>PCC7120</td><td>Cyanobacteria</td><td>CACTCTGTGCTCGTTGCTACAC</td><td>(Figure 3)</td></tr><tr><td><i>Synechocystis </i>PCC 6803</td><td>Cyanobacteria</td><td>CAGACAGCAAGCAGCACTACAC</td><td>(Figure 3)</td></tr></table>
e3c70c4c9c0ab48127a95f4c58aea08cdf30c5de3a290b086af6808a485c5b1d.png
complex
<table><tr><td rowspan="3"></td><td colspan="2">Odds Ratio (95% Confidence Interval)</td></tr><tr><td colspan="2">Any pneumococcal serotype</td></tr><tr><td><i>Univariable</i></td><td><i>Multivariable</i></td></tr><tr><td>Male</td><td><i>1.56 (1.35</i>&#8211;<i>1.81)</i></td><td>0.81 (0.67&#8211;0.99)</td></tr><tr><td colspan="3">Age increase by 12 months</td></tr><tr><td> 0&#8211;11 months</td><td><i>4.60 (2.83</i>&#8211;<i>7.50)</i></td><td><i>4.19 (2.39</i>&#8211;<i>7.33)</i></td></tr><tr><td> 1 to 19 yr</td><td><i>0.85 (0.84</i>&#8211;<i>0.87)</i></td><td><i>0.85 (0.84</i>&#8211;<i>0.87)</i></td></tr><tr><td> 20 + years</td><td>0.99 (0.98&#8211;1.01)</td><td>1.00 (0.99&#8211;1.02)</td></tr><tr><td colspan="3">Annual increase</td></tr><tr><td> Pre-PCV13</td><td>1.07 (0.98&#8211;1.18)</td><td><i>0.86 (0.75</i>&#8211;<i>0.98)</i></td></tr><tr><td> Post-PCV13</td><td>0.88 (0.75&#8211;1.05)</td><td><i>1.37 (1.08</i>&#8211;<i>1.74)</i></td></tr><tr><td>Respiratory symptoms</td><td><i>1.48 (1.14</i>&#8211;<i>1.94)</i></td><td>1.01 (0.72&#8211;1.43)</td></tr><tr><td>Nasal discharge</td><td><i>4.84 (4.01</i>&#8211;<i>5.74)</i></td><td><i>2.49 (2.00</i>&#8211;<i>3.09)</i></td></tr><tr><td>Recent antibiotic use</td><td><i>0.73 (0.55</i>&#8211;<i>0.98)</i></td><td><i>0.48 (0.33</i>&#8211;<i>0.69)</i></td></tr><tr><td colspan="3">Remoteness</td></tr><tr><td> Metropolitan</td><td>Ref</td><td>Ref</td></tr><tr><td> Regional</td><td>1.36 (0.97&#8211;1.89)</td><td>1.31 (0.88&#8211;1.96)</td></tr><tr><td> Remote</td><td><i>1.86 (1.47</i>&#8211;<i>2.35)</i></td><td><i>2.21 (1.67</i>&#8211;<i>2.92)</i></td></tr><tr><td>ETS</td><td><i>1.24 (1.06</i>&#8211;<i>1.46)</i></td><td>1.06 (0.87&#8211;1.29)</td></tr><tr><td>&#8805;5 people sharing (crowding)</td><td><i>1.35 (1.15</i>&#8211;<i>1.58)</i></td><td><i>1.36 (1.11</i>&#8211;<i>1.67)</i></td></tr><tr><td>Sharing with &#8805;1 child &lt;5 years</td><td>1.15 (0.96&#8211;1.37)</td><td>1.07 (0.85&#8211;1.34)</td></tr><tr><td colspan="3">Season</td></tr><tr><td> Spring</td><td>Ref</td><td>Ref</td></tr><tr><td> Summer</td><td>0.91 (0.66&#8211;1.27)</td><td>0.95 (0.62&#8211;1.45)</td></tr><tr><td> Autumn</td><td>0.86 (0.70&#8211;1.07)</td><td>1.35 (0.91&#8211;2.00)</td></tr><tr><td> Winter</td><td><i>1.29 (1.08</i>&#8211;<i>1.53)</i></td><td>1.11 (0.73&#8211;1.69)</td></tr><tr><td><i>H. influenzae</i></td><td><i>10.29 (8.60</i>&#8211;<i>12.30)</i></td><td>N/A</td></tr><tr><td><i>M. catarrhalis</i></td><td><i>7.10 (6.01</i>&#8211;<i>8.39)</i></td><td>N/A</td></tr><tr><td><i>S. aureus</i></td><td><i>0.56 (0.44</i>&#8211;<i>0.72)</i></td><td>N/A</td></tr></table>
6e4e7848c07eb51819c9134d9ff25de079b274d467141912f10ebb441632b4b3.png
complex
<table><tr><td>Parameter</td><td colspan="3">Responders (n = 15)</td><td colspan="3">Nonresponders (n = 13)</td></tr><tr><td></td><td>Baseline</td><td>Before INO</td><td><i>P </i>value</td><td>Baseline</td><td>Before INO</td><td><i>P </i>value</td></tr><tr><td>Leucocytes (10<sup>6</sup>/ml)</td><td>10.4 &#177; 4.4</td><td>1.6 &#177; 1.0<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>8.8 &#177; 2.4</td><td>0.9 &#177; 0.3* <sup>&#8224;</sup></td><td>&#8804; 0.01</td></tr><tr><td>Neutrophils (%)</td><td>56 &#177; 12</td><td>65 &#177; 14</td><td>0.074</td><td>53 &#177; 10</td><td>48 &#177; 17*</td><td>0.45</td></tr><tr><td>Macrophage (%)</td><td>44 &#177; 12</td><td>34 &#177; 15</td><td>0.064</td><td>47 &#177; 10</td><td>51 &#177; 17*</td><td>0.45</td></tr><tr><td>Thrombocytes (10<sup>6</sup>/ml)</td><td>408 &#177; 77</td><td>185 &#177; 54<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>355 &#177; 61</td><td>175 &#177; 68<sup>&#8224;</sup></td><td>&#8804; 0.01</td></tr><tr><td>Proteins (mg/ml)</td><td>47 &#177; 6.0</td><td>33 &#177; 5.4<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>46 &#177; 6</td><td>34 &#177; 5<sup>&#8224;</sup></td><td>&#8804; 0.01</td></tr><tr><td>Endotoxin (pg/ml)</td><td>0</td><td>45 (3.8 to 296)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>0 (0 to 4.5)</td><td>32 (0 to 392)<sup>&#8224;</sup></td><td>0.011</td></tr><tr><td>Endothelin-1 (pg/ml)</td><td>0</td><td>3.0 (1.8 to 8)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>0</td><td>0.1 (0.1 to 8)</td><td>0.31</td></tr><tr><td>PGF<sub>2&#945; </sub>(pg/ml)</td><td>265 (236 to 327)</td><td>759 (356 to 1498)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>218 (171 to 512)</td><td>380 (342 to 1632)<sup>&#8224;</sup></td><td>&#8804; 0.01</td></tr><tr><td>TXB<sub>2 </sub>(pg/ml)</td><td>692 (530 to 778)</td><td>2881 (860 to 4504)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>643 (574 to 821)</td><td>3883 (2286 to 5051)<sup>&#8224;</sup></td><td>&#8804; 0.01</td></tr><tr><td>6-keto-PGF<sub>1&#945; </sub>(pg/ml)</td><td>291 (232 to 323)</td><td>1023 (810 to 1560)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>518 (274 to 899)</td><td>603 (557 to 1099)</td><td>0.33</td></tr><tr><td>LTB<sub>4 </sub>(pg/ml)</td><td>28 (16 to 41)</td><td>372 (41 to 486)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>38 (9 to 48)</td><td>274 (46 to 414)<sup>&#8224;</sup></td><td>&#8804; 0.01</td></tr><tr><td>TNF&#945; (pg/ml)</td><td>15 (11 to 22)</td><td>18 (10 to 39)</td><td>0.083</td><td>12 (8 to 21)</td><td>10 (5 to 27)</td><td>1.0</td></tr><tr><td>IL-8 (ng/ml)</td><td>0</td><td>24(7.2 to 32)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>0</td><td>4 (1.5 to 47)<sup>&#8224;</sup></td><td>0.03</td></tr><tr><td>Nitrates (nmol/ml)</td><td>212 (173 to 352)</td><td>183 (147 to 236)<sup>&#8224;</sup></td><td>&#8804; 0.01</td><td>183 (133 to 255)</td><td>173 (150 to 212)</td><td>0.58</td></tr></table>
4802dd782ee295a7c8ec86bc1f3e4b8bd0dfde785ea9bf05a720230b974a234c.png
simple
<table><tr><td>Breast Clinicopathological details</td><td>Cancer</td><td>Fibroadenoma</td><td>Normal</td></tr><tr><td>Number of patients</td><td>103</td><td>35</td><td>30</td></tr><tr><td>Median Patient Age yrs</td><td>56 (35-90)</td><td>44 (17-62)</td><td>46.5 (24-58)</td></tr><tr><td>Menopausal Status</td><td></td><td></td><td></td></tr><tr><td>Post</td><td>72</td><td></td><td></td></tr><tr><td>Pre</td><td>32</td><td></td><td></td></tr><tr><td>Histological Subtype</td><td></td><td></td><td></td></tr><tr><td>Invasive Ductal</td><td>78</td><td></td><td></td></tr><tr><td>Invasive Lobular</td><td>11</td><td></td><td></td></tr><tr><td><i>Other</i></td><td><i>14</i></td><td></td><td></td></tr><tr><td>Intrinsic Subtype</td><td></td><td></td><td></td></tr><tr><td>Luminal A (ER/PR+, HER2/neu-)</td><td>42</td><td></td><td></td></tr><tr><td>Luminal B (ER/PR+, HER2/neu+)</td><td>18</td><td></td><td></td></tr><tr><td>HER2 Over expressing (ER-, PR-, HER2/neu+)</td><td>16</td><td></td><td></td></tr><tr><td>Triple-Negative (ER-, PR-, HER2/neu-)</td><td>16</td><td></td><td></td></tr><tr><td><i>Unknown</i></td><td><i>11</i></td><td></td><td></td></tr><tr><td>Tumour Grade</td><td></td><td></td><td></td></tr><tr><td>1</td><td>5</td><td></td><td></td></tr><tr><td>2</td><td>32</td><td></td><td></td></tr><tr><td>3</td><td>55</td><td></td><td></td></tr><tr><td>Tumour size</td><td></td><td></td><td></td></tr><tr><td>1</td><td>19</td><td></td><td></td></tr><tr><td>2</td><td>39</td><td></td><td></td></tr><tr><td>3</td><td>10</td><td></td><td></td></tr><tr><td>UICC Stage</td><td></td><td></td><td></td></tr><tr><td>Stage 1</td><td>23</td><td></td><td></td></tr><tr><td>Stage 2</td><td>36</td><td></td><td></td></tr><tr><td>Stage 3</td><td>21</td><td></td><td></td></tr><tr><td>Stage 4</td><td>10</td><td></td><td></td></tr></table>
714a81da5b0bbb63079b1a6f5773bb379729518134a6cb28a39f8e5947cb531c.png
complex
<table><tr><td></td><td colspan="2">Estrogen</td><td colspan="2">Progesterone</td><td colspan="3">Her-2</td></tr><tr><td>Polymorphisms</td><td>Negative</td><td>Positive</td><td>Negative</td><td>Positive</td><td>Negative</td><td>Positive</td><td>Inconclusive</td></tr><tr><td>rs3803662 - TT N (%)</td><td>13 (16.5)</td><td>20 (18.0)</td><td>16 (18.0)</td><td>17 (16.5)</td><td>23 (16.9)</td><td>7 (14.9)</td><td>3 (100.0)</td></tr><tr><td>rs3803662 - TC N (%)</td><td>33 (41.8)</td><td>56 (50.5)</td><td>51 (41.8)</td><td>38 (42,7)</td><td>66 (48.5)</td><td>21 (44.7)</td><td>0 (0.0)</td></tr><tr><td>rs3803662 &#8211; CC N (%)</td><td>33 (41.8)</td><td>35 (31.5)</td><td>46 (37.7)</td><td>35 (39.3)</td><td>47 (34.6)</td><td>19 (40.4)</td><td>0 (0.0)</td></tr><tr><td>Total</td><td>79 (100.0)</td><td>111 (100.0)</td><td>122 (100.0)</td><td>89 (100.0)</td><td>136 (100.0)</td><td>47 (100.0)</td><td>3 (100.0)</td></tr><tr><td>P value<sup>a</sup></td><td colspan="2">0.257</td><td colspan="2">0.504</td><td colspan="3">0.469</td></tr><tr><td>rs2981582 &#8211; TT N (%)</td><td>15 (219.2)</td><td>31 (27.2)</td><td>16 (18.0)</td><td>30 (28.6)</td><td>33 (23.9)</td><td>21 (25.5)</td><td>1 (33.4)</td></tr><tr><td>rs2981582 &#8211; TC</td><td>38 (48.7)</td><td>60 (52.6)</td><td>47 (52.8)</td><td>52 (49.5)</td><td>65 (47.1)</td><td>28 (59.6)</td><td>2 (66.6)</td></tr><tr><td>N (%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>rs2981582 &#8211; CC</td><td>25 (32.1)</td><td>23 (20.2)</td><td>26 (29.2)</td><td>23 (21.9)</td><td>40 (29.0)</td><td>7 (14.9)</td><td>0 (0.0)</td></tr><tr><td><sup>N (%)</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total</td><td>78 (100.0)</td><td>114 (100.0)</td><td>89 (100.0)</td><td>105 (100.0)</td><td>138 (100.0)</td><td>47 (100.0)</td><td>3 (100.0)</td></tr><tr><td>P value<sup>a</sup></td><td colspan="2">0.054</td><td colspan="2">0.076</td><td colspan="3">0.120</td></tr><tr><td>rs13281615 - AA N (%)</td><td>20 (25.3)</td><td>30 (26.3)</td><td>26 (28.9)</td><td>25 (23.8)</td><td>32 (23.2)</td><td>14 (29.2)</td><td>2 (66.6)</td></tr><tr><td>rs13281615 - AG N (%)</td><td>35 (44.3)</td><td>56 (49.1)</td><td>40 (44.4)</td><td>51 (48.6)</td><td>68 (49.3)</td><td>20 (41.7)</td><td>1 (33.4)</td></tr><tr><td>rs13281615 - GG N (%)</td><td>24 (30.4)</td><td>28 (24.6)</td><td>24 (26.7)</td><td>29 (27.6)</td><td>38 (27.5)</td><td>14 (29.2)</td><td>0 (0.0)</td></tr><tr><td>Total</td><td>79 (100.0)</td><td>114 (100.0)</td><td>90 (100.0)</td><td>105 (100.0)</td><td>138 (100.0)</td><td>48 (100.0)</td><td>3 (100.0)</td></tr><tr><td>P value<sup>a</sup></td><td colspan="2">0.523</td><td colspan="2">0.566</td><td colspan="3">0.291</td></tr><tr><td>rs889312 - CC N (%)</td><td>12 (15.2)</td><td>15 (13.2)</td><td>10 (11,1)</td><td>17 (16.2)</td><td>21 (15.2)</td><td>5 (10.4)</td><td>0 (0.0)</td></tr><tr><td>rs889312 - CA N (%)</td><td>35 (44.3)</td><td>54 (47.4)</td><td>45 (50.0)</td><td>45 (42.9)</td><td>61 (44.2)</td><td>25 (52.1)</td><td>1 (33.3)</td></tr><tr><td>rs889312 - AA N (%)</td><td>32 (40.5)</td><td>45 (39.5)</td><td>35 (38.9)</td><td>43 (41.0)</td><td>56 (40.6)</td><td>18 (37.5)</td><td>2 (66.7)</td></tr><tr><td>Total</td><td>79 (100.0)</td><td>114 (100.0)</td><td>90 (100.0)</td><td>105 (100.0)</td><td>138 (100.0)</td><td>48 (100.0)</td><td>3 (100.0)</td></tr><tr><td>P value<sup>a</sup></td><td colspan="2">0.921</td><td colspan="2">0.760</td><td colspan="3">0.554</td></tr><tr><td>rs3817198 - TT N (%)</td><td>42 (53.8)</td><td>51 (44.7)</td><td>49 (55.1)</td><td>45 (42,9)</td><td>68 (49.3)</td><td>21 (44.7)</td><td>0 (0.0)</td></tr><tr><td>rs3817198 - TC N (%)</td><td>31 (39,7)</td><td>54 (47.4)</td><td>34 (38.2)</td><td>52 (49,5)</td><td>59 (42.8)</td><td>23 (48.9)</td><td>3 (100)</td></tr><tr><td>rs3817198 - CC N (%)</td><td>5 (6.4)</td><td>9 (7.9)</td><td>6 (6.7)</td><td>8 (7.6)</td><td>11 (8.0)</td><td>3 (6.4)</td><td>0 (0.0)</td></tr><tr><td>Total</td><td>78 (100.0)</td><td>114 (100.0)</td><td>89 (100.0)</td><td>105 (100.0)</td><td>138 (100.0)</td><td>47 (100.0)</td><td>3 (100.0)</td></tr><tr><td>P value<sup>a</sup></td><td colspan="2">0.248</td><td colspan="2">0.145</td><td colspan="3">0.449</td></tr></table>
c4124da5a7eaa654384f22034e94a8e7d1b14ae6e1be48ca242c720c29c3ec23.png
complex
<table><tr><td></td><td>Participants from wards with high staff morale<sup>a</sup> (<i>n</i> = 12)</td><td>Participants from wards with low staff morale<sup>a</sup> (<i>n</i> = 9)</td></tr><tr><td>Gender</td><td>50 % (6/12) male; 50 % (6/12) female</td><td>89 % (8/9) male; 11 % (1/9) female</td></tr><tr><td rowspan="6">Age</td><td>25 % (3/12) 16&#8211;17 years</td><td>22 % (2/9) 18&#8211;25 years</td></tr><tr><td>8 % (1/12) 18&#8211;25 years</td><td>33 % (3/9) 26&#8211;35 years</td></tr><tr><td>25 % (3/12) 26&#8211;35 years</td><td>11 % (1/9) 36&#8211;45 years</td></tr><tr><td>16 % (2/12) 36&#8211;45 years</td><td>33 % (3/9) 46&#8211;55 years</td></tr><tr><td>8 % (1/12) 46&#8211;55 years</td><td></td></tr><tr><td>16 % (2/12) 56&#8211;65 years</td><td></td></tr><tr><td rowspan="6">Ethnicity</td><td>50 % (6/12) British or White British</td><td>33 % (3/9) British or White British</td></tr><tr><td>17 % (2/12) White &amp; Black Caribbean</td><td>22 % (2/9) Black African</td></tr><tr><td>8 % (1/12) Indian</td><td>11 % (1/9) Caribbean</td></tr><tr><td>8 % (1/12) White other</td><td>11 % (1/9) Black other</td></tr><tr><td>8 % (1/12) Black other</td><td>11 % (1/9) Asian</td></tr><tr><td>8 % (1/12) Mixed ethnicity</td><td>11 % (1/9) Mixed ethnicity</td></tr><tr><td>Ward type</td><td>25 % (3/12) Female acute ward</td><td>33 % (3/9) Male psychiatric intensive care unit</td></tr><tr><td></td><td>25 % (3/12) Mixed gender recovery unit</td><td>33 % (3/9) Male acute ward</td></tr><tr><td></td><td>25 % (3/12) Mixed gender child and adolescent unit</td><td>33 % (3/9) Mixed gender acute ward</td></tr><tr><td></td><td>25 % (3/12) Male rehabilitation unit</td><td></td></tr></table>
91d1bd63e449ae062debf869477c2d602fc38c29af21be43cb4e8b08b82d4e25.png
simple
<table><tr><td>Parameter</td><td></td><td>BSP</td><td>Control</td><td>P</td></tr><tr><td>Gender</td><td>Male</td><td>62</td><td>65</td><td>&gt;0.05</td></tr><tr><td></td><td>Female</td><td>38</td><td>35</td><td></td></tr><tr><td>Age</td><td>&#8804;40</td><td>33</td><td>29</td><td>&gt;0.05</td></tr><tr><td></td><td>&gt;41</td><td>67</td><td>71</td><td></td></tr><tr><td>Etiology</td><td>Trauma</td><td>31</td><td>31</td><td>&gt;0.05</td></tr><tr><td></td><td>Other</td><td>69</td><td>69</td><td></td></tr></table>
f127cf2a4d605c176cd8f51da4d7df70d605c9738f9cccfa7015c927fbf2e09c.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Group 1 (<i>n</i> = 33) admitted to HSS</td><td colspan="3">Group 2 (<i>n</i> = 27) admitted to RS</td><td rowspan="2">P value<sup>a)</sup></td></tr><tr><td>Total number</td><td>Mean per patient</td><td>SD</td><td>Total number</td><td>Mean per patient</td><td>SD</td></tr><tr><td><i>Specialist health care services</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>In-patient days (total number)</td><td>245</td><td>7.4</td><td>12.1</td><td>300</td><td>11.1</td><td>22.1</td><td>0.872</td></tr><tr><td>Number in-patient days at HSS</td><td>118</td><td>3.6</td><td>7.0</td><td>156</td><td>5.8</td><td>11.7</td><td>0.621</td></tr><tr><td>Number in-patient days at RS</td><td>117</td><td>3.5</td><td>6.4</td><td>131</td><td>4.9</td><td>11.4</td><td>0.813</td></tr><tr><td>Number in-patient days other hospitals</td><td>10</td><td>0.3</td><td>1.0</td><td>13</td><td>0.5</td><td>1.5</td><td>0.952</td></tr><tr><td>Out-patient/X-ray consult. (total number)</td><td>70</td><td>2.1</td><td>3.0</td><td>37</td><td>1.4</td><td>2.3</td><td>0.201</td></tr><tr><td>Out-patient/X-ray consultations at HSS</td><td>26</td><td>0.8</td><td>1.4</td><td>6</td><td>0.2</td><td>0.5</td><td>0.044*</td></tr><tr><td>Out-patient/X-ray consultations at RS</td><td>29</td><td>0.9</td><td>1.3</td><td>16</td><td>0.6</td><td>1.0</td><td>0.318</td></tr><tr><td>Out-patient/X-ray consult. other hospitals</td><td>15</td><td>0.5</td><td>0.9</td><td>15</td><td>0.6</td><td>1.4</td><td>0.752</td></tr><tr><td><i>Municipal health care services</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nursing homes (days)</td><td>355</td><td>10.8</td><td>30.0</td><td>524</td><td>19.4</td><td>50.0</td><td>0.078</td></tr><tr><td>Home care total (hours)</td><td>2415</td><td>73.2</td><td>136.2</td><td>3019</td><td>111.8</td><td>245.6</td><td>0.796</td></tr><tr><td>Home nursing (hours)</td><td>1983</td><td>60.1</td><td>117.6</td><td>2669</td><td>98.9</td><td>227.4</td><td>0.856</td></tr><tr><td>Practical help (hours)</td><td>432</td><td>13.1</td><td>26.4</td><td>350</td><td>13.0</td><td>24.0</td><td>0.970</td></tr><tr><td>GP office consultations (number)</td><td>470</td><td>14.2</td><td>11.8</td><td>352</td><td>13.0</td><td>13.3</td><td>0.562</td></tr><tr><td>GP consultations (number)</td><td>263</td><td>8.0</td><td>7.2</td><td>193</td><td>7.2</td><td>7.6</td><td>0.612</td></tr><tr><td>Nurse consultations (number)</td><td>207</td><td>6.3</td><td>7.4</td><td>159</td><td>5.9</td><td>7.4</td><td>0.976</td></tr></table>
7fd16486a970d53c970f8fdee976056c0f18f4db8662f53230cd1be9d887ba9f.png
simple
<table><tr><td></td><td>Cod</td><td>Whey</td><td>Gluten</td><td>Casein</td></tr><tr><td>MCP-1</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>22 &#177; 11</td><td>21 &#177; 7</td><td>23 &#177; 12</td><td>21 &#177; 11</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>- 826 &#177; 1255x</td><td>- 77 &#177; 1092y</td><td>-943 &#177; 925x</td><td>-469 &#177; 757xy</td></tr><tr><td>CCL5</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>340 &#177; 238</td><td>490 &#177; 396</td><td>490 &#177; 321</td><td>409 &#177; 297</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>50 764 &#177; 58 218x</td><td>- 18 510 &#177; 81 999y</td><td>11 235 &#177; 55 558yz</td><td>44 488 &#177; 37 862xz</td></tr><tr><td>IL-1ra</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>68 &#177; 18</td><td>79 &#177; 39</td><td>76 &#177; 34</td><td>66 &#177; 24</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>743 &#177; 2 871</td><td>-1 972 &#177; 4 005</td><td>-1 454 &#177; 5 068</td><td>2 173 &#177; 4 320</td></tr><tr><td>PDGF-bb1</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>40 &#177; 41</td><td>161 &#177; 260</td><td>65 &#177; 78</td><td>110 &#177; 232</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>11 837 (6 285 - 20 952)</td><td>4 303 (2 102 - 6 995)</td><td>6 660 (4851 - 10 742)</td><td>8 604 (6348 - 10 435)</td></tr><tr><td>IFN-g</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>25 &#177; 12</td><td>28 &#177; 25</td><td>30 &#177; 21</td><td>28 &#177; 24</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>865 &#177; 1 610</td><td>-1 300 &#177; 3 747</td><td>-791 &#177; 2 622</td><td>397 &#177; 2 614</td></tr><tr><td>Adiponectin</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>1.5 &#177; 0.5</td><td>1.5 &#177; 0.6</td><td>1.5 &#177; 0.6</td><td>1.5 &#177; 0.5</td></tr><tr><td> iAUC 0-240 min (&#956;g/ml&#183;240 min)</td><td>-7.7 &#177; 48</td><td>-8.5 &#177; 49</td><td>6.3 &#177; 38</td><td>-6.9 &#177; 36</td></tr><tr><td>Eotaxin</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>52 &#177; 12</td><td>53 &#177; 14</td><td>51 &#177; 14</td><td>49 &#177; 16</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>- 45 &#177; 819</td><td>601 &#177; 2237</td><td>- 64 &#177; 686</td><td>983 &#177; 1039</td></tr><tr><td>G-CSF</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>11 &#177; 3</td><td>12 &#177; 6</td><td>11 &#177; 4</td><td>12 &#177; 7</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>23 &#177; 719</td><td>-420 &#177; 1 242</td><td>-114 &#177; 685</td><td>-194 &#177; 955</td></tr><tr><td>IP-10</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>579 &#177; 166</td><td>558 &#177; 109</td><td>588 &#177; 226</td><td>542 &#177; 142</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>-2 343 &#177; 24 198</td><td>-10 371 &#177; 19 737</td><td>-3 403 &#177; 21 448</td><td>-5 159 &#177; 10 121</td></tr><tr><td>MIP-1b</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>45 &#177; 16</td><td>46 &#177; 16</td><td>44 &#177; 14</td><td>43 &#177; 15</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>-908 &#177; 1 248</td><td>-331 &#177; 1 411</td><td>-302 &#177; 534</td><td>-219 &#177; 428</td></tr><tr><td>VEGF</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>7 &#177; 3</td><td>10 &#177; 6</td><td>7 &#177; 3</td><td>8 &#177; 4</td></tr><tr><td> iAUC 0-240 min (pg/ml&#183;240 min)</td><td>693 &#177; 921</td><td>270 &#177; 1 058</td><td>233 &#177; 448</td><td>317 &#177; 419</td></tr><tr><td>Insulin</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>65 &#177; 28</td><td>63 &#177; 33</td><td>66 &#177; 31</td><td>62 &#177; 32</td></tr><tr><td> iAUC 0-240 min (pmol/l&#183;240 min)</td><td>41 158 &#177; 11 003x</td><td>73 693 &#177; 28 022y</td><td>38 738 &#177; 10 691x</td><td>50 978 &#177; 21 477x</td></tr><tr><td>Triglycerides</td><td></td><td></td><td></td><td></td></tr><tr><td> Fasting</td><td>2.0 &#177; 1.0</td><td>1.8 &#177; 0.8</td><td>1.9 &#177; 0.7</td><td>1.8 &#177; 0.9</td></tr><tr><td> iAUC 0-240 min (mmol/l&#183;240 min)</td><td>138 &#177; 108</td><td>122 &#177; 95</td><td>132 &#177; 95</td><td>127 &#177; 94</td></tr></table>
8bd40974738a083eb5e494a51a618a3ccd4364fd32225f1f9ee85f3e6ee3f9b1.png
complex
<table><tr><td>Stage</td><td>Serum creatinine criteria</td></tr><tr><td rowspan="3">1</td><td>1.5-1.9 times baseline</td></tr><tr><td>OR</td></tr><tr><td>&#8805; 26.5 5 &#956;mol/l (0.3 mg/dl) increase within 48 hours<sup>a</sup></td></tr><tr><td>2</td><td>2.0-2.9 times baseline</td></tr><tr><td rowspan="5">3</td><td>&#8805; 3.0 times baseline</td></tr><tr><td>OR</td></tr><tr><td>Increase in serum creatinine to &#8805; 354 &#956;mol/l (4.0 mg/dl)<sup>b</sup></td></tr><tr><td>OR</td></tr><tr><td>Initiation of renal replacement therapy</td></tr></table>
b80c61be61abec1a4d11eab173ca0625bd9c2beb223d075a24d20093bf706801.png
simple
<table><tr><td>DMFT component</td><td>Disabledmean &#177; SD</td><td>Normalmean &#177; SD</td><td>t-value</td><td>df</td><td>P value</td></tr><tr><td>Decayed (D)</td><td>0.64 &#177; 1.32</td><td>1.06 &#177; 1.40</td><td>2.33</td><td>234</td><td>0.02</td></tr><tr><td>Missing (M)</td><td>0.68 &#177; 2.23</td><td>0.03 &#177; 0.21</td><td>3.2</td><td>234</td><td>0.002</td></tr><tr><td>Filled (F)</td><td>0.14 &#177; 0.72</td><td>0</td><td>2.1</td><td>234</td><td>0.037</td></tr><tr><td>Decayed (d)</td><td>0.08 &#177; 0.38</td><td>0</td><td>2.35</td><td>234</td><td>0.019</td></tr><tr><td>Filled (f)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>&#8212;</td></tr></table>
b1c8acee1ce9b449fc99501095ab083b210331a8ca8a7d6480dd98b15b873cda.png
complex
<table><tr><td>Characteristic</td><td colspan="2">VA</td><td colspan="2">FFS</td></tr><tr><td></td><td>OR (95% CI)</td><td>p-value</td><td>OR (95% CI)</td><td>p-value</td></tr><tr><td>Comorbidity</td><td></td><td></td><td></td><td></td></tr><tr><td> Unadjusted</td><td>0.78 (0.61, 1.00)</td><td>0.04</td><td>1.08 (0.82, 1.42)</td><td>0.59</td></tr><tr><td> Adjusted</td><td>0.76 (0.58, 1.00)</td><td>0.045</td><td>1.09 (0.82, 1.44)</td><td>0.57</td></tr><tr><td>Age (&#8805; 70 years)</td><td></td><td></td><td></td><td></td></tr><tr><td> Unadjusted</td><td>0.98 (0.79, 1.23)</td><td>0.88</td><td>0.97 (0.80, 1.18)</td><td>0.76</td></tr><tr><td> Adjusted</td><td>1.08 (0.85, 1.36)</td><td>0.54</td><td>0.96 (0.78, 1.17)</td><td>0.67</td></tr><tr><td>Race (white)</td><td></td><td></td><td></td><td></td></tr><tr><td> Unadjusted</td><td>0.80 (0.49, 1.31)</td><td>0.39</td><td>1.12 (0.61, 2.08)</td><td>0.72</td></tr><tr><td> Adjusted</td><td>0.83 (0.51, 1.37)</td><td>0.47</td><td>1.12 (0.60, 2.09)</td><td>0.72</td></tr></table>
450dbb0141c2577e76d62c8d4c04141c2fbc911960b3296bcec373712514997b.png
simple
<table><tr><td>Factors</td><td>Categories</td><td>No. of patients (%)</td><td><i>P </i>value</td></tr><tr><td>Gender</td><td>Female</td><td>465(27.1)</td><td>0.301</td></tr><tr><td></td><td>Male</td><td>1250(72.9)</td><td></td></tr><tr><td>age</td><td></td><td>57.5 &#177; 10.9</td><td>&lt;0.001</td></tr><tr><td>Past medical history</td><td>No</td><td>1258(73.4)</td><td>0.022</td></tr><tr><td></td><td>Yes</td><td>457(26.6)</td><td></td></tr><tr><td>Family history of gastric cancer</td><td>No</td><td>1431(83.4)</td><td>0.431</td></tr><tr><td></td><td>Yes</td><td>284(16.6)</td><td></td></tr><tr><td>Location of tumor</td><td>Lower third</td><td>1086(63.3)</td><td>&lt;0.001</td></tr><tr><td></td><td>Middle third</td><td>281(16.4)</td><td></td></tr><tr><td></td><td>Upper third</td><td>193(11.3)</td><td></td></tr><tr><td></td><td>Whole stomach</td><td>155(9.03)</td><td></td></tr><tr><td>Eradicative degree of surgery</td><td>Utterly</td><td>809(47.8)</td><td>&lt;0.001</td></tr><tr><td></td><td>Relatively</td><td>473(27.6)</td><td></td></tr><tr><td></td><td>Palliative</td><td>433(25.2)</td><td></td></tr><tr><td>Tumor size(mm)</td><td>&lt;40</td><td>364(21.2)</td><td>&lt;0.001</td></tr><tr><td></td><td>&#8805;40</td><td>1315(78.8)</td><td></td></tr><tr><td>Stage</td><td>I</td><td>301(17.5)</td><td>&lt;0.001</td></tr><tr><td></td><td>II</td><td>425(24.8)</td><td></td></tr><tr><td></td><td>III</td><td>497(29.0)</td><td></td></tr><tr><td></td><td>IV</td><td>492(28.7)</td><td></td></tr><tr><td>Combined evisceration</td><td>No</td><td>1323(77.1)</td><td>&lt;0.001</td></tr><tr><td></td><td>Yes</td><td>392(22.9)</td><td></td></tr><tr><td>Histologic grade</td><td>Well differentiated</td><td>521(30.3)</td><td>&lt;0.001</td></tr><tr><td></td><td>Moderately differentiated</td><td>253(14.8)</td><td></td></tr><tr><td></td><td>Poorly differentiated</td><td>941(54.9)</td><td></td></tr><tr><td>Depth of invasion</td><td>T1</td><td>145(8.5)</td><td>&lt;0.001</td></tr><tr><td></td><td>T2</td><td>879(51.3)</td><td></td></tr><tr><td></td><td>T3</td><td>549(32.0)</td><td></td></tr><tr><td></td><td>T4</td><td>142(8.3)</td><td></td></tr><tr><td>Lymph node status</td><td>N0</td><td>629(36.7)</td><td>&lt;0.001</td></tr><tr><td></td><td>N1</td><td>717(41.8)</td><td></td></tr><tr><td></td><td>N2</td><td>272(15.9)</td><td></td></tr><tr><td></td><td>N3</td><td>97(5.7)</td><td></td></tr></table>
aa3e81c5a0d4c1b60d8ec9188c4e3d05e4fa42e96306a106569affbbe02dafcb.png
simple
<table><tr><td>Method</td><td>Algorithm</td><td>False positive rate</td><td>False negative rate</td></tr><tr><td>MEMSAT-SVM</td><td>SVM</td><td>0.00%</td><td>0.44%</td></tr><tr><td>MEMSAT3</td><td>NN</td><td>0.50%</td><td>0.50%</td></tr><tr><td>SOSUI</td><td>Hydrophobicity analysis</td><td>0.33%</td><td>1.10%</td></tr><tr><td>OCTOPUS</td><td>NN + HMM</td><td>0.00%</td><td>2.51%</td></tr><tr><td>PHOBIUS</td><td>HMM</td><td>2.72%</td><td>0.44%</td></tr></table>
2780f5d604981f488afdda9e02c7338ffbe5e7b693d613f0c0f31520f4585ae1.png
complex
<table><tr><td></td><td>Denmark</td><td>Norway</td><td>Sweden</td></tr><tr><td colspan="4">TKA</td></tr><tr><td> Mean</td><td>146</td><td>70</td><td>143</td></tr><tr><td> Median</td><td>132</td><td>53</td><td>105</td></tr><tr><td> Range</td><td>1&#8211;345</td><td>1&#8211;275</td><td>1&#8211;527</td></tr><tr><td colspan="4">UKA</td></tr><tr><td> Mean</td><td>35</td><td>19</td><td>30</td></tr><tr><td> Median</td><td>29</td><td>16</td><td>24</td></tr><tr><td> Range</td><td>1&#8211;85</td><td>1&#8211;57</td><td>1&#8211;104</td></tr></table>
92bd6d6a4228ff7b2225682ad865e3bd64c503a736e57432be3353cfa1cde5b6.png
complex
<table><tr><td>Genotypes</td><td>Azoospermic men (n=108)</td><td>Controls (n=119)</td><td>p-value</td><td>OR (CI; 95%)</td></tr><tr><td>AA</td><td>19 (17.6)</td><td>51 (42.8)</td><td colspan="2"></td></tr><tr><td>AG</td><td>52 (48.2)</td><td>22 (38.7)</td><td>0.149</td><td>1.47 (0.869-2.498)</td></tr><tr><td>GG</td><td>37 (34.3)</td><td>46 (18.5)</td><td>0.007</td><td>2.298 (1.248-4.229)</td></tr></table>
140c48cb5ae7072c24a13b47e631c15c01bbf8de17faa9edd0fc2a4d67d893f6.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td>HR (95% CI)</td><td>p-value</td><td>HR (95% CI)</td><td>p-value</td></tr><tr><td> Age (Years)</td><td>1.04 (0.98-1.11)</td><td>0.23</td><td>1.02 (0.95-1.09)</td><td>0.68</td></tr><tr><td> PSA</td><td>1.02 (1.01-1.03)</td><td>&lt;0.0001</td><td>1.01 (1.00-1.03)</td><td>0.10</td></tr><tr><td>Gleason</td><td></td><td></td><td></td><td></td></tr><tr><td> &lt;7</td><td>Reference</td><td>&lt;0.0001</td><td>Reference</td><td>0.02</td></tr><tr><td> 7</td><td>2.97(1.52-5.82)</td><td>0.002</td><td>2.28 (1.12-4.65)</td><td>0.02</td></tr><tr><td> &gt;7</td><td>6.27 (2.59-15.22)</td><td>&lt;0.0001</td><td>3.78 (1.43-9.99)</td><td>0.04</td></tr><tr><td>pT stage</td><td></td><td></td><td></td><td></td></tr><tr><td> T2</td><td>Reference</td><td>&lt;0.0001</td><td>Reference</td><td>0.42</td></tr><tr><td> T3</td><td>2.01 (1.10-3.69)</td><td>0.03</td><td>1.06 (0.54-2.10)</td><td>0.86</td></tr><tr><td> T4</td><td>4.63 (2.08-10.33)</td><td>&lt;0.0001</td><td>1.77 (0.72-4.39)</td><td>0.21</td></tr><tr><td>Surgical margin</td><td>2.97 (1.71-5.16)</td><td>&lt;0.0001</td><td>2.03 (1.09-3.78)</td><td>0.03</td></tr><tr><td>ERG expression</td><td>0.91 (0.51-1.61)</td><td>0.74</td><td>0.88 (0.47-1.64)</td><td>0.70</td></tr><tr><td>p-mTOR</td><td>0.36 (0.20-0.66)</td><td>0.001</td><td>0.45 (0.24-0.84)</td><td>0.01</td></tr></table>
8bddc5a825b4463d8c634a16c4619fc1483f4d1a89a46489f2a351a1a9b54ec9.png
complex
<table><tr><td>Parameter</td><td>HR</td><td>95 % CI</td><td><i>P</i></td></tr><tr><td colspan="4">Disease-free survival: Cox regression model</td></tr><tr><td>TNM stage</td><td></td><td></td><td>0.06</td></tr><tr><td> III-IV (vs. I-II)</td><td>2.528</td><td>1.299&#8211;4.921</td><td></td></tr><tr><td>Tumor differentiation</td><td></td><td></td><td>0.021</td></tr><tr><td> Poor (vs. Well/moderate)</td><td>1.785</td><td>1.089&#8211;2.925</td><td></td></tr><tr><td>AREG expression</td><td></td><td></td><td>0.168</td></tr><tr><td> Positive (vs. Negative)</td><td>1.418</td><td>0.863&#8211;2.331</td><td></td></tr><tr><td>AREG/EGFR coexpression</td><td></td><td></td><td>0.587</td></tr><tr><td> Negative (vs. Positive)</td><td>0.922</td><td>0.687&#8211;1.237</td><td></td></tr><tr><td colspan="4">Overall survival: Cox regression model</td></tr><tr><td>Tumor size</td><td></td><td></td><td>0.485</td></tr><tr><td> T3-4 (vs. T1-2)</td><td>1.24</td><td>0.677&#8211;2.271</td><td></td></tr><tr><td>TNM stage</td><td></td><td></td><td>0.03</td></tr><tr><td> III-IV (vs. I-II)</td><td>2.25</td><td>1.081&#8211;4.684</td><td></td></tr><tr><td>Tumor differentiation</td><td></td><td></td><td>0.004</td></tr><tr><td> Poor (vs. Well/moderate)</td><td>2.125</td><td>1.277&#8211;3.537</td><td></td></tr><tr><td>Resection margins</td><td></td><td></td><td>0.045</td></tr><tr><td> Positive (vs. Negative)</td><td>1.84</td><td>1.277&#8211;3.537</td><td></td></tr><tr><td>Lymph node metastasis</td><td></td><td></td><td>0.417</td></tr><tr><td> Yes (vs. No)</td><td>1.233</td><td>0.743&#8211;2.048</td><td></td></tr><tr><td>AREG expression</td><td></td><td></td><td>0.03</td></tr><tr><td> Positive (vs. Negative)</td><td>1.822</td><td>1.058&#8211;3.137</td><td></td></tr></table>
392584e510b2dd6233e0e2916959cebcf01b3fa32234e257b0942cba9b031c8b.png
simple
<table><tr><td>Comparison</td><td>CTCs</td><td>ctDNA</td><td>Exosomes</td></tr><tr><td>Origin</td><td>Includes apoptotic tumor and viable tumor cells from a primary or metastatic tumor [71, 73].</td><td>Includes cfDNA, from the viable tumor cells or from CTCs [17, 219, 221, 224, 225].</td><td>Includes DNA, proteins, lipids, RNAs and metabolites and are discharged by all cells including tumor cells [333, 336, 352, 355&#8211;357].</td></tr><tr><td>Bio-banked samples used for study</td><td>Frozen plasma, urine and other biofluids cannot be used for study of CTCs [116].</td><td>Frozen plasma, urine and other biofluids can be used for study of cfDNA [116, 260].</td><td>Frozen plasma, urine and other biofluids can be used for study of exosomes [260].</td></tr><tr><td>Stability</td><td>Unstable [114, 116, 117]</td><td>Stable [116]</td><td>Very stable [334]</td></tr><tr><td>Genetic materials</td><td>DNA and RNA [117, 122, 123]</td><td>DNA [17, 219, 221]</td><td>DNA and RNA [355, 357, 359&#8211;361]</td></tr><tr><td>Analytic Techniques</td><td>CellSearch [84, 148&#8211;150, 180, 182, 190], Microfluidic [187, 181], SE-iFISH [186], MetaCell [184], Immunofluorescence [181, 185, 188], ScreenCell [185], ISET Test [188, 190] etc.</td><td>dPCR [289], CAPP-Seq [293], TAM-Seq [276], ddPCR [290, 307, 308, 310], COLD-PCR [167], Safe-Seq [294], NGS [299, 308&#8211;310], BEAMing [291, 292], WGA [297, 298] etc.</td><td>Ultracentrifugation [387, 386, 389&#8211;391, 393], ExoChip [392], Precipitation [386], Size-based isolation [386], Immunoaffinity-based isolation [386], Microfluidics-based isolation etc [386].</td></tr><tr><td>Morphological study and functional study of tumor cells <i>ex vivo</i></td><td>Yes [128, 129, 188, 190, 206, 210, 213, 214]</td><td>No</td><td>No</td></tr><tr><td>Analysis of protein location on tumor cells</td><td>Yes [101, 102]</td><td>No</td><td>No</td></tr><tr><td>Identification of mutations</td><td>Yes [165, 185, 187]</td><td>Yes [306, 319]</td><td>Yes [387, 390, 393]</td></tr><tr><td>Identification of epigenetic changes</td><td>Yes [414, 415]</td><td>Yes [322&#8211;325]</td><td>Yes [357]</td></tr><tr><td>Analysis of RNA transcription profiles</td><td>Yes [157, 192]</td><td>No</td><td>Yes [359&#8211;361, 367]</td></tr><tr><td>Proteomics Analysis</td><td>Yes [157]</td><td>No</td><td>Yes [367, 387, 392]</td></tr><tr><td>Analysis tumor heterogeneity</td><td>Yes [206]</td><td>Yes [332]</td><td>No</td></tr><tr><td>Use as drug delivery vehicle</td><td>No</td><td>No</td><td>Yes [406, 410]</td></tr></table>
4ec8e24ef2b6cf363185b25212e2c269630406a01807c46ab202765004cc076d.png
simple
<table><tr><td></td><td>Label</td><td>Start</td><td>Name</td><td>Function</td><td>References</td></tr><tr><td>ldRNA</td><td>BSU_misc_RNA_3</td><td>119855</td><td>ldlJ</td><td>Ribosomal protein L10 leader mRNA sequence</td><td>26101249</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_7</td><td>486092</td><td>swaO</td><td>ATP&#8208;, cyclic di&#8208;AMP&#8208;sensing riboswitch</td><td>25086507, 25086509</td></tr><tr><td>CDS</td><td>BSU04785</td><td>528025</td><td>cmpA</td><td>Factor allowing degradation of SpoIVA by ClpXP</td><td>26387458</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_65</td><td>532642</td><td>sncO</td><td>ICEBs1 mobile element: conserved small untranslated RNA</td><td>20525796, 22505685</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_66</td><td>559610</td><td>sncZ</td><td>No identified function: borders undefined</td><td>20525796</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_8</td><td>626446</td><td>aswA</td><td>Adenine riboswitch</td><td>25573585</td></tr><tr><td>CDS</td><td>BSU09958</td><td>1071402</td><td>sscA</td><td>Spore assembly and germination protein</td><td>21670523</td></tr><tr><td>CDS</td><td>BSU09959</td><td>1071613</td><td>sscB</td><td>Spore assembly and germination protein</td><td>21670523</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_67</td><td>1233405</td><td>roxS</td><td>Small regulatory RNA (NO regulated)</td><td>28436820</td></tr><tr><td>CDS</td><td>BSU12815</td><td>1348356</td><td>spoIISC</td><td>Three component toxin/antitoxin/antitoxin SpoIISABC, antitoxin C</td><td>25039482, 26300872, 27294956</td></tr><tr><td>Riboswitch</td><td>BSU_misc_RNA_16</td><td>1376328</td><td>guwA</td><td>Guanidinium riboswitch</td><td>28212758</td></tr><tr><td>Riboswitch</td><td>BSU_misc_RNA_68</td><td>1395622</td><td>swmG</td><td>Magnesium riboswitch (modest affinity)</td><td>28455443</td></tr><tr><td>Riboswitch</td><td>BSU_misc_RNA_87</td><td>1410633</td><td>mnrW</td><td>Manganese ion riboswitch</td><td>25794618, 25794619</td></tr><tr><td>Riboswitch</td><td>BSU_misc_RNA_88</td><td>1457005</td><td>gswA</td><td>Riboswitch regulating ptsGHI expression via GlcT binding</td><td>15155854, 22750856</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_69</td><td>1483557</td><td>fsrA</td><td>Regulatory RNA controlling iron&#8208;dependent metabolism</td><td>24576839</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_70</td><td>1534070</td><td>srrA</td><td>Small regulatory RNA and messenger RNA (arginine metabolism)</td><td>27449348</td></tr><tr><td>CDS</td><td>BSU14629</td><td>1534120</td><td>rgpA</td><td>Regulator of GapA synthesis</td><td>27449348</td></tr><tr><td>CDS</td><td>BSU15140</td><td>1580622</td><td>rsmH</td><td>16S rRNA m4C1402 methyltransferase</td><td>27711192</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_89</td><td>1780554</td><td>surX</td><td>sigW&#8208;dependent</td><td>23155385</td></tr><tr><td>CDS</td><td>BSU17845</td><td>1916955</td><td>yzzP</td><td>No identified function, present in some S. pneumoniae strains</td><td>27144405</td></tr><tr><td>CDS</td><td>BSU18978</td><td>2069883</td><td>bsrE</td><td>Type I toxin (BsrE/AsrE)</td><td>26940229</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_74</td><td>2070115</td><td>asrE</td><td>Small regulatory antitoxin RNA, toxin&#8208;antitoxin type I system (BsrE/AsrE)</td><td>26940229</td></tr><tr><td>CDS</td><td>BSU19749</td><td>2146053</td><td>yoyG</td><td>Putative toxin of a type I toxin family (sporulation operon)</td><td>20156992, 21670523</td></tr><tr><td>fCDS</td><td>BSU20049</td><td>2160397</td><td>nrdFBc</td><td>Phage SP beta nucleoside diphosphate reductase minor subunit (C&#8208;terminus)</td><td>23391036</td></tr><tr><td>fCDS</td><td>BSU20051</td><td>2161778</td><td>nrdFBn</td><td>Phage SP beta nucleoside diphosphate reductase minor subunit (N&#8208;terminus)</td><td>23391036</td></tr><tr><td>suRNA</td><td>BSU_ncRNA_1</td><td>2208880</td><td>aimX</td><td>Small RNA controlling lysogeny of phage SPbeta</td><td>28099413</td></tr><tr><td>CDS</td><td>BSU20850</td><td>2208980</td><td>aimP</td><td>Arbitrium lysis /lysogeny regulatory peptide (GMPRGA)</td><td>28099413</td></tr><tr><td>CDS</td><td>BSU20860</td><td>2210154</td><td>aimR</td><td>Arbitrium peptide sensor regulator</td><td>28099413</td></tr><tr><td>asRNA</td><td>BSU_misc_RNA_90</td><td>2219849</td><td>apbT</td><td>Antisense RNA of Toxin SpbT</td><td>24576839</td></tr><tr><td>CDS</td><td>BSU21000</td><td>2219960</td><td>spbT</td><td>Toxin</td><td>24576839</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_91</td><td>2472880</td><td>pswI</td><td>Proline T&#8208;box riboswitch upstream of porI</td><td>21233158</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_82</td><td>2773783</td><td>surF</td><td>Expressed under sporulation conditions</td><td>25790031</td></tr><tr><td>ldRNA</td><td>BSU_misc_RNA_43</td><td>2855915</td><td>ldlU</td><td>Ribosomal protein L21 leader mRNA sequence</td><td>27381917</td></tr><tr><td>CDS</td><td>BSU28475</td><td>2910746</td><td>lysCB</td><td>Beta subunit of aspartokinase II</td><td>1980002</td></tr><tr><td>ldRNA</td><td>BSU_misc_RNA_47</td><td>2953550</td><td>ldlT</td><td>Ribosomal protein L20 leader mRNA sequence</td><td>23611891</td></tr><tr><td>ldRNA</td><td>BSU_misc_RNA_93</td><td>3035589</td><td>ldsD</td><td>Ribosomal protein S4 leader mRNA sequence</td><td>23611891</td></tr><tr><td>asRNA</td><td>BSU_ncRNA_2</td><td>3335545</td><td>auzJ</td><td>Putative antisense RNA for YuzJ putative toxin (toxin I signature)</td><td>20156992, 21670523</td></tr><tr><td>suRNA</td><td>BSU_misc_RNA_94</td><td>4169919</td><td>mswM</td><td>Manganese riboswitch</td><td>25794618, 25794619</td></tr></table>
7e0c115f2494bd6816937c328d09dda63b62263eeab545736f5efd0ff3a543b1.png
complex
<table><tr><td>Characteristic</td><td colspan="2">Beijing</td><td colspan="2">Chongqing</td><td colspan="2">Guangzhou</td><td>Total</td><td></td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Number of children</td><td>10,372</td><td>42.70%</td><td>9,846</td><td>40.53%</td><td>4,072</td><td>16.77%</td><td>24,290</td><td></td></tr><tr><td>Response rate</td><td>98.60%</td><td></td><td>97.21%</td><td></td><td>90.90%</td><td></td><td>96.62%</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td>5,455</td><td>52.59%</td><td>5,258</td><td>53.40%</td><td>2,195</td><td>53.90%</td><td>12,908</td><td>53.14%</td></tr><tr><td> Female</td><td>4,917</td><td>47.41%</td><td>4,588</td><td>46.60%</td><td>1,877</td><td>46.10%</td><td>11,382</td><td>46.86%</td></tr><tr><td>Age (mean &#177; SD)</td><td>7.63 &#177; 4.04</td><td></td><td>8.74 &#177; 2.72</td><td></td><td>8.39 &#177; 3.53</td><td></td><td>8.20 &#177; 3.51</td><td></td></tr></table>
7036e862d4b382340efe05a5924c1694bdf93c1354c374e2d625d58916cc9b9b.png
complex
<table><tr><td rowspan="2">Top 16 most significant in order</td><td rowspan="2">Chemical shift (ppm)</td><td colspan="3">I/II stage of CRC vs healthy controls</td><td rowspan="2">Related metabolomic pathway</td></tr><tr><td>VIP<sup>a</sup></td><td><i>p</i>-value<sup>b</sup></td><td>Variations vs HC</td></tr><tr><td>Choline</td><td>3.19(s)</td><td>2.25</td><td>0.000</td><td>&#8595;</td><td>Choline metabolism, Lipid metabolism</td></tr><tr><td>Phenylalanine</td><td>3.19(m)3.98(dd)</td><td>2.251.43</td><td>0.0000.004</td><td>&#8595;&#8595;</td><td>Amino acid metabolism, Phenylalanine metabolism</td></tr><tr><td>Asparagine</td><td>2.80(dd)</td><td>1.90</td><td>0.000</td><td>&#8595;</td><td>Urea metabolism, Amino acid metabolism</td></tr><tr><td>Isocitrate</td><td>3.98(d)</td><td>1.84</td><td>0.005</td><td>&#8595;</td><td>TCA cycle</td></tr><tr><td>Cysteine</td><td>3.97(dd)3.06(m)</td><td>1.841.70</td><td>0.0030.000</td><td>&#8595;&#8595;</td><td>Amino acid metabolism, Glutamate Metabolism, Glutathione Metabolism</td></tr><tr><td>Hippurate</td><td>3.96(d)</td><td>1.84</td><td>0.005</td><td>&#8595;</td><td>Gut microflora metabolism</td></tr><tr><td>Dimethyl sulfone</td><td>3.138(s)</td><td>1.72</td><td>0.000</td><td>&#8595;</td><td>Gut microflora metabolism, Endogenous methanethiol metabolism</td></tr><tr><td>Creatinine</td><td>3.03(s)4.05(s)</td><td>1.701.43</td><td>0.0070.003</td><td>&#8595;&#8595;</td><td>Urea metabolism, Creatinine metabolism</td></tr><tr><td>Alanine</td><td>1.46(d)</td><td>1.67</td><td>0.017</td><td>&#8595;</td><td>Amino acid metabolism, Gluconeogenesis</td></tr><tr><td>Methylamine</td><td>2.59(s)</td><td>1.12</td><td>0.018</td><td>&#8595;</td><td>Gut microflora metabolism, Disulfiram Pathway</td></tr><tr><td>Homocysteine</td><td>2.14(m)</td><td>1.76</td><td>0.014</td><td>&#8593;</td><td>Amino acid metabolism, Methionine metabolism</td></tr><tr><td>Glutamine</td><td>2.12(m)3.76(t)</td><td>1.761.53</td><td>0.0010.017</td><td>&#8593;&#8593;</td><td>Glutaminolysis, TCA cycle</td></tr><tr><td>cis-Aconitate</td><td>3.43(d)</td><td>1.64</td><td>0.043</td><td>&#8593;</td><td>TCA cycle, Glyoxylate, Dicarboxylate metabolism</td></tr><tr><td>Acetoacetate</td><td>2.27(s)3.43(s)</td><td>1.591.64</td><td>0.0090.043</td><td>&#8593;&#8593;</td><td>Fatty acid metabolism, TCA cycle</td></tr><tr><td>trans-Aconitate</td><td>3.74(s)</td><td>1.54</td><td>0.019</td><td>&#8593;</td><td>TCA cycle</td></tr><tr><td>Guanidoacetate</td><td>3.78(s)</td><td>1.53</td><td>0.017</td><td>&#8593;</td><td>Urea metabolism</td></tr></table>
9366449ab6e69b68f4dbe1935ab331a0faf592b946cb09a4a1268c8a2064756a.png
complex
<table><tr><td>Carbon</td><td>1</td><td>2</td><td>3</td><td>8</td><td>9</td><td>10</td></tr><tr><td>1</td><td>158.0 (s)</td><td>161.2 (s)</td><td>160.0 (s)</td><td>162.1 (s)</td><td>160.0 (s)</td><td>159.3(s)</td></tr><tr><td>2</td><td>113.5 (d)</td><td>94.3 (d)</td><td>92.7 (d)</td><td>118.2 (s)</td><td>117.5 (s)</td><td>160.2 (s)</td></tr><tr><td>3</td><td>152.6 (s)</td><td>162.4 (s)</td><td>161.3 (s)</td><td>166.5 (s)</td><td>166.4 (s)</td><td>166.5 (s)</td></tr><tr><td>4</td><td>104.8 (d)</td><td>90.7 (d)</td><td>130.2 (s)</td><td>123.0 (s)</td><td>122.1 (s)</td><td>131.2 (s)</td></tr><tr><td>4a</td><td>143.3 (s)</td><td>140.7 (s)</td><td>141.2 (s)</td><td>139.3 (s)</td><td>139.0 (s)</td><td>124.8 (s)</td></tr><tr><td>5a</td><td>144.0 (s)</td><td>140.7 (s)</td><td>141.3 (s)</td><td>139.3 (s)</td><td>140.2 (s)</td><td>133.2 (s)</td></tr><tr><td>5</td><td>145.1 (s)</td><td>104.4 (d)</td><td>146.2 (s)</td><td>115.0 (d)</td><td>116.1 (d)</td><td>114.5 (d)</td></tr><tr><td>6</td><td>143.3 (s)</td><td>144.0 (s)</td><td>119.8 (d)</td><td>131.2 (d)</td><td>131.3 (d)</td><td>131.4 (d)</td></tr><tr><td>7</td><td>118.3 (d)</td><td>117.2 (d)</td><td>143.1 (s)</td><td>123.0 (d)</td><td>123.0 (d)</td><td>123.6 (d)</td></tr><tr><td>8</td><td>162.3 (d)</td><td>126.9 (d)</td><td>117.2 (d)</td><td>124.0 (d)</td><td>124.1 (d)</td><td>126.8 (d)</td></tr><tr><td>8a</td><td>115.6 (s)</td><td>120.4 (s)</td><td>121.5 (s)</td><td>121.5 (s)</td><td>121.6 (s)</td><td>122.1 (s)</td></tr><tr><td>9</td><td>178.2 (s)</td><td>180.8 (s)</td><td>181.1 (s)</td><td>177.2 (s)</td><td>178.3 (s)</td><td>181.6 (s)</td></tr><tr><td>9a</td><td>104.7 (s)</td><td>108.2 (s)</td><td>108.1 (s)</td><td>114.9 (s)</td><td>114.9 (s)</td><td>116.2 (s)</td></tr><tr><td rowspan="3">OMe</td><td>57.5 (q)</td><td>56.4 (q)</td><td>60.9 (q)</td><td>62.8 (q)</td><td>-</td><td>-</td></tr><tr><td>59.3 (q)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>61.9 (q)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>N-Me</td><td>-</td><td>-</td><td>34.3 (q)</td><td>30.5 (q)</td><td>31.5 (q)</td><td>31.7 (q)</td></tr><tr><td>2&#8217;</td><td>-</td><td>-</td><td>-</td><td>73.4 (s)</td><td>73.4 (s)</td><td>72.3 (s)</td></tr><tr><td rowspan="2">2&#8217;Me</td><td rowspan="2">-</td><td rowspan="2">-</td><td rowspan="2">-</td><td>24.4 (q)</td><td>25.0 (q)</td><td>24.7 (q)</td></tr><tr><td>26.1 (q)</td><td>26.2 (q)</td><td>26.0 (q)</td></tr><tr><td>3&#8217;</td><td>-</td><td>-</td><td>-</td><td>28.1 (t)</td><td>28.2 (t)</td><td>28.1 (t)</td></tr><tr><td>4&#8217;</td><td>-</td><td>-</td><td>-</td><td>79.6 (d)</td><td>78.6 (d)</td><td>92.3 (d)</td></tr></table>
169ecc289562d9a8c6099d2d0136a2798265350d8dc7be98eb11d81578e895f2.png
simple
<table><tr><td>Group</td><td>Mean &#177; SD</td><td>P value</td></tr><tr><td> A </td><td> 77.17&#177;1.00 </td><td> &lt;0.001 </td></tr><tr><td> B </td><td> 76.99&#177;.65 </td><td> &lt;0.001 </td></tr><tr><td> C </td><td> 78.31&#177;1.22 </td><td> &lt;0.001 </td></tr></table>
dbdfd24b1aafcc923730e8bcc70d3421d282e4454dfd73a4a76987449214f156.png
simple
<table><tr><td>Characteristic</td><td>HIV infected patients</td><td>Normal controls</td></tr><tr><td>Subject no.</td><td>32</td><td>35</td></tr><tr><td>Age (years, mean &#177; SD)</td><td>34 &#177; 6</td><td>36 &#177; 6</td></tr><tr><td>Male (No, %)</td><td>15 (46.9%)</td><td>15 (42.9%)</td></tr><tr><td>Han Ethnic (No, %)</td><td>32 (100%)</td><td>35 (100%)</td></tr><tr><td>CD4 (cells/&#956;L, mean &#177; SD)</td><td>331 &#177; 235</td><td>N/A</td></tr><tr><td>VL [log copies/mL (mean &#177; SD)]</td><td>4.15 &#177; 1.09</td><td>N/A</td></tr><tr><td>Time since diagnosis (weeks, mean, range)</td><td>65 (1&#8211;336)</td><td>N/A</td></tr></table>
5b3e86dab5583d65326c7cf29a4c89bd00ea520ed003b8122169bd0a23f44e55.png
simple
<table><tr><td>Model mechanism</td><td>Symbol</td><td>Mathematical expressions</td></tr><tr><td>First-order decay (<i>n</i>=1)</td><td>F1</td><td>(1&#8211;<i>&#945;</i>)</td></tr><tr><td>Second-order decay (<i>n</i>=2)</td><td>F2</td><td>(1&#8211; <i>&#945;</i>)<sup>2</sup></td></tr><tr><td>Third-order decay (<i>n</i>=3)</td><td>F3</td><td>0.5 &#183; (1&#8211; <i>&#945;</i>)<sup>3</sup></td></tr><tr><td>Avrami-Erofeev (<i>n</i>=2)</td><td>A2</td><td>2 &#183; (1&#8211; <i>&#945;</i>) &#183; [&#8211;ln(1&#8211; <i>&#945;</i>)]<sup>0.5</sup></td></tr></table>
594cde889ce0eec7ce17826b5f3abcabd4845ab93ee4890c1011f81c2d9e796d.png
complex
<table><tr><td> </td><td> </td></tr><tr><td colspan="2">Preamble</td></tr><tr><td colspan="2">These recommendations are relevant to all practitioners and organizations communicating the new Canadian Physical Activity Guidelines for Youth. These recommendations should be used to create a clear understanding of the new Canadian Physical Activity Guidelines for Youth and to construct and to deliver messages that promote achievement of the guidelines.</td></tr><tr><td colspan="2">Recommendations</td></tr><tr><td>Target Audience</td><td>Messages should separately target younger youth (12-14 yrs) and their parents and older youth (15-17 yrs) and their parents.</td></tr><tr><td>Clarification Messages</td><td>Clarification messages should: a) provide concise and clear descriptions of the guidelines and physical activity, b) define different levels of physical activity intensity (e.g., vigorous, vs. moderate), c) identify physical activity opportunities, d) include information about where to access more information about physical activity, e) indicate that science has evolved since the release of the old guidelines and that the new guidelines reflect latest evidence about physical activity, f) address the semantic differences between the old and new guidelines (e.g., up to 90 minutes vs. at least 60 minutes), and g) provide a wide variety of examples of physical activity &#8211; from active living to sport.</td></tr><tr><td rowspan="9">Motivational Messages</td><td>Motivational messages should emphasize a) parents&#8217; pivotal role in encouraging and supporting their youth&#8217;s physical activity, b) a variety of benefits that physical activity offers including emotional, developmental, physical and academic benefits, c) that physical activity can be a collective-social movement that promotes community, active living and the environment, d) the importance of planning physical activity by parents and youth, e) strategies for overcoming barriers to physical activity, and f) empowering youth to choose how they will meet the guidelines.</td></tr><tr><td><i>Examples</i></td></tr><tr><td>60 minutes every day! As a parent, you can help your teen get there.</td></tr><tr><td>Move your teen to move more.</td></tr><tr><td>Life looks better with physical activity.</td></tr><tr><td>Pick a time. Pick a place. Move your teens to move more.</td></tr><tr><td>Pick a time. Pick a place. How you want to get active is up to you!</td></tr><tr><td>Plan ahead for roadblocks!</td></tr><tr><td>Expand your horizons! How you want to get active is up to you!</td></tr><tr><td rowspan="2">Channels of Delivery</td><td>Messages should be disseminated to parents through websites, mass media campaigns featuring celebrities, magazines and news articles, and smart phone applications.</td></tr><tr><td>Messages should be disseminated to youth through websites, promotional materials within their school, public service announcements featuring celebrities, social media, smart phone applications, and community organizations and events.</td></tr></table>
33f06199fc4f1319feb0fa811f680b22994c698eb3afa7cbb62a26ff98c33237.png
complex
<table><tr><td></td><td colspan="2">Univariable</td><td colspan="2">Multivariable</td></tr><tr><td>Variable</td><td>OR [95 % CI]</td><td><i>p</i>-value</td><td>OR [95 % CI]</td><td><i>p</i>-value</td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> 15</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> 16</td><td>1.1 (0.5-2.6)</td><td>0.808</td><td>0.81 (0.29-2.24)</td><td>0.685</td></tr><tr><td> 17</td><td>1.5 (0.7-3.3)</td><td>0.328</td><td>1.39 (0.57-3.43)</td><td>0.469</td></tr><tr><td> 18</td><td>1.5 (0.7-3.2)</td><td>0.320</td><td>1.65 (0.71-3.85)</td><td>0.243</td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Female</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>0.6 (0.3-1.0)</td><td>0.044</td><td>0.35 (0.18-0.73)</td><td>0.004</td></tr><tr><td colspan="5">Setting</td></tr><tr><td> Rural</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> Urban</td><td>1.7 (1.1-3.2)</td><td>0.025</td><td>2.21 (1.21-4.05)</td><td>0.010</td></tr><tr><td colspan="5">Education Level</td></tr><tr><td> No schooling</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> Primary</td><td>0.4 (0.1-1.9)</td><td>0.264</td><td>0.28 (0.06-1.26)</td><td>0.098</td></tr><tr><td> Secondary</td><td>0.4 (0.1-1.6)</td><td>0.175</td><td>0.31 (0.07-1.32)</td><td>0.113</td></tr><tr><td> Tertiary</td><td>1.9 (0.2-22.8)</td><td>0.602</td><td>1.93 (0.16-22.83)</td><td>0.603</td></tr><tr><td colspan="5">Marital status</td></tr><tr><td> Never married</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> Currently or living as married</td><td>1.4 (0.6-3.1)</td><td>0.407</td><td>1.91 (0.84-4.32)</td><td>0.121</td></tr><tr><td> Divorced or separated</td><td>4.4 (0.6-33.7)</td><td>0.156</td><td>6.0 (0.77-46.21)</td><td>0.087</td></tr><tr><td colspan="5">Employment status</td></tr><tr><td> Unemployed</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> Employed</td><td>1.5 (0.4-6.8)</td><td>0.564</td><td>1.0 (0.13-7.56)</td><td>0.989</td></tr><tr><td> Pupil/Student</td><td>0.4 (0.2-0.6)</td><td>0.000</td><td>0.33 (0.17-0.63)</td><td>0.001</td></tr><tr><td colspan="5">Wealth Quintile</td></tr><tr><td> Lowest</td><td>Ref</td><td></td><td></td><td></td></tr><tr><td> Second lowest</td><td>1.7 (0.6-5.0)</td><td>0.334</td><td>1.8 (0.3-3.9)</td><td>0.095</td></tr><tr><td> Middle</td><td>2.3 (0.8-6.5)</td><td>0.100</td><td>2.3 (0.3-4.4)</td><td>0.026</td></tr><tr><td> Fourth</td><td>2.0 (0.7-5.7)</td><td>0.207</td><td>1.8 (0.3-3.9)</td><td>0.085</td></tr><tr><td> Highest</td><td>1.5 (0.5-4.4)</td><td>0.461</td><td>2.0 (0.0-4.1)</td><td>0.055</td></tr></table>
2bfd46d0c6cc9c169b6fa1ef8701370ce9e60c6721a695beb21a7a5a264081c5.png
simple
<table><tr><td>Gene</td><td>Variant</td><td>Position</td><td>OR</td><td>Common/Rare</td><td>Domain</td><td>Variant domain effect</td><td>Effect on AP</td><td>Ref</td></tr><tr><td><i>C3</i></td><td>R102G</td><td>19:6718387</td><td>1.7&#8211;2.6</td><td>Common</td><td>Macroglobulin 1</td><td>Decreased binding efficiency of C3b to its inhibitor CFH decreasing CFH&#8217;s cofactor activity</td><td>Increased AP</td><td>[20, 65]</td></tr><tr><td><i>C3</i></td><td>P314L</td><td>19:6713262</td><td>1.5</td><td>Common</td><td>Macroglobulin 3</td><td>Decreased binding efficiency of C3b to its inhibitor CFH decreasing CFH&#8217;s cofactor activity</td><td>Increased AP</td><td>[65]</td></tr><tr><td><i>C3</i></td><td>K155Q</td><td>19:6718146</td><td>2.8&#8211;3.8</td><td>Rare</td><td>Macroglobulin 2</td><td>Reduces binding to FH and C3b proteolytic cleavage by CFI</td><td>Increase C3 convertase production</td><td>[59, 65]</td></tr><tr><td><i>CFB</i></td><td>R32Q</td><td>6:31914180</td><td>0.32</td><td>Common</td><td>Ba</td><td>Reduced affinity for C3b and reduced hemolytic activity</td><td>Decrease formation of C3 convertase; reduced AP</td><td>[130]</td></tr><tr><td><i>CFB</i></td><td>L9H</td><td>6:31914024</td><td>0.37</td><td>Common</td><td>Signal peptide</td><td>Affects secretion of CFB</td><td>Decrease formation of C3 convertase; reduced AP</td><td>[12]</td></tr><tr><td><i>CFH</i></td><td>Y402H</td><td>1:196659291</td><td>2.45&#8211;5.57</td><td>Common</td><td>Complement control protein 7</td><td>Affects binding to GAG heparin sulfate, sialic acid, and C-reactive protein</td><td>Reduces ability of CFH to degrade C3: increased AP</td><td>[131]</td></tr><tr><td><i>CFH</i></td><td>R1210C</td><td>1:196716375</td><td>23.11</td><td>Rare</td><td>Complement control protein 20</td><td>Defective binding to C3b, C3d, and heparin</td><td>Impaired CFH attachment to host surfaces; reduces AP regulation</td><td>[58]</td></tr><tr><td><i>CFH</i></td><td>R53C</td><td>1:196642206</td><td></td><td>Rare</td><td>Complement control protein 1</td><td>Reduced accelerating activity for AP C3 convertase</td><td>Altered CFH-mediated cofactor activity or decay-accelerating activity; increased AP</td><td>[63]</td></tr><tr><td><i>CFH</i></td><td>D90G</td><td>1:196643011</td><td></td><td>Rare</td><td>Complement control protein 2</td><td>Alters CFI cofactor activity</td><td>Decreased cofactor-mediated inactivation; increased AP</td><td>[63]</td></tr><tr><td><i>CFH</i></td><td>I62V</td><td>1:196642233</td><td>1.95&#8211;2.79</td><td>Common</td><td>Complement control protein 2</td><td>Binds more efficiently to C3b</td><td>Enhanced cofactor activity and increased formation of iC3b; reduced AP</td><td>[63]</td></tr><tr><td><i>CFH</i></td><td>N1050Y</td><td>1:196712596</td><td>0.4</td><td>Common</td><td>Complement control protein 18</td><td>Possibly affects GAG and sialic acid binding</td><td>Increased AP</td><td>[62]</td></tr><tr><td><i>CFHR1/3</i></td><td>CFHR1/3del</td><td></td><td>0.29</td><td>Common</td><td>n/a</td><td>n/a</td><td>Reduces cofactor activity for CFI and inhibits C5 convertase; reduced AP</td><td>[13] [132&#8211;135]</td></tr><tr><td><i>CFI</i></td><td>G119R</td><td>4:110685820</td><td>22.2</td><td>Rare</td><td>Scavenger receptor cysteine-rich</td><td>Perturbs interdomain packing and stability of CFI</td><td>Diminished ability to degrade C3b; increased formation of C5 convertase; increased AP</td><td>[19]</td></tr><tr><td><i>CFI</i></td><td>G188A</td><td>4:110682768</td><td></td><td>Rare</td><td>Scavenger receptor cysteine-rich</td><td>Perturbs interdomain packing and stability of CFI</td><td>Diminished ability to degrade C3b; increased formation of C5 convertase; increased AP</td><td>[19]</td></tr><tr><td><i>C9</i></td><td>P167S</td><td>5:39331894</td><td>2.2</td><td>Rare</td><td>Membrane attack complex/perforin</td><td>Alters oligomerization and possibly inhibits C9's lytic activity</td><td>Affects binding with CD59; alters pore formation</td><td>[59]</td></tr></table>
c22d6bd16230af5747c2b99dba4c8211fda51fc3ce7623bba5f4b908a67ac98c.png
complex
<table><tr><td>Alcohol consumption</td><td><i>MTHFR</i> genotype</td><td>Cases <i>n</i> (%)</td><td>Controls <i>n</i> (%)</td><td>Age-adjusted OR (95% CI)</td></tr><tr><td>Low</td><td>CC</td><td>3 (8)</td><td>29 (20)</td><td>1.00 (ref)</td></tr><tr><td>Low</td><td>CT + TT</td><td>5 (14)</td><td>39 (27)</td><td>1.25 (0.28&#8211;5.65)</td></tr><tr><td>High</td><td>CC</td><td>14 (38)</td><td>31 (21)</td><td>4.43 (1.15&#8211;17.05)</td></tr><tr><td>High</td><td>CT + TT</td><td>15 (41)</td><td>47 (32)</td><td>3.10 (0.83&#8211;11.65)</td></tr><tr><td colspan="2"><i>p-interaction (multiplicative)</i></td><td></td><td></td><td>0.51</td></tr><tr><td colspan="2"><i>p-interaction (additive)</i></td><td></td><td></td><td>0.58</td></tr></table>
9e638d3f409a1f9a16992fa4ff67b71549bcc52be8ae571c1736302c8a0e5f54.png
simple
<table><tr><td>Variable</td><td>Women alive (0) (n)%</td><td>Women dead (1) (n)%</td><td>P-value</td></tr><tr><td>Overall (n = 42,703)</td><td>(n = 39,605) 92.75</td><td>(n = 3,098) 7.25</td><td></td></tr><tr><td>Age in years at entry</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> 15&#8211;19</td><td>(18,220) 46.0</td><td>(491) 15.85</td><td></td></tr><tr><td> 20&#8211;24</td><td>(6,174) 15.59</td><td>(615) 19.85</td><td></td></tr><tr><td> 25&#8211;29</td><td>(4,722) 11.92</td><td>(655) 21.14</td><td></td></tr><tr><td> 30&#8211;34</td><td>(3,579) 9.04</td><td>(534) 17.24</td><td></td></tr><tr><td> 35&#8211;39</td><td>(2,895) 7.31</td><td>(402) 12.98</td><td></td></tr><tr><td> 40&#8211;44</td><td>(2,346) 5.92</td><td>(293) 9.46</td><td></td></tr><tr><td> 45&#8211;49</td><td>(1,669) 4.21</td><td>(108) 3.49</td><td></td></tr><tr><td>Area of residence</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> Rural</td><td>(22,737) 57.4</td><td>(1,802) 58.17</td><td></td></tr><tr><td> Urban</td><td>(4,023) 10.16</td><td>(142) 4.58</td><td></td></tr><tr><td> Peri-urban</td><td>(12,753) 32.20</td><td>(1,154) 37.25</td><td></td></tr><tr><td>Migration status</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> Never moved</td><td>(11,495) 29.02</td><td>(1,314) 42.41</td><td></td></tr><tr><td> Internal only</td><td>(3,982) 10.05</td><td>(273) 8.81</td><td></td></tr><tr><td> External only</td><td>(7,237) 18.27</td><td>(606) 19.56</td><td></td></tr><tr><td> Internal and external</td><td>(16,891) 42.65</td><td>(905) 29.21</td><td></td></tr><tr><td>Minimum HSE class index</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> Upper 20%</td><td>(4,568) 12.73</td><td>(225) 7.59</td><td></td></tr><tr><td> Middle 40%</td><td>(12,064) 33.61</td><td>(1,007) 33.96</td><td></td></tr><tr><td> Lower 40%</td><td>(19,263) 53.66</td><td>(1,733) 58.45</td><td></td></tr><tr><td>Ever married</td><td></td><td></td><td>0.015</td></tr><tr><td> No</td><td>(32,752) 82.7</td><td>(2,615) 84.41</td><td></td></tr><tr><td> Yes</td><td>(6,853) 17.3</td><td>(483) 15.59</td><td></td></tr><tr><td>Ever employed</td><td></td><td></td><td>0.353</td></tr><tr><td> No</td><td>(29,701) 74.99</td><td>(2,300) 74.24</td><td></td></tr><tr><td> Yes</td><td>(9,904) 25.01</td><td>(798) 25.76</td><td></td></tr><tr><td>Highest level of education</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> More than 8 years</td><td>(24,647) 71.88</td><td>(1,469) 62.25</td><td></td></tr><tr><td> Less than 8 years</td><td>(8,083) 23.57</td><td>(742) 31.44</td><td></td></tr><tr><td> No school</td><td>(1,559) 4.55</td><td>(149) 6.31</td><td></td></tr><tr><td>Self-reported minimum general health</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> Good</td><td>(17,095) 79.68</td><td>(770) 69.43</td><td></td></tr><tr><td> Fair</td><td>(3,808) 17.75</td><td>(253) 22.81</td><td></td></tr><tr><td> Poor</td><td>(5,51) 2.57</td><td>(86) 7.75</td><td></td></tr><tr><td>Woman HIV status</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> HIV tested and negative</td><td>(9,532) 24.07</td><td>(117) 3.78</td><td></td></tr><tr><td> HIV tested and positive</td><td>(4,645) 11.73</td><td>(532) 17.17</td><td></td></tr><tr><td> Never tested</td><td>(25,428) 64.20</td><td>(2,449) 79.05</td><td></td></tr><tr><td>Maximum parity (M, SD)</td><td>1.79, 2.13</td><td>2.28, 2.06</td><td>&lt;0.001</td></tr><tr><td>Pregnancy outcome summarized from maternity history</td><td></td><td></td><td>&lt;0.001</td></tr><tr><td> All live births</td><td>(22,005) 55.56</td><td>(1,917) 61.88</td><td></td></tr><tr><td>&#8805; 1 pregnancy was a still birth</td><td>(29,68) 7.49</td><td>(317) 10.23</td><td></td></tr><tr><td> No outcome reported</td><td>(14,632) 36.94</td><td>(864) 27.89</td><td></td></tr></table>
7268e95d57581cf5389c15adb7a8f305cf6576a1f447bf6610bbbd881460821a.png
complex
<table><tr><td>Model</td><td colspan="2">Fatal + non-fatal events</td><td colspan="2">Fatal events</td></tr><tr><td></td><td>Women</td><td>Men</td><td>Women</td><td>Men</td></tr><tr><td>Crude</td><td>1.16 (1.04&#8211;1.29</td><td>1.05 (0.96&#8211;1.15)</td><td>1.27(1.04&#8211;1.55)</td><td>1.24 (1.02&#8211;1.50)</td></tr><tr><td>Adjusted*</td><td>1.06 (0.95&#8211;1.17)</td><td>0.96 (0.88&#8211;1.06)</td><td>1.11 (0.91&#8211;1.35)</td><td>1.09 (0.90&#8211;1.33)</td></tr></table>
e8f5028f27c6bac2e7f89fe19e3df177ddeb90fd5d8eb0fb5352ef1eb236c530.png
simple
<table><tr><td>Formulation</td><td>Hardness (kg/cm<sup>2</sup>)</td><td>Friability (%)</td><td>%Drug content</td><td>Disintegration time (sec.)</td></tr><tr><td>S1</td><td>3.6&#177;0.17</td><td>0.61&#177;0.10</td><td>98.99&#177;0.3</td><td>67.4&#177;1.2</td></tr><tr><td>S2</td><td>3.7&#177;0.11</td><td>0.67&#177;0.11</td><td>99.29&#177;0.7</td><td>38.5&#177;1.8</td></tr><tr><td>S3</td><td>3.3&#177;0.15</td><td>0.65&#177;0.11</td><td>99.45&#177;0.11</td><td>42.1&#177;1.3</td></tr><tr><td>S4</td><td>3.8&#177;0.11</td><td>0.63&#177;0.15</td><td>99.75&#177;0.15</td><td>30.2&#177;1.5</td></tr><tr><td>S5</td><td>3.5&#177;0.12</td><td>0.62&#177;0.09</td><td>99.89&#177;0.12</td><td>14.4&#177;1</td></tr><tr><td>S6</td><td>3.2&#177;0.10</td><td>0.60&#177;0.16</td><td>99.25&#177;0.13</td><td>71.2&#177;1.5</td></tr><tr><td>S7</td><td>3.9&#177;0.08</td><td>0.62&#177;0.13</td><td>99.76&#177;0.11</td><td>69.3&#177;1.7</td></tr><tr><td>S8</td><td>3.5&#177;0.16</td><td>0.62&#177;0.16</td><td>99.69&#177;0.10</td><td>52.8&#177;1.2</td></tr><tr><td>S9</td><td>3.6&#177;0.15</td><td>0.63&#177;0.11</td><td>99.88&#177;0.09</td><td>48.6&#177;1.4</td></tr><tr><td>S10</td><td>3.8&#177;0.14</td><td>0.62&#177;0.12</td><td>99.92&#177;0.11</td><td>38.7&#177;1.3</td></tr></table>
f7404d2122c2a7a259d61de2d00ad71a52db1ffd7b61a8813f74e92ef7b769ec.png
complex
<table><tr><td rowspan="3">Peak torque (Nm)</td><td colspan="3">Mean &#177; SD</td><td>Within</td><td>Between</td><td>All</td><td rowspan="3">P-value</td><td>95% CI</td><td>SEM (%) &#177;</td></tr><tr><td>Session 1</td><td>Session 2</td><td>Session 3</td><td>ICC (2&#8211;3)</td><td>ICC (1&#8211;2)</td><td>ICC</td><td>lower; upper</td><td>MDC (%)</td></tr><tr><td><i>Quadriceps right</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Concentric at 60os<sup>&#8722;1</sup></td><td>229.4 &#177; 37.5</td><td>223.5 &#177; 33.9</td><td>224.5 &#177; 37.5</td><td>.93</td><td>.93</td><td>.95</td><td>0.290</td><td>0.90; 0.98</td><td>3.6 &#177; 9.9</td></tr><tr><td>Isometric</td><td>257.8 &#177; 46.9</td><td>255.3 &#177; 55.7</td><td>245.9 &#177; 55.4</td><td>.99</td><td>.92</td><td>.96</td><td>0.210</td><td>0.92; 0.98</td><td>4.2 &#177; 11.6</td></tr><tr><td>Eccentric at 60os<sup>&#8722;1</sup></td><td>303.0 &#177; 63.6</td><td>303.3 &#177; 66.7</td><td>298.4 &#177; 62.7</td><td>.97</td><td>.93</td><td>.96</td><td>0.055</td><td>0.93; 0.98</td><td>4.1 &#177; 11.3</td></tr><tr><td><i>Hamstrings right</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Concentric at 60os<sup>&#8722;1</sup></td><td>125.0 &#177; 27.3</td><td>129.9 &#177; 29.6</td><td>129.7 &#177; 27.9</td><td>.97</td><td>.89</td><td>.95</td><td>0.021</td><td>0.90; 0.98</td><td>4.9 &#177; 13.5</td></tr><tr><td>Isometric</td><td>138.1 &#177; 34.1</td><td>139.9 &#177; 33.8</td><td>131.1 &#177; 33.5</td><td>.99</td><td>.93</td><td>.96</td><td>0.660</td><td>0.92; 0.98</td><td>4.8 &#177; 13.3</td></tr><tr><td>Eccentric at 60os<sup>&#8722;1</sup></td><td>171.5 &#177; 33.8</td><td>166.9 &#177; 40.9</td><td>162.4 &#177; 40.3</td><td>.97</td><td>.91</td><td>.95</td><td>0.088</td><td>0.91; 0.98</td><td>5.1 &#177; 14.1</td></tr><tr><td><i>Quadriceps left</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Concentric at 60os<sup>&#8722;1</sup></td><td>219.4 &#177; 36.5</td><td>215.9 &#177; 38.0</td><td>213.8 &#177; 38.5</td><td>.96</td><td>.96</td><td>.95</td><td>0.343</td><td>0.91; 0.98</td><td>3.8 &#177; 10.5</td></tr><tr><td>Isometric</td><td>236.0 &#177; 43.9</td><td>235.3 &#177; 46.5</td><td>235.3 &#177; 43.7</td><td>.94</td><td>.94</td><td>.93</td><td>0.688</td><td>0.87; 0.97</td><td>4.8 &#177; 13.3</td></tr><tr><td>Eccentric at 60os<sup>&#8722;1</sup></td><td>267.8 &#177; 58.8</td><td>268.4 &#177; 59.9</td><td>271.8 &#177; 59.6</td><td>.96</td><td>.96</td><td>.96</td><td>0.988</td><td>0.92; 0.98</td><td>4.4 &#177; 12.2</td></tr><tr><td><i>Hamstrings left</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Concentric at 60os<sup>&#8722;1</sup></td><td>129.3 &#177; 26.6</td><td>127.6 &#177; 25.9</td><td>130.0 &#177; 31.2</td><td>.96</td><td>.96</td><td>.96</td><td>0.809</td><td>0.91; 0.98</td><td>4.8 &#177; 13.3</td></tr><tr><td>Isometric</td><td>129.8 &#177; 33.5</td><td>129.6 &#177; 31.2</td><td>127.7 &#177; 31.0</td><td>.91</td><td>.91</td><td>.94</td><td>0.755</td><td>0.89; 0.97</td><td>5.7 &#177; 15.8</td></tr><tr><td>Eccentric at 60os<sup>&#8722;1</sup></td><td>162.2 &#177; 36.4</td><td>156.2 &#177; 33.7</td><td>161.8 &#177; 34.1</td><td>.98</td><td>.98</td><td>.97</td><td>0.075</td><td>0.94; 0.99</td><td>3.5 &#177; 9.7</td></tr></table>
52a8ec39a031137a21941b7c8a419315613e62a894b0e4ec82842404bab9f0ee.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Age &lt; 65 (<i>n</i> = 43)</td><td colspan="2">Age &#8805; 65 (<i>n</i> = 23)</td><td rowspan="2"><i>P</i> Value</td></tr><tr><td>Mean</td><td>Std Dev</td><td>Mean</td><td>Std Dev</td></tr><tr><td>Volume</td><td>1610.9</td><td>395.6</td><td>1677.6</td><td>434.6</td><td>0.61</td></tr><tr><td>D98%</td><td>48.9</td><td>1.8</td><td>48.8</td><td>1.6</td><td>0.50</td></tr><tr><td>D2%</td><td>53.9</td><td>1.5</td><td>53.9</td><td>1.3</td><td>0.61</td></tr><tr><td>Median</td><td>51.7</td><td>1.6</td><td>51.9</td><td>1.3</td><td>0.61</td></tr><tr><td>Mean</td><td>51.7</td><td>1.6</td><td>51.7</td><td>1.2</td><td>0.30</td></tr><tr><td>Homogeneity index</td><td>0.1</td><td>0.0</td><td>0.1</td><td>0.0</td><td>0.61</td></tr><tr><td>Conformity index</td><td>0.9</td><td>0.1</td><td>0.9</td><td>0.2</td><td>0.30</td></tr></table>
6250736ab3ba69a93d9a47df56ce822b8245cbbab024a7a4d048eaa990bc357f.png
complex
<table><tr><td></td><td colspan="3">Strain detected</td></tr><tr><td>Pathogen</td><td>Only by BC</td><td>Only by Septi<i>Fast</i></td><td>Both methods</td></tr><tr><td><i>S.aureus </i>(MSSA)</td><td>0</td><td>3</td><td>3</td></tr><tr><td><i>S.aureus </i>(MRSA)</td><td>2</td><td>0</td><td>4</td></tr><tr><td><i>S.pneumoniae</i></td><td>0</td><td>1</td><td>0</td></tr><tr><td>Streptococcus spp.</td><td>0</td><td>2</td><td>1</td></tr><tr><td><i>Enterococcus faecalis</i></td><td>0</td><td>1</td><td>0</td></tr><tr><td><i>Enterococcus faecium</i></td><td>2</td><td>0</td><td>0</td></tr><tr><td><i>Enterobacter aerogenes/cloacae</i></td><td>0</td><td>3</td><td>1</td></tr><tr><td><i>Escherichia coli</i></td><td>0</td><td>3</td><td>9</td></tr><tr><td><i>Klebsiella pneumoniae/oxytoca</i></td><td>1</td><td>5</td><td>1</td></tr><tr><td><i>Pseudomonas aeruginosa</i></td><td>1</td><td>4</td><td>1</td></tr><tr><td><i>Candida albicans</i></td><td>0</td><td>1</td><td>0</td></tr><tr><td><i>Candida tropicalis</i></td><td>0</td><td>1</td><td>1</td></tr><tr><td>Sub-total</td><td>6</td><td>24</td><td>21</td></tr><tr><td>Not detectable by SeptiFast</td><td>5</td><td>0</td><td>0</td></tr><tr><td>Total</td><td>11</td><td>24</td><td>21</td></tr></table>
6492bdee0228ba49bce41f716fd289652156e52866864fd0726a71e4cef2761e.png
complex
<table><tr><td>Negative binomial counts &gt; 0</td><td colspan="3">Univariate</td><td colspan="3">Multivariable</td></tr><tr><td>Variable</td><td>IRR</td><td colspan="2">95 % CI</td><td>IRR</td><td colspan="2">95 % CI</td></tr><tr><td>No. of persons sleeping in house</td><td>0.902</td><td>0.740</td><td>1.100</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>No. of ITNs per house</td><td>0.559*</td><td>0.349*</td><td>0.897*</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>IRS, ever</td><td>0.902</td><td>0.440</td><td>1.851</td><td>1.039</td><td>0.444</td><td>2.433</td></tr><tr><td>Closed eaves</td><td>0.217</td><td>0.016</td><td>2.956</td><td>0.102*</td><td>0.011*</td><td>0.904*</td></tr><tr><td>Metal roof</td><td>3.197</td><td>0.287</td><td>35.610</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Fire burned previous night</td><td>0.810</td><td>0.252</td><td>2.608</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Open well</td><td>2.229*</td><td>1.078*</td><td>4.608*</td><td>2.257*</td><td>1.068*</td><td>4.766*</td></tr><tr><td>Rainy season</td><td>1.420</td><td>0.714</td><td>2.824</td><td>1.000</td><td>0.360</td><td>2.776</td></tr><tr><td>Within 3 km of Lake Mweru</td><td>0.601</td><td>0.291</td><td>1.243</td><td>0.204*</td><td>0.072*</td><td>0.581*</td></tr><tr><td>Interaction: Season by inland/lakeside</td><td>0.634</td><td>0.145</td><td>2.766</td><td>3.932*</td><td>1.024<sup>a</sup></td><td>15.096*</td></tr></table>
dd9ce572d5da07b19f1775ed517aac7d6762d73c535ba443d8ffa15c159b85f6.png
simple
<table><tr><td>Year</td><td>Authors</td><td>Age, gender</td><td>Concurrent malignancy (location)</td><td>Past history of recurrence</td><td>Diagnostic modality</td></tr><tr><td>2015</td><td>Jerraya H, et al.</td><td>59, F</td><td>Insulinoma (pancreas)</td><td>NA</td><td>NA</td></tr><tr><td>2015</td><td>Jung SY, et al.</td><td>11, F</td><td>Insulinoma (pancreas)</td><td>Non</td><td>US, CT, MRI</td></tr><tr><td>2009</td><td>Wheeler YY, et al.</td><td>62, M</td><td>Renal cell carcinoma (right kidney)</td><td>Non</td><td>CECT</td></tr><tr><td>2015</td><td>Present case</td><td>23, M</td><td>SCS (abdominal)</td><td>Abdominal</td><td>US, CECT, MRI</td></tr></table>
950caf77042c9f4b6df15b0fb0dd41085733635542994424746e68b0135e54b8.png
complex
<table><tr><td> </td><td>LOO AUC (SE)</td><td>Sensitivity</td><td>Specificity</td><td>Median number of peaks per LOO iteration</td><td>Mean number of peaks per LOO iteration (SD)</td></tr><tr><td colspan="6">Lymph node status</td></tr><tr><td> Negative <i>vs</i> Positive</td><td>0.95 (0.03)</td><td>73.9</td><td>91.7</td><td>1</td><td>1 (0)</td></tr><tr><td colspan="6">Histological subtype</td></tr><tr><td> Squamous ca. <i>vs</i> adenoca.</td><td>0.88 (0.05)</td><td>88.2</td><td>59.0</td><td>1</td><td>1 (0)</td></tr><tr><td> Squamous ca. <i>vs</i> adsq ca.</td><td>0.85 (0.06)</td><td>84.6</td><td>100</td><td>4</td><td>3.8 (0.9)</td></tr><tr><td> Adenoca. <i>vs</i> adsq ca.</td><td>0.94 (0.06)</td><td>94.1</td><td>100</td><td>1</td><td>0.9 (0.3)</td></tr><tr><td colspan="6">LVSI</td></tr><tr><td> Negative <i>vs</i> Positive</td><td>0.81 (0.06)</td><td>78.1</td><td>73.1</td><td>1</td><td>1 (0)</td></tr><tr><td colspan="6">Recurrence</td></tr><tr><td> Negative <i>vs</i> Positive</td><td>0.92 (0.04)</td><td>79.2</td><td>90.0</td><td>3</td><td>3 (0)</td></tr></table>
cf4c1fe390827f3abbe47b4b55f647ad8224884be95a3dffb9b773555480bb8a.png
simple
<table><tr><td></td><td>Annual expenses ($)</td></tr><tr><td>Annual cost of mobile health clinic</td><td>565,700</td></tr><tr><td>Total annual visits</td><td>4,848</td></tr><tr><td>Total visits discounted by 20%</td><td>3,878</td></tr><tr><td>Cost per visit</td><td>117</td></tr><tr><td>Cost of preventable emergency department visit [9]</td><td>923</td></tr><tr><td>Cost avoided per mobile clinic visit</td><td>806</td></tr><tr><td>Annual projected costs avoided</td><td>3,125,668</td></tr></table>
4e459f840eace4d1d2ebd55c5a51a7eb48330fd7a8da3f511c1b547e67668444.png
complex
<table><tr><td>Cohorts</td><td>TCGA</td><td>TCGA-sub</td><td>RT-qPCR</td><td>Ivshina</td><td>Schmidt</td><td>Symmans</td><td>Wang</td></tr><tr><td>N</td><td>520</td><td>59</td><td>71</td><td>249</td><td>200</td><td>298</td><td>286</td></tr><tr><td colspan="8">Histological type</td></tr><tr><td> Ductal</td><td>442 (85.0)</td><td>51 (86.4)</td><td>56 (78.9)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Lobular</td><td>41 (7.9)</td><td>3 (5.1)</td><td>5 (7.0)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Mixed and others</td><td>36 (6.9)</td><td>5 (8.5)</td><td>9 (12.7)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">Tumour diameter</td></tr><tr><td> &#8804;2.0 cm</td><td>133 (25.6)</td><td>20 (33.9)</td><td>39 (54.9)</td><td>126 (50.6)</td><td>112 (56.0)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> &gt;2.0 cm</td><td>364 (70.0)</td><td>38 (64.4)</td><td>32 (45.1)</td><td>123 (49.4)</td><td>88 (44.0)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">Regional lymph nodes</td></tr><tr><td> Negative</td><td>253 (48.7)</td><td>25 (42.4)</td><td>34 (47.9)</td><td>159 (63.9)</td><td>200 (100)</td><td>175 (58.7)</td><td>286 (100)</td></tr><tr><td> Positive</td><td>256 (49.2)</td><td>34 (57.6)</td><td>36 (50.7)</td><td>81 (32.5)</td><td>0 (0)</td><td>112 (37.6)</td><td>0 (0)</td></tr><tr><td colspan="8">Distant metastasis</td></tr><tr><td> Negative</td><td>491 (94.4)</td><td>57 (96.6)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Positive</td><td>15 (2.9)</td><td>1 (1.7)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">TNM stage</td></tr><tr><td> I</td><td>89 (17.1)</td><td>13 (22.0)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> II</td><td>290 (55.8)</td><td>34 (57.6)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> III</td><td>110 (21.2)</td><td>11 (18.6)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> IV</td><td>14 (2.7)</td><td>1 (1.7)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">Tumour grade</td></tr><tr><td> Grade 1</td><td>&#8211;</td><td>&#8211;</td><td>7 (9.9)</td><td>68 (27.3)</td><td>29 (14.5)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Grade 2</td><td>&#8211;</td><td>&#8211;</td><td>25 (35.2)</td><td>126 (50.6)</td><td>136 (68.0)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Grade 3</td><td>&#8211;</td><td>&#8211;</td><td>36 (50.7)</td><td>55 (22.1)</td><td>35 (17.5)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">ER status</td></tr><tr><td> Negative</td><td>117 (22.5)</td><td>9 (15.3)</td><td>18 (25.4)</td><td>34 (13.7)</td><td>&#8211;</td><td>0 (0)</td><td>77 (26.9)</td></tr><tr><td> Positive</td><td>396 (76.2)</td><td>48 (81.4)</td><td>52 (73.2)</td><td>211 (84.7)</td><td>&#8211;</td><td>298 (100)</td><td>209 (73.1)</td></tr><tr><td colspan="8">PR status</td></tr><tr><td> Negative</td><td>176 (33.8)</td><td>16 (27.1)</td><td>22 (31.0)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Positive</td><td>336 (64.6)</td><td>41 (69.5)</td><td>48 (67.6)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">HER2 status</td></tr><tr><td> Negative</td><td>361 (69.4)</td><td>48 (81.4)</td><td>60 (84.5)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Positive</td><td>101 (19.4)</td><td>10 (16.9)</td><td>10 (14.1)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">Triple-negative</td></tr><tr><td> True</td><td>72 (13.8)</td><td>7 (11.9)</td><td>11 (15.5)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> False</td><td>448 (86.2)</td><td>52 (89.1)</td><td>60 (84.5)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td colspan="8">PAM50 subtype</td></tr><tr><td> Basal-like</td><td>96 (18.5)</td><td>11 (18.6)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> HER2-enriched</td><td>58 (11.2)</td><td>4 (6.8)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Luminal A</td><td>231 (44.4)</td><td>32 (54.2)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Luminal B</td><td>127 (24.4)</td><td>12 (20.3)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Normal-like</td><td>8 (1.5)</td><td>0 (0)</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td><td>&#8211;</td></tr></table>
cf4a2a09e80683961e3b1d159dd317d92bfbab52ddcba21e3c03f26cf8bd6483.png
simple
<table><tr><td>Primer</td><td>Gene</td><td>Sequence</td><td>Fragment size (bp)</td></tr><tr><td>rpoB-FS</td><td></td><td>TGGTCCGCTTGCACGAGGGTCAGA</td><td></td></tr><tr><td></td><td><i>rpoB</i></td><td></td><td>758</td></tr><tr><td>rpoB-RS</td><td></td><td>CAGGAAGGGAATCATCGCGG</td><td></td></tr><tr><td>katG-FS</td><td></td><td>TGCAGATGGGGCTGATCTACG</td><td></td></tr><tr><td></td><td><i>katG</i></td><td>ACCCATGTCTCGGTGGATCAG</td><td>596</td></tr><tr><td>katG-RS</td><td></td><td></td><td></td></tr><tr><td>inhA-FS</td><td></td><td>ACATACCTGCTGCGCAAT</td><td></td></tr><tr><td></td><td><i>inhA</i></td><td>TCACATTCGACGCCAAAC</td><td>400</td></tr><tr><td>inhA-RS</td><td></td><td></td><td></td></tr></table>
43d434a1d8023044b539a3aec21d08c6cfe499e5d281b27a8ef10f9edea5ffee.png
simple
<table><tr><td>Toxo DB type<sup>a</sup></td><td>No. of isolates</td><td>Designation</td></tr><tr><td>9, (Chinese1)</td><td>1</td><td>TgDgCo4</td></tr><tr><td>10 (Type I)</td><td>2</td><td>TgCtCo 2, 7</td></tr><tr><td>14</td><td>6</td><td>TgDgCo9,12,15,18; TgCkCo2;TgCtco14</td></tr><tr><td>18</td><td>3</td><td>TgCtCo 12, 13; TgDgCo3</td></tr><tr><td>23</td><td>1</td><td>TgDgCo19</td></tr><tr><td>28</td><td>2</td><td>TgCtCo 1; TgCkCo5</td></tr><tr><td>29</td><td>5</td><td>TgDgCo1,2,10,20; TgCkCo20</td></tr><tr><td>38</td><td>13</td><td>TgCkCo6,8,10,12,13,15,21,23,24; TgCtCo 4,10,11; TgDgCo17</td></tr><tr><td>40</td><td>1</td><td>TgCtCo5x</td></tr><tr><td>44</td><td>3</td><td>TgDgCo5,6,11</td></tr><tr><td>46</td><td>3</td><td>TgDgCo8,14,16</td></tr><tr><td>61</td><td>2</td><td>TgCtCo 5,6</td></tr><tr><td>62</td><td>2</td><td>TgCtCo3,9</td></tr><tr><td>79</td><td>1</td><td>TgDgCo13</td></tr><tr><td>101</td><td>1</td><td>TgCtCo15</td></tr><tr><td>122</td><td>1</td><td>TgDgCo7</td></tr><tr><td>128</td><td>1</td><td>TgCtCo8</td></tr><tr><td>178</td><td>1</td><td>TgCkCo4</td></tr><tr><td>179</td><td>2</td><td>TgCkCo17,22</td></tr><tr><td>188</td><td>1</td><td>TgCkCo9</td></tr></table>
f30833786152e08c8a50f4e1e1592835cf4fa19934e058265ab492341301d2ef.png
complex
<table><tr><td>Region-based test result</td><td colspan="2">Truth</td><td></td></tr><tr><td></td><td>True H<sub><i>A</i></sub></td><td>True H<sub>0</sub></td><td>Total</td></tr><tr><td><i>p</i>-value &lt; Threshold: reject null hypothesis</td><td>A</td><td>C</td><td>A + C</td></tr><tr><td><i>p</i>-value &#8805; Threshold: do not reject null hypothesis</td><td>B</td><td>D</td><td>B + D</td></tr><tr><td>Total</td><td>A + B</td><td>C + D</td><td></td></tr></table>
9d2fd4f88cc8a74873254147a9dbf6838208cc2c14919434d11c8ef9be9ed5fc.png
complex
<table><tr><td></td><td colspan="2">Informatively cued letter-parity task</td><td colspan="2">Non-informatively cued letter-parity task</td><td colspan="2">Informatively cued color-shape task</td></tr><tr><td></td><td>Young</td><td>Older</td><td>Young</td><td>Older</td><td>Young</td><td>Older</td></tr><tr><td>Hits</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TS</td><td>89 &#177; 7</td><td>67 &#177; 15</td><td>87 &#177; 6</td><td>67 &#177; 15</td><td>93 &#177; 6</td><td>73 &#177; 16</td></tr><tr><td>TR</td><td>88 &#177; 6</td><td>70 &#177; 15</td><td>88 &#177; 7</td><td>71 &#177; 13</td><td>94 &#177; 5</td><td>77 &#177; 15</td></tr><tr><td>Errors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TS</td><td>10 &#177; 7</td><td>29 &#177; 14</td><td>13 &#177; 6</td><td>31 &#177; 15</td><td>7 &#177; 6</td><td>26 &#177; 15</td></tr><tr><td>TR</td><td>12 &#177; 5</td><td>27 &#177; 13</td><td>11 &#177; 6</td><td>28 &#177; 12</td><td>5 &#177; 4</td><td>21 &#177; 13</td></tr><tr><td>RT</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TS</td><td>769 &#177; 145</td><td>1095 &#177; 171</td><td>1016 &#177; 156</td><td>1311 &#177; 148</td><td>611 &#177; 129</td><td>1038 &#177; 188</td></tr><tr><td>TR</td><td>762 &#177; 147</td><td>1063 &#177; 158</td><td>997 &#177; 160</td><td>1282 &#177; 143</td><td>575 &#177; 110</td><td>1005 &#177; 229</td></tr><tr><td>SC</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>7 &#177; 53</td><td>32 &#177; 61</td><td>19 &#177; 62</td><td>28 &#177; 78</td><td>36 &#177; 41</td><td>33 &#177; 103</td></tr><tr><td>MC</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>164 &#177; 109</td><td>309 &#177; 132</td><td>402 &#177; 109</td><td>510 &#177; 109</td><td>89 &#177; 84</td><td>338 &#177; 192</td></tr></table>
53b503b93f773930fa034bde2f0d0643d4693b5350b353e2f9553aaf0cc4e28e.png
complex
<table><tr><td colspan="2">Items</td><td>Cu NPs</td><td>Cu MPs</td></tr><tr><td colspan="2">Shape</td><td>Spherical</td><td>Spherical</td></tr><tr><td colspan="2">Primary size<sup>a</sup></td><td>32.7 &#177; 10.5 nm</td><td>25.3 &#177; 6.6 &#956;m</td></tr><tr><td rowspan="3">Hydrodynamic size (nm)<sup>b</sup></td><td>pH 1.5</td><td>n.a</td><td>n.a</td></tr><tr><td>pH 6.5</td><td>516 &#177; 116.9</td><td>n.a</td></tr><tr><td>pH 7.8</td><td>334 &#177; 128.3</td><td>n.a</td></tr><tr><td colspan="2">Surface area (m<sup>2</sup>/g)<sup>c</sup></td><td>14.7</td><td>0.16</td></tr><tr><td rowspan="3">Zeta potential (mV)<sup>d</sup></td><td>pH 1.5</td><td>25.5 &#177; 0.8</td><td>n.a</td></tr><tr><td>pH 6.5</td><td>1.32 &#177; 1.2</td><td>n.a</td></tr><tr><td>pH 7.8</td><td>&#8722;6.2 &#177; 0.2</td><td>n.a</td></tr></table>
3be8cb4ea3df62c05ab615669ec86b06457febdd2371515aaa6217169a780233.png
simple
<table><tr><td>Category label</td><td>Observed average</td><td>Infit MNSQ</td><td>Outfit MNSQ</td><td>Structure calibration</td></tr><tr><td>1</td><td>-23.71</td><td>1.10</td><td>41.06</td><td>None</td></tr><tr><td>2</td><td>-14.67</td><td>1.01</td><td>.99</td><td>-21.95</td></tr><tr><td>3</td><td>-5.31</td><td>0.98</td><td>.94</td><td>-9.63</td></tr><tr><td>4</td><td>.54</td><td>1.10</td><td>1.06</td><td>3.82</td></tr><tr><td>5</td><td>9.94</td><td>0.81</td><td>.80</td><td>7.69</td></tr><tr><td>6</td><td>16.12</td><td>.93</td><td>.94</td><td>20.07</td></tr></table>
885cc5cfe3ff7f585fd20f6e0f22dae28bb0c412097e61869cfa157f1cc4d31b.png
simple
<table><tr><td> </td><td><i>&#946;</i> intercept (standardised coefficient)</td><td><i>P </i>value</td></tr><tr><td>Height</td><td>0.094</td><td>0.48</td></tr><tr><td>Weight</td><td>0.003</td><td>0.98</td></tr><tr><td>Fat%</td><td>0.058</td><td>0.53</td></tr><tr><td>Physical activity</td><td>0.215</td><td>&lt;0.01</td></tr><tr><td>Age of onset of diabetes</td><td>0.16</td><td>0.09</td></tr><tr><td>Duration of diabetes</td><td>&#8722;0.046</td><td>0.56</td></tr><tr><td>HbA1c</td><td>&#8722;0.451</td><td>&lt;0.01</td></tr><tr><td>Insulin dose</td><td>0.20</td><td>0.07</td></tr><tr><td>Calcium intake</td><td>0.05</td><td>0.53</td></tr><tr><td>25(OH) vitamin D3</td><td>&#8722;0.003</td><td>0.964</td></tr><tr><td>Alkaline phosphatase</td><td>&#8722;0.19</td><td>0.09</td></tr><tr><td>PTH </td><td>&#8722;0.026</td><td>0.71</td></tr><tr><td>IGF-1</td><td>0.31</td><td>&lt;0.01</td></tr><tr><td>Testosterone</td><td>0.14</td><td>0.12</td></tr><tr><td>SHBG</td><td>0.11</td><td>0.24</td></tr></table>
c858b01687efc1fb43310cdac6c0fbf1ce8ad4c0d285adf8e4c033d38cbdd078.png
simple
<table><tr><td>Parameter</td><td>Meaning</td><td>Value</td></tr><tr><td><i>kphr</i></td><td>Phosphorylation of RsbR</td><td>0.1 / 1</td></tr><tr><td><i>kdpr</i></td><td>Dephosphorylation of RsbR-P</td><td>0.06</td></tr><tr><td><i>kphs</i></td><td>Phosphorylation of RsbS</td><td>0.4</td></tr><tr><td><i>kdps</i></td><td>Dephosphorylation of RsbS-P</td><td>1</td></tr></table>
22cdd35500f2a7305afb9078853f0bf78c9bb9cb9c3f032a40b12fb1f212ed33.png
simple
<table><tr><td>Ethnic Genotype</td><td><i>N</i></td><td>TC (mmol/l)</td><td>TAG (mmol/l)</td><td>HDL-C (mmol/l)</td><td>LDL-C (mmol/)</td><td>Apo A1 (g/l)</td><td>ApoB (g/l)</td><td>ApoA1/ApoB</td></tr><tr><td>Han</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> CC</td><td>566</td><td>5.23&#177;1.37</td><td>1.14(0.86)</td><td>1.68&#177;0.43</td><td>2.92&#177;1.00</td><td>1.35&#177;0.27</td><td>0.89&#177;0.23</td><td>1.59&#177;0.49</td></tr><tr><td> CT</td><td>197</td><td>5.02&#177;0.86</td><td>1.12(0.78)</td><td>1.73&#177;0.41</td><td>2.91&#177;0.76</td><td>1.36&#177;0.26</td><td>0.87&#177;0.19</td><td>1.63&#177;0.51</td></tr><tr><td> TT</td><td>102</td><td>4.92&#177;0.9</td><td>0.98(0.70)</td><td>2.00&#177;1.14</td><td>2.72&#177;0.70</td><td>1.40&#177;0.27</td><td>0.82&#177;0.21</td><td>1.82&#177;0.60</td></tr><tr><td> <i>F</i></td><td></td><td>4.073</td><td>&#8722;0.064</td><td>14.725</td><td>1.974</td><td>2.021</td><td>4.750</td><td>8.280</td></tr><tr><td> <i>P</i></td><td></td><td>0.017</td><td>0.949</td><td>0.000</td><td>0.140</td><td>0.133</td><td>0.009</td><td>0.000</td></tr><tr><td>Mulao</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> CC</td><td>555</td><td>5.06&#177;1.22</td><td>2.88(2.39)</td><td>1.74&#177;0.43</td><td>2.97&#177;0.89</td><td>1.35&#177;0.39</td><td>1.00&#177;0.58</td><td>1.66&#177;1.29</td></tr><tr><td> CT</td><td>230</td><td>4.95&#177;1.16</td><td>2.86(2.31)</td><td>1.83&#177;0.55</td><td>2.87&#177;0.87</td><td>1.32&#177;0.48</td><td>1.07&#177;0.71</td><td>1.64&#177;0.85</td></tr><tr><td> TT</td><td>117</td><td>4.88&#177;1.69</td><td>2.68(2.15)</td><td>1.86&#177;0.65</td><td>2.72&#177;1.09</td><td>1.26&#177;0.58</td><td>1.02&#177;0.67</td><td>1.56&#177;0.98</td></tr><tr><td> <i>F</i></td><td></td><td>1.386</td><td>&#8722;6.446</td><td>4.582</td><td>3.810</td><td>7.813</td><td>1.127</td><td>3.028</td></tr><tr><td> <i>P</i></td><td></td><td>0.251</td><td>0.000</td><td>0.010</td><td>0.023</td><td>0.000</td><td>0.324</td><td>0.049</td></tr></table>
06dbb998915a8a9b9f48690741ecffb12898e68ff6aeacb4ac9a41fb7b29b93d.png
simple
<table><tr><td></td><td>Sex</td><td>Age</td><td>Pituitary MRI</td><td>Internal carotid RMI</td><td>Other characteristics</td><td>Molecular studies</td><td>References</td></tr><tr><td>1</td><td>N</td><td>N</td><td>Not specified (except for normal posterior pituitary).</td><td>Absence of ICA and carotid canal.</td><td>Not specified.</td><td>NP</td><td>[14]</td></tr><tr><td>2</td><td>M</td><td>18 m</td><td>Pituitary hypoplasia.</td><td>Anomaly of right ICA.</td><td>TSH, GH, ACTH deficiency. Central diabetes insipidus. Possible hypogonadism.</td><td>NP</td><td>[13]</td></tr><tr><td>3</td><td>F</td><td>5 m</td><td>Absence of anterior pituitary and ectopic pituitary posterior lobe.</td><td>Absence of right common carotid artery, right ICA, right anterior cerebral artery.</td><td>TSH, ACTH and GH deficiency. No evidence of diabetes insipidus. Genitalia were normal. Single central maxillary incisor.</td><td>NP</td><td>[7]</td></tr><tr><td>4</td><td>M</td><td>23 year</td><td>Absence of anterior pituitary and ectopic pituitary posterior lobe.</td><td>Absence of right ICA and carotid canal and A1 segment of the right anterior cerebral artery.</td><td>Congenital microphthalmia with cataract and coloboma of the right eye, encephalocele. Hormonal substitution treatments not specified.</td><td>NP</td><td>[5]</td></tr><tr><td>5</td><td>M</td><td>37 year</td><td>Absence of anterior pituitary.</td><td>Hypoplasia of right ICA and carotid canal.</td><td>Amblyopia of the left eye caused by an optic nerve coloboma, encephalocele. Hormonal substitution treatments not specified.</td><td>NP</td><td>[5]</td></tr><tr><td>6</td><td>F</td><td>29 year</td><td>Pituitary hypoplasia and ectopic pituitary posterior lobe.</td><td>Absence of right ICA, carotid canal, and A1 segment of the right anterior cerebral artery.</td><td>TSH, ACTH, and GH deficiency. No evidence of diabetes insipidus. Hypogonadism. Chiari I malformation with syringomyelia.</td><td>NP</td><td>[9]</td></tr><tr><td>7</td><td>M</td><td>5 year</td><td>Absence of anterior pituitary and ectopic pituitary posterior lobe.</td><td>Absence of left ICA and carotid canal, A1 segment of the left anterior cerebral artery and the anterior communicating artery.</td><td>Retrognathia, microphallus, and cryptorchidism. TSH, ACTH, GH deficiency, but no evidence of diabetes insipidus. Possibile hypogonadism.</td><td>NP</td><td>[10]</td></tr><tr><td>8</td><td>M</td><td>11 year</td><td>Pituitary hypoplasia</td><td>Absence of left ICA and carotid canal; hypoplasia of A1 segment of left anterior cerebral artery</td><td>TSH, ACTH, GH deficiency. Central diabetes insipidus. Microphallus with possible hypogonadism.</td><td>NP</td><td>[6]</td></tr><tr><td>9</td><td>F</td><td>10 year</td><td>Hypoplastic anterior pituitary, flat sella turcica, absent pituitary stalk</td><td>Agenesis of the left ICA and the left carotid canal</td><td>GH, TSH, gonadotropin deficiency. No evidence of diabetes insipidus. Born out of a consanguineous marriage.</td><td>No <i>HESX1</i>, <i>LHX4</i>, <i>OTX2</i> mutations</td><td>[8]</td></tr><tr><td>10</td><td>F</td><td>7 month</td><td>Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity</td><td>Absence of the left ICA</td><td>Desaturation episodes, recurrent respiratory infections. Short hands and feet. GH, ACTH and TSH deficiency.</td><td>17q24.2 deletion</td><td>[3]</td></tr><tr><td>11</td><td>F</td><td>2 year</td><td>Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity</td><td>Absence of the right ICA</td><td>GH, TSH, and gonadotropin deficiency. No clinical evidence of diabetes insipidus.</td><td>NP</td><td>[11]</td></tr><tr><td>12</td><td>M</td><td>3 week</td><td>Absence of anterior pituitary with ectopic posterior pituitary</td><td>Absence of the left ICA and carotid canal</td><td>GH, TSH, ACTH and gonadotropin deficiency. Microphallus.</td><td>NP</td><td>[12]</td></tr><tr><td>13</td><td>M</td><td>17 year</td><td>Adenohypophyseal hypoplasia with a lack of posterior pituitary hyperintensity</td><td>Agenesis of the left ICA</td><td>GH deficiency. No other pituitary deficiencies. No clinical evidence of diabetes insipidus.</td><td>Normal array-CGH</td><td>Our case</td></tr></table>
9b60f3b7feec610bd3c0841a19627ca6a8c8836a93105d8fbb61db37800db6f9.png
simple
<table><tr><td>#</td><td>SET I (8-week-old)</td><td>Summary</td></tr><tr><td>1</td><td>Control diet (CD)</td><td>Peliosis, nuclear dysplasia and nuclear retreat.</td></tr><tr><td>2</td><td>CD + Quercetin</td><td>Small &amp; large lymphoplasmacytic clusters.</td></tr><tr><td>3</td><td>CD + &#948;-Tocotrienol</td><td>Large lymphoplasmacytic (LP) cluster, Councilman body.</td></tr><tr><td>4</td><td>CD + Dexamethasone</td><td>Councilman body, nuclear retreat and dysplasia, microvesicular steatosis, large lymphoplasmacytic (LP) cluster, closed sinusoids, cytoplasmic condensation.</td></tr><tr><td></td><td>SET II (46-week-old)</td><td>Summary</td></tr><tr><td>5</td><td>Control diet (CD)</td><td>LP clusters, nuclear Retreat and dysplasia, microvesicular steatosis.</td></tr><tr><td>6</td><td>CD + Quercetin</td><td>Coucilman body, nuclear dysplasia and nuclear retreat.</td></tr><tr><td>7</td><td>CD + &#948;-Tocotrienol</td><td>Small &amp; large Lymphoplasmacytic clusters.</td></tr><tr><td>8</td><td>CD + Dexamethasone</td><td>Small LP cluster, Councilman body, nuclear Retreat and dysplasia cytoplasmic condensation.</td></tr></table>
9ea21e3efd5defafa0d9988f3696cc2769bde9d29c6a42616a6fd689cfd3f5ca.png
simple
<table><tr><td></td><td>TLE (<i>n</i> = 20)</td><td>Controls (<i>n</i> = 12)</td></tr><tr><td>Age</td><td>33.60 (7.32)</td><td>31.58 (3.03)</td></tr><tr><td>Years of education</td><td>15.35 (1.98)</td><td>16.75 (1.14)</td></tr><tr><td>Duration of epilepsy (years)</td><td>20.40 (11.22)</td><td></td></tr><tr><td>Age at epilepsy onset (years)</td><td>13.65 (8.67)</td><td></td></tr><tr><td>Seizure freq. (per month)</td><td>3.50 (0.91)</td><td></td></tr><tr><td>AEDs (number)</td><td>1.85 (0.62)</td><td></td></tr><tr><td> 1</td><td> 30%</td><td></td></tr><tr><td> 2</td><td> 55%</td><td></td></tr><tr><td> &#8805; 3</td><td> 15%</td><td></td></tr></table>
80b98ef55f29fa1f3bbc5ce93effc1bd1aa7d0724340ef49c678c4baaefc67f9.png
simple
<table><tr><td>Acronym</td><td>Description</td><td>Source</td></tr><tr><td>GDP</td><td>Gross Domestic Product per capita (PPS$), i.e. a measure of the economic activity and of the wealth of a country.</td><td>(1)</td></tr><tr><td>Real GDP Growth rate</td><td>The growth rate of the GDP in terms of volume (%), values determined by the prices of the previous year, and thus computed volume changes are imposed on the level of a reference year so that price movements will not inflate the growth rate.</td><td>(2)</td></tr><tr><td>Government Debt</td><td>General government gross debt (% of GDP, million EUR).</td><td>(1)</td></tr><tr><td>U</td><td>Unemployment rate (%), i.e. the percentage of unemployed people in the active population.</td><td>(3)</td></tr></table>
5879162caae63451938a6c91a246a04a7bdc1457b5c3c1d5f77d9cdd559565bf.png
simple
<table><tr><td>Variable</td><td>Mean</td><td>95% CI</td></tr><tr><td>Children seen per day</td><td>1.8</td><td>1.8-1.9</td></tr><tr><td>Time spent on seeing children (hrs)/day</td><td>0.4</td><td>20.9-21.1</td></tr><tr><td>No of Health education activities/day</td><td>2.5</td><td>2.3-2.6</td></tr><tr><td>Time spent on IEC (hrs)</td><td>0.2</td><td>11.4-12.8</td></tr><tr><td>Follow-ups/day</td><td>**2.6</td><td>2.4-2.8</td></tr><tr><td>Hours on follow-up/child</td><td>1.7</td><td>1.5-1.8</td></tr><tr><td>Total hours spent on CCMm activities/day</td><td>*4.8</td><td>3.9-5.3</td></tr></table>
9903da823ec0027f737b7a783abd1d846502b3f6d7661a9a88a2fd6be4eb736a.png
complex
<table><tr><td>Study</td><td>Cell type</td><td>Treatment</td><td>Time points</td><td>Array</td></tr><tr><td colspan="5">Expression profiling studies on 3T3-L1 cell line</td></tr><tr><td>Guo <i>et al</i>. 2000 [14]</td><td>3T3-L1</td><td>DMI</td><td>0h, 6d</td><td>18k mouse cDNA filter arrays</td></tr><tr><td>Soukas <i>et al</i>. 2000 [15]</td><td>3T3-L1</td><td>DMI</td><td>PC,0h,6h,12h,24h,2d,3d, 4d, 7d,28d</td><td>Affymetrix mouse Mu11k</td></tr><tr><td>Ross <i>et al</i>. 2002 [16]</td><td>3T3-L1</td><td>DMI|DMI+Wnt-1&#8593;</td><td>0h, 16h, 32h, 2d, d14</td><td>Affymetrix mouse U74A</td></tr><tr><td>Burton <i>et al</i>. 2002 [17]</td><td>3T3-L1</td><td>DMI</td><td>0h,2h,8h,16h,24h</td><td>AffymetrixmouseMu11k</td></tr><tr><td>Burton <i>et al</i>. 2004 [18]</td><td>3T3-L1</td><td>DMI|DMI+TSA</td><td>0h,2h,8h,16h,24h,d2,d4</td><td>Affymetrix mouse U74A</td></tr><tr><td>Jessen at al. 2002 [19]</td><td>3T3-L1</td><td>DMI</td><td>0h, 1d, 4d, 7d</td><td>Affymetrix Mu11kB| U74Av2</td></tr><tr><td>Gerhold <i>et al</i>. 2002 [20]</td><td>3T3-L1</td><td>DMI+TZD|nTZD</td><td>0h, PA 6hT, PA 48hT, AD 6hT, AD 48hT</td><td>4k Affymetrix mouse mu6800</td></tr><tr><td>Hsiao <i>et al</i>. 2004 [21]</td><td>3T3-L1</td><td>TZDs</td><td>AD 24hT</td><td>Affymetrix mouse U74Av2</td></tr><tr><td>Hackl <i>et al</i>. 2005 [22]</td><td>3T3-L1</td><td>DMI</td><td>PC,0h,6h,12h,24h,2d,3d,4d,7d,14d</td><td>27K mouse cDNA microarray</td></tr><tr><td>Liu <i>et al</i>. 2005 [23]</td><td>3T3-L1</td><td>DMI|DI</td><td></td><td>Affymetrix mouse MOE430A</td></tr><tr><td>Pantoja <i>et al</i>. 2005 [24]</td><td>3T3-L1</td><td>D&#8596;M I| M&#8596;D I</td><td></td><td>38 k MEEBO microarray oligo set</td></tr><tr><td colspan="5">Adipogenesis expression studies on other mouse cell models including over-expression and knock out strategies</td></tr><tr><td>Huo <i>et al</i>. 2006 [25]</td><td>3T3-F442A</td><td>GH</td><td></td><td>Affymetrix mouse U74Av2</td></tr><tr><td>Akerblad <i>et al</i>. 2005 [26]</td><td>NIH-3T3</td><td>Ebf1&#8593;|Pparg&#8593;</td><td></td><td>Affymetrix mouse U74Av2</td></tr><tr><td>Baudry <i>et al</i>. 2006 [27]</td><td>PKB-/-MEF</td><td></td><td></td><td>22k Affy mouse MOE430A</td></tr><tr><td>Christian <i>et al</i>. 2005 [28]</td><td>RIPKO</td><td></td><td></td><td>Affymetrix mouse MOE430 2.0</td></tr><tr><td>Otto TC <i>et al</i>. 2007 [29]</td><td>C3H10T1/2</td><td>Bmp4&#8593;</td><td></td><td>Affymetrix mouse MOE430 2.0</td></tr><tr><td>Tseng <i>et al</i>. 2005 [30]</td><td>IRSKO PA</td><td></td><td></td><td>Affymetrix mouse U74Av2</td></tr><tr><td>Timmons <i>et al</i>. 2007 [31]</td><td>wPA, bPA</td><td></td><td>0d, 1d, 4d, 8d</td><td>Affymetrix mouse U74Av2</td></tr><tr><td colspan="5">Adipogenesis of human cell models</td></tr><tr><td>Hung <i>et al</i>. 2004 [32]</td><td>hMSC</td><td>DMI</td><td>0h,3d</td><td>8k human Universochip</td></tr><tr><td>Sekiya <i>et al</i>. 2004 [33]</td><td>hMSC</td><td></td><td>0h,1d,7d,14d,21d</td><td>12k Affymetrix human U95Av2</td></tr><tr><td>Nakamura <i>et al</i>. 2003 [34]</td><td>hMSC</td><td></td><td></td><td>3.4k focused cDNA microarray</td></tr><tr><td>Scheideler <i>et al</i>. 2008 [35]</td><td>hMADS</td><td>DMI+ROS</td><td>PC,-2d, 0h, 8h, 1d, 2d, 5d, 10d, 15d</td><td>30k human spotted oligo array</td></tr><tr><td>Urs <i>et al</i>. 2004 [36]</td><td>PA|AD</td><td></td><td></td><td>19K human cDNA microarray</td></tr></table>
b47096b214685cb13aa2ff67d4c21498ceea16ffc2207f1fa00ebe3a91d8b42b.png
simple
<table><tr><td>Indicator</td><td><i>r</i></td><td><i>p</i> value</td></tr><tr><td>GDP</td><td>0.812</td><td>0.000</td></tr><tr><td>GERD</td><td>0.758</td><td>0.000</td></tr><tr><td>RDP</td><td>0.533</td><td>0.000</td></tr><tr><td>NP</td><td>0.804</td><td>0.000</td></tr><tr><td>NC</td><td>0.837</td><td>0.000</td></tr><tr><td>NTP</td><td>0.822</td><td>0.000</td></tr></table>
004228d4237dd5855fe1f2e80649d08b8c054a3bd7097a00c6e402e2b776e61a.png
complex
<table><tr><td>Characteristic</td><td>Crude odds ratios with 95% confidence interval</td><td>Adjusted odds ratios with 95% confidence interval</td></tr><tr><td>Age above 25 years</td><td>1.65 (1.33-2.04)*</td><td>.74 (.54-1.02)</td></tr><tr><td>Age 24 years &amp; below -Ref</td><td> </td><td> </td></tr><tr><td>Income 5001 NPR or above</td><td>.85 (.71-1.00)</td><td>1.30 (1.04-1.62)**</td></tr><tr><td>5000 NPR or less/month- Ref</td><td> </td><td> </td></tr><tr><td>Education secondary or higher</td><td>.35 (.27-.44)*</td><td>.41 (.31-.55)*</td></tr><tr><td>Uneducated or Primary level- Ref</td><td> </td><td> </td></tr><tr><td>Hindu religion</td><td>.15 (.09-.24)*</td><td>.09 (.05-.18)*</td></tr><tr><td>Non-Hindu - Ref</td><td> </td><td> </td></tr><tr><td>&#8805; 3 Children</td><td>2.48 (1.93-3.19)*</td><td>2.05 (1.56-2.71)*</td></tr><tr><td>&#8804; 2 Children - Ref</td><td> </td><td> </td></tr><tr><td>Desire more children</td><td>.78 (.62-.99)**</td><td>.72 (.55-.95)**</td></tr><tr><td>No more desire - Ref</td><td> </td><td> </td></tr><tr><td>Men attempt domestic violence</td><td>1.87 (1.56-2.24)*</td><td>1.29 (1.04-1.61)**</td></tr><tr><td>Not attempt - Ref</td><td> </td><td> </td></tr><tr><td colspan="3">Associated factors for male decision making to contraceptive use (N = 2394)</td></tr><tr><td>Age above 25 years</td><td>1.63 (1.30-2.05)*</td><td>1.57 (1.15-2.14)**</td></tr><tr><td>Age 24 years &amp; below -Ref</td><td> </td><td> </td></tr><tr><td>Income 5001 NPR or above</td><td>1.09 (.92-1.30)</td><td>.67 (.54-.82)*</td></tr><tr><td>5000 NPR or less/month- Ref</td><td> </td><td> </td></tr><tr><td>Education secondary or higher</td><td>4.54 (3.53-5.84)*</td><td>4.11 (3.12 - 5.42)*</td></tr><tr><td>Uneducated or Primary level- Ref</td><td> </td><td> </td></tr><tr><td>Hindu religion</td><td>2.32 (1.70-3.16)*</td><td>1.43 (.95-2.16)</td></tr><tr><td>Non-Hindu - Ref</td><td> </td><td> </td></tr><tr><td>Non-Indigenous ethnicity</td><td>2.40 (1.85 -3.10)*</td><td>1.49 (1.06-2.10)**</td></tr><tr><td>Indigenous ethnicity - Ref</td><td> </td><td> </td></tr><tr><td>&#8805; 3 Children</td><td>.67 (.54-.82)*</td><td>.70 (.55-.88)**</td></tr><tr><td>&#8804; 2 Children - Ref</td><td> </td><td> </td></tr><tr><td>Desire more children</td><td>.64 (.50-.82)*</td><td>.66 (.50-.87)**</td></tr><tr><td>No more desire - Ref</td><td> </td><td> </td></tr><tr><td>Men attempt domestic violence</td><td>.62 (.52-.73)*</td><td>.83 (.68-1.02)</td></tr><tr><td>Not attempt - Ref</td><td> </td><td> </td></tr></table>
774d024d051ce934b0ab07250a2dbf04ed70ed8d9636c8a78036e7c3b7780b48.png
complex
<table><tr><td rowspan="3">Variable</td><td colspan="2">HZ patients(<i>n</i> = 38 743)</td><td colspan="2">Comparison patients(<i>n</i> = 116 229)</td><td rowspan="3"><i>P</i> value</td></tr><tr><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>20 514</td><td>52.95</td><td>61 542</td><td>52.95</td><td> </td></tr><tr><td> Female</td><td>18 229</td><td>47.05</td><td>54 687</td><td>47.05</td><td> </td></tr><tr><td>Age, years</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 50&#8211;59</td><td>12 174</td><td>31.42</td><td>36 679</td><td>31.56</td><td>0.8824</td></tr><tr><td> 60&#8211;69</td><td>11 847</td><td>30.58</td><td>35 490</td><td>30.53</td><td> </td></tr><tr><td> &#8805;70</td><td>14 722</td><td>38.00</td><td>44 060</td><td>37.91</td><td> </td></tr><tr><td>Diabetes</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>4984</td><td>12.86</td><td>11 308</td><td>9.73</td><td>&lt;0.0001</td></tr><tr><td> No</td><td>33 759</td><td>87.14</td><td>104 921</td><td>90.27</td><td> </td></tr><tr><td>Monthly income (NT$)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Financially dependent</td><td>11 942</td><td>30.82</td><td>33 855</td><td>29.13</td><td>&lt;0.0001</td></tr><tr><td> 1&#8211;15 840</td><td>10 066</td><td>25.98</td><td>22 550</td><td>19.40</td><td> </td></tr><tr><td> 15 841&#8211;25 200</td><td>9818</td><td>25.34</td><td>43 673</td><td>37.57</td><td> </td></tr><tr><td> &#8805;25 201</td><td>6917</td><td>17.85</td><td>16 151</td><td>13.90</td><td> </td></tr><tr><td>Urbanization</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Metropolitan</td><td>24 068</td><td>62.12</td><td>48 105</td><td>41.39</td><td>&lt;0.0001</td></tr><tr><td> City</td><td>6509</td><td>16.80</td><td>28 048</td><td>24.13</td><td> </td></tr><tr><td> Town</td><td>5528</td><td>14.27</td><td>25 957</td><td>22.33</td><td> </td></tr><tr><td> Rural</td><td>2638</td><td>6.81</td><td>14 119</td><td>12.15</td><td> </td></tr><tr><td>Charlson comorbidity index(means &#177; SD)</td><td colspan="2">0.41 &#177; 0.84</td><td colspan="2">0.29 &#177; 0.67</td><td>&lt;0.0001</td></tr></table>
50bd23c901edc0b8fd81316293b2c23af7de8a58d35413bd3b55c28f2315d700.png
complex
<table><tr><td></td><td></td><td colspan="3">cELISA</td></tr><tr><td></td><td></td><td>Positive</td><td>Negative</td><td>Total</td></tr><tr><td><i>T. equi</i> (A)</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"> IFAT</td><td>Positive</td><td>48</td><td>7</td><td>55</td></tr><tr><td>Negative</td><td>10</td><td>43</td><td>53</td></tr><tr><td>Total</td><td>58</td><td>50</td><td>108</td></tr><tr><td><i>B. caballi</i> (B)</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"> IFAT</td><td>Positive</td><td>4</td><td>16</td><td>20</td></tr><tr><td>Negative</td><td>3</td><td>85</td><td>88</td></tr><tr><td>Total</td><td>7</td><td>101</td><td>108</td></tr></table>
8e94baf0a4485346c4ad1e946fad0b18cf0ac4841eaa459a7c562485f327c76f.png
simple
<table><tr><td>Quality of life measure</td><td>BaselineN = 159</td><td>1-monthN = 136</td><td>4-monthsN = 127</td><td>p-value*</td></tr><tr><td>General health</td><td><i>77.3 </i>(<i>20.5</i>)</td><td><i>72.2 </i>(<i>23.7</i>)</td><td><i>72.0 </i>(<i>21.5</i>)</td><td>.<i>008</i></td></tr><tr><td> Spouse</td><td>74.0 (19.8)</td><td>70.5 (19.8)</td><td>70.4 (22.0)</td><td>.237</td></tr><tr><td> Adult child</td><td>80.9 (19.9)</td><td>69.5 (26.4)</td><td>72.3 (22.3)</td><td>.008</td></tr><tr><td> Other relative</td><td>77.4 (22.4)</td><td>79.7 (20.7)</td><td>76.0 (18.7)</td><td>.940</td></tr><tr><td>Mental health</td><td><i>72.5 </i>(<i>20.3</i>)</td><td><i>74.7 </i>(<i>19.8</i>)</td><td><i>76.6 </i>(<i>18.7</i>)</td><td>.<i>009</i></td></tr><tr><td> Spouse</td><td>70.4 (21.5)</td><td>70.6 (21.5)</td><td>74.8 (17.9)</td><td>.029</td></tr><tr><td> Adult child</td><td>72.9 (19.2)</td><td>75.6 (18.8)</td><td>76.7 (20.1)</td><td>.308</td></tr><tr><td> Other relative</td><td>76.5 (19.8)</td><td>80.5 (17.0)</td><td>81.7 (17.6)</td><td>.144</td></tr><tr><td>Physical functioning</td><td><i>80.4 </i>(<i>24.4</i>)</td><td><i>78.2 </i>(<i>24.6</i>)</td><td><i>78.4 </i>(<i>22.4</i>)</td><td>.<i>263</i></td></tr><tr><td> Spouse</td><td>75.5 (25.8)</td><td>72.9 (26.5)</td><td>73.9 (23.1)</td><td>.439</td></tr><tr><td> Adult child</td><td>89.8 (16.9)</td><td>80.8 (24.6)</td><td>85.3 (19.1)</td><td>.261</td></tr><tr><td> Other relative</td><td>73.1 (28.3)</td><td>83.1 (19.7)</td><td>76.0 (24.0)</td><td>.659</td></tr></table>
394454b38ee8f3bf293daf849f3e5c764cb297649d77621e7925dc3f34404e8c.png
simple
<table><tr><td></td><td>Aniso nucleosis (&#177;)</td><td>Large cherry red nucleoli (&#177;)</td><td>Small cherry red nucleoli (&#177;)</td><td>Large cells (&#177;)</td><td>Mesothelial like sheets (&#177;)</td><td>3 dimensional cluster (&#177;)</td></tr><tr><td>Malignant</td><td>7/4</td><td>9/2</td><td>2/9</td><td>4/7</td><td>5/6</td><td>11/0</td></tr><tr><td>Non-malignant</td><td>17/26</td><td>1/42</td><td>20/23</td><td>39/4</td><td>21/22</td><td>NA</td></tr><tr><td>p value</td><td>*</td><td>0.0252</td><td>*</td><td>*</td><td>*</td><td>&lt;0.0001</td></tr></table>
83e30b3cbd5481e174e5c09e1f567d3a058cdb14345d75df605f98d79f2d20b3.png
simple
<table><tr><td>Variables</td><td>Disability Beta (SD)</td><td><i>T</i></td><td>Anxiety</td><td><i>t</i></td><td>Depression</td><td><i>t</i></td></tr><tr><td>Age</td><td>0.011 (0.016)</td><td>0.71</td><td>&#8722;0.046 (0.014)</td><td>&#8722;3.24 **</td><td>&#8722;0.014 (0.011)</td><td>&#8722;1.33</td></tr><tr><td>Organic Beliefs</td><td>0.222 (0.052)</td><td>4.26 ***</td><td>0.035 (0.046)</td><td>0.76</td><td>0.071 (0.035)</td><td>2.01 *</td></tr><tr><td>Psychological Beliefs</td><td>0.229 (0.058)</td><td>3.94 ***</td><td>0.259 (0.052)</td><td>5.02 ***</td><td>0.086 (0.039)</td><td>2.19 *</td></tr><tr><td>Self-efficacy</td><td>&#8722;0.225 (0.019)</td><td>&#8722;12.31 ***</td><td>&#8722;0.103 (0.017)</td><td>&#8722;6.24 ***</td><td>&#8722;0.163 (0.013)</td><td>&#8722;12.93 ***</td></tr><tr><td>LOC&#8212;Internal</td><td>&#8722;0.041 (0.044)</td><td>&#8722;0.93</td><td>&#8722;0.003 (0.040)</td><td>&#8722;0.07</td><td>0.002 (0.030)</td><td>0.07</td></tr><tr><td>LOC&#8212;Chance</td><td>&#8722;0.015 (0.043)</td><td>&#8722;0.34</td><td>0.170 (0.038)</td><td>4.47 ***</td><td>0.074 (0.029)</td><td>2.55 *</td></tr><tr><td>LOC&#8212;Other</td><td>&#8722;0.021 (0.036)</td><td>&#8722;0.57</td><td>0.048 (0.032)</td><td>1.49</td><td>&#8722;0.001 (0.024)</td><td>&#8722;0.06</td></tr></table>
77c800c3cdbd22c9fe21948ec8410496d8b913a3d7d536f5ac2d01738231e35f.png
complex
<table><tr><td rowspan="2" colspan="2"></td><td colspan="2">No DGE</td><td colspan="2">DGE</td><td rowspan="2"><i>P</i></td></tr><tr><td colspan="2"><i>n</i> = 70</td><td colspan="2"><i>n</i> = 98</td></tr><tr><td colspan="2">Age, years</td><td colspan="2">62 (51&#8211;69)</td><td colspan="2">68 (60&#8211;74)</td><td><i>0.003</i></td></tr><tr><td colspan="6">Gender</td><td>0.39</td></tr><tr><td colspan="2"> female</td><td>24</td><td>(34%)</td><td>40</td><td>(41%)</td><td></td></tr><tr><td colspan="2"> male</td><td>46</td><td>(66%)</td><td>58</td><td>(59%)</td><td></td></tr><tr><td colspan="2">BMI</td><td colspan="2">24,6 &#177; 3,8</td><td colspan="2">24,4 &#177; 4</td><td>0.888</td></tr><tr><td colspan="7">Diagnosis</td></tr><tr><td colspan="2">Malignant</td><td>54</td><td>(77%)</td><td>76</td><td>(78%)</td><td>0.95</td></tr><tr><td colspan="2"> Ductal adenocarcinoma</td><td>31</td><td>(44%)</td><td>40</td><td>(41%)</td><td></td></tr><tr><td colspan="2"> Ampullary carcinoma</td><td>10</td><td>(14%)</td><td>19</td><td>(19%)</td><td></td></tr><tr><td colspan="2"> Distal bile duct carcinoma</td><td>7</td><td>(10%)</td><td>9</td><td>(9%)</td><td></td></tr><tr><td colspan="2">Benign</td><td>16</td><td>(23%)</td><td>22</td><td>(22%)</td><td></td></tr><tr><td colspan="2"> Pancreatitis</td><td>13</td><td>(19%)</td><td>15</td><td>(15%)</td><td></td></tr><tr><td>DM</td><td>pre</td><td>12</td><td>(17%)</td><td>19</td><td>(19%)</td><td>0.712</td></tr><tr><td></td><td>post</td><td>15</td><td>(21%)</td><td>20</td><td>(20%)</td><td>0.835</td></tr><tr><td>Alcohol</td><td></td><td>19</td><td>(27%)</td><td>19</td><td>(19%)</td><td>0.236</td></tr><tr><td>Smoker</td><td></td><td>31</td><td>(44%)</td><td>38</td><td>(39%)</td><td>0.474</td></tr><tr><td>Weight loss</td><td></td><td>32</td><td>(46%)</td><td>32</td><td>(33%)</td><td>0.086</td></tr><tr><td colspan="2">Preoperative biliary drainage</td><td>43</td><td>(61%)</td><td>58</td><td>(59%)</td><td>0.831</td></tr><tr><td>Cholangitis</td><td></td><td>20</td><td>(29%)</td><td>17</td><td>(17%)</td><td>0.083</td></tr></table>
3e6e4c1a82d0a2f9a1c0ae4286aa0751246e0bef191f4e4e3f2ff06c8a9e3fd1.png
complex
<table><tr><td>Review</td><td>Professional background (code used in the quotes)</td><td>Knowledge of the clinical area</td><td>DTA-related knowledge</td><td>Systematic review methods</td><td>Academic role within university</td><td>Policy- making experience</td></tr><tr><td>Galactomannan detection for invasive aspergillosis in immune-compromized patients</td><td>Hematologist (H1)</td><td>Yes</td><td>Good</td><td>Some</td><td>Yes</td><td>Yes</td></tr><tr><td rowspan="5"> </td><td>Hematologist (H2)</td><td>Yes</td><td>Good</td><td>Some</td><td>Yes</td><td>Yes</td></tr><tr><td>Policy maker (PM1)</td><td>No</td><td>Some</td><td>Good</td><td>Yes</td><td>Yes</td></tr><tr><td>Systematic reviewer (SR1)</td><td>No</td><td>Little</td><td>Good</td><td>Yes</td><td>No</td></tr><tr><td>Health economist (HE1)</td><td>No</td><td>Little</td><td>Good</td><td>No</td><td>No</td></tr><tr><td>Systematic reviewer (SR2)</td><td>No</td><td>Good</td><td>Good</td><td>Yes</td><td>Yes</td></tr><tr><td rowspan="6">Physical examination for lumbar radiculopathy due to disc herniation in patients with low back pain</td><td>GP (GP1)</td><td>Yes</td><td>Little</td><td>Little</td><td>No</td><td>No</td></tr><tr><td>GP (GP2)</td><td>Yes</td><td>Little</td><td>Little</td><td>No</td><td>No</td></tr><tr><td>Physiotherapist (PH1)</td><td>Yes</td><td>Little</td><td>Good</td><td>Yes</td><td>No</td></tr><tr><td>GP (GP3)</td><td>Yes</td><td>Good</td><td>Good</td><td>No</td><td>Yes</td></tr><tr><td>Physiotherapist (PH2)</td><td>Yes</td><td>Good</td><td>Good</td><td>Yes</td><td>Yes</td></tr><tr><td>Policy maker (PM2)</td><td>Yes</td><td>Good</td><td>Good</td><td>Yes</td><td>Yes</td></tr><tr><td> </td><td>Policy maker (PM3)</td><td>No</td><td>Some</td><td>Good</td><td>Yes</td><td>Yes</td></tr><tr><td rowspan="8">MRI versus CT for detection of acute vascular lesions in patients presenting with stroke symptoms</td><td>Radiologist (R1)</td><td>Yes</td><td>Little</td><td>Little</td><td>No</td><td>No</td></tr><tr><td>Systematic reviewer (SR3)</td><td>No</td><td>Little</td><td>Some</td><td>No</td><td>No</td></tr><tr><td>Health economist (HE2)</td><td>No</td><td>Good</td><td>Good</td><td>No</td><td>Yes</td></tr><tr><td>Health economist (HE3)</td><td>No</td><td>Little</td><td>Some</td><td>No</td><td>No</td></tr><tr><td>Systematic reviewer (SR4)</td><td>No</td><td>Little</td><td>Good</td><td>Yes</td><td>No</td></tr><tr><td>Systematic reviewer (SR5)</td><td>No</td><td>Good</td><td>Good</td><td>Yes</td><td>No</td></tr><tr><td>Systematic reviewer (SR6)</td><td>Yes</td><td>Some</td><td>Good</td><td>Yes</td><td>No</td></tr><tr><td>Policy maker (PM4)</td><td>Yes</td><td>Good</td><td>Good</td><td>Yes</td><td>Yes</td></tr></table>
8125576ce772c845e7510469679c7a056c0c8fddaad07490125e7c22cce7ea0f.png
simple
<table><tr><td>Variable</td><td>Cases (<i>n</i>=454)</td><td>Controls (<i>n</i>=512)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td>61.04 &#177; 10.81</td><td>61.05 &#177; 11.01</td><td>0.990</td></tr><tr><td>Female/male</td><td>167/287</td><td>180/332</td><td>0.599</td></tr><tr><td>Smoking (No/Yes)</td><td>184/270</td><td>358/154</td><td>&lt;0.001</td></tr><tr><td>Drinking (No/Yes)</td><td>329/125</td><td>436/76</td><td>&lt;0.001</td></tr><tr><td>Diabetes (No/Yes)</td><td>295/159</td><td>435/77</td><td>&lt;0.001</td></tr><tr><td>FPG (mmol/l)</td><td>6.40 &#177; 1.65</td><td>5.65 &#177; 1.46</td><td>&lt;0.001</td></tr><tr><td>Hypertension (No/Yes)</td><td>185/269</td><td>300/212</td><td>&lt;0.001</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>27.77 &#177; 3.11</td><td>25.50 &#177; 3.13</td><td>&lt;0.001</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.81 &#177; 1.05</td><td>4.52 &#177; 1.05</td><td>&lt;0.001</td></tr><tr><td>HDL (mmol/l)</td><td>1.13 &#177; 0.33</td><td>1.61 &#177; 0.39</td><td>&lt;0.001</td></tr><tr><td>LDL (mmol/l)</td><td>2.89 &#177; 0.88</td><td>2.69 &#177; 0.75</td><td>&lt;0.001</td></tr></table>
f01beaaa82ed9a1a19c1d491d72d578fc43c58aefc43103daae448242da44eac.png
simple
<table><tr><td></td><td>$3000 single</td><td>12 mo. spacing</td><td>60 mo. spacing</td><td>$1000 single</td></tr><tr><td>$3000 single</td><td></td><td></td><td></td><td></td></tr><tr><td>12 mo. spacing</td><td><i>t</i> = &#8722;1.539, <i>p</i> = 0.14</td><td></td><td></td><td></td></tr><tr><td>60 mo. spacing</td><td><i>t</i> = &#8722;1.31, <i>p</i> = 0.20</td><td><i>t</i> = 0.77, <i>p</i> = 0.45</td><td></td><td></td></tr><tr><td>$1000 single</td><td><i>t</i> = 0.87, <i>p</i> = 0.40</td><td><i>t</i> = 1.67, <i>p</i> = 0.11</td><td><i>t</i> = 1.09, <i>p</i> = 0.29</td><td></td></tr></table>
73b132560a2fdce13c776130a5d04070c81be19a725c6aaba84dbcaaf93fef80.png
complex
<table><tr><td>Question</td><td>Session</td><td><i>n</i></td><td>&#8805; 4 (%)</td></tr><tr><td rowspan="2">I believe the work in this session is relevant for professional nurses</td><td>1</td><td>52</td><td>98</td></tr><tr><td>2</td><td>49</td><td>84</td></tr><tr><td rowspan="2">I believe the work in this session is relevant for me as an individual</td><td>1</td><td>52</td><td>96</td></tr><tr><td>2</td><td>49</td><td>88</td></tr><tr><td rowspan="2">Overall I am satisfied with this session</td><td>1</td><td>49</td><td>94</td></tr><tr><td>2</td><td>49</td><td>76</td></tr></table>
6e85437b65f9bfbd00e89add70f07ecb2ca72cc496feaa14d0ec12a202d62a30.png
simple
<table><tr><td>Algorithms</td><td>MAPE (%)</td><td>RMSPE (%)</td><td>Error of RUL prediction</td></tr><tr><td>INW&#8211;ESN (dynamica)</td><td>9.32</td><td>7.27</td><td>23 min</td></tr><tr><td>INW&#8211;ESN (static)</td><td>17.14</td><td>14.64</td><td>Failed</td></tr><tr><td>RNN (dynamica)</td><td>16.38</td><td>13.44</td><td>138 min</td></tr><tr><td>ESN (dynamica)</td><td>14.60</td><td>10.87</td><td>161 min</td></tr><tr><td>ELM (static)</td><td>13.91</td><td>9.48</td><td>69 min</td></tr></table>
dbf7baa0040eea10ce213b1d465680305ef711ee92ff17dfd6427791ad7c8227.png
complex
<table><tr><td>PCR</td><td>Forward (F) primer/reverse (R) primer (5&#8242;&#8211;3&#8242;)</td><td>PCR mixture</td><td>Cycling conditions</td></tr><tr><td rowspan="7">rDNA21</td><td>Nest1 F: GCTGTAGGTGAACCTGCAGCAGCTGGATCATT</td><td rowspan="7">50 &#956;L reaction; 5 &#956;L DNA from filter papers (or 5 &#956;L N1), 25 &#956;L QIAGEN HotStar Taq Master Mix (QIAGEN), 0.3 &#956;M primers</td><td>95&#176;C, 15 minutes</td></tr><tr><td>Nest1 R: GCGGGTAGTCCTGCCAAACACTCAGGTCTG</td><td>35&#8211;40 cycles</td></tr><tr><td>Nest2 F: GCAGCTGGATCATTTTCC</td><td>94&#176;C, 0.5 minutes</td></tr><tr><td>Nest2 R: AACACTCAGGTCTGTAAAC</td><td>58&#176;C, 0.5 minutes</td></tr><tr><td></td><td>72&#176;C, 1.5 minutes</td></tr><tr><td></td><td>60&#176;C, 1 minutes</td></tr><tr><td></td><td>75&#176;C, 10 minutes</td></tr><tr><td rowspan="6">ITS222</td><td>F: GGGAGAAGCTCTATTGTG</td><td rowspan="6">25 &#956;L reaction; 1 &#956;L N2 product from rDNA PCR, KCl buffer (15 mM MgCl2, Bioline, London, UK), 2 mM deoxynucleotide triphosphates, 0.4 &#956;M primers, 1U Taq polymerase</td><td>94&#176;C, 2 minutes</td></tr><tr><td>R: ACACTCAGGTCTGTAAAC</td><td>40 cycles</td></tr><tr><td></td><td>94&#176;C, 20 seconds</td></tr><tr><td></td><td>53&#176;C, 30 seconds</td></tr><tr><td></td><td>72&#176;C, 1 minutes</td></tr><tr><td></td><td>72&#176;C, 10 minutes</td></tr><tr><td rowspan="7">kDNA6</td><td>Nest1 F: C/GA/GTA/GCAGAAAC/TCCCGTTCA</td><td rowspan="7">50 &#956;L reaction; 5 &#956;L DNA from filter papers (OR 5 &#956;L N1), 25 &#956;L QIAGEN HotStar Taq Master Mix, 0.3 &#956;M primers</td><td>95&#176;C, 15 minutes</td></tr><tr><td>Nest1 R: ATTTTTCG/CGA/TTTT/CGCAGAACG</td><td>30 cycles at</td></tr><tr><td>Nest2 F: ACTGGGGGTTGGTGTAAAATAG</td><td>94&#176;C, 1 minutes</td></tr><tr><td>Nest2 R: TCGCAGAACGCCCCT</td><td>55&#176;C, 1 minutes</td></tr><tr><td></td><td>72&#176;C, 1.5 minutes</td></tr><tr><td></td><td>60&#176;C, 1 minutes</td></tr><tr><td></td><td>75&#176;C,10 minutes</td></tr></table>